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Discoveries in the world of non-coding RNAs made during the turn of the last century chal-
lenge the flow of information described by Francis Crick in his description of the central
dogma of molecular biology – the information encoded by the DNA no longer solely re-
quires a protein intermediate to control the fate of a living cell. Dozens of mechanisms
involving RNA-protein, protein-protein and RNA-RNA interactions have been described
that govern regulation of information controlled at the level of replication, transcription and
translation. The networks that emerge from these interactions support unique, context de-
pendent regulation of gene expression, are dynamic in nature, and provide multiple layers
of complexity underlying the biological system. Advancements in molecular biology allow
researchers to dissect complex interactions between components of gene regulatory net-
works, interpretation of which is only feasible using automated computer-aided approaches.
Inevitably, uncovering novel mechanisms involved in biological systems benefits from an
integrated approach between experimental biology and computational modelling.
This thesis investigates the function of a group of non-coding RNAs, microRNAs, that
regulate gene expression at a post-transcriptional level. Firstly, Argonaute-2, the crucial ef-
fector of microRNA function, is revealed as a novel direct target of microRNA-132. The
functional role of this regulation is explored in primary lymphatic endothelial cells dur-
ing cell activation. Secondly, the regulation of two microRNA-132 targets – Argonaute-2,
required for microRNA-mediated gene regulation, and E1A-associated Protein p300, neces-
sary for microRNA-132 transcription – are incorporated into an agent-based model. Follow-
ing the CoSMoS process, a rigorous methodology for model development, the documented
regulatory network is captured in a model that is able to simulate the expected behaviour of
the real-world problem domain. Finally, using the gathered data on microRNA-132 regula-
tion and cell activation, the model is used to evaluate the domain knowledge of microRNA-
mediated gene silencing in silico, proposing testable hypothesis for in vitro experimentation.
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Since their discovery two decades ago by Lee et al. (1993) and recognition as a class of tiny
regulatory RNAs, termed microRNAs (miRNAs) (Lagos-Quintana et al., 2001; Lau et al.,
2001; Lee and Ambros, 2001), the miRNA field has been rapidly expanding, with ~2500
sequences documented in the publicly available miRNA database (Kozomara and Griffiths-
Jones, 2014). Their involvement in nearly all aspects of cell biology has generated a more
dynamic understanding of gene regulation. Although many pathways of miRNA-gene target
regulatory models have been described, a large proportion of research is still needed to es-
tablish context-dependent miRNA biogenesis and function. The field of miRNA biology has
benefited through the use of several computational tools, which aid with the identification of
potential miRNA target genes. Together with advancements in sequencing technologies and
single-cell -omics analysis approaches, the general mechanisms of miRNA-mediated gene
silencing are being established.
It has been shown that the effect of a single miRNA in miRNA-mediated gene regula-
tion is commonly mild. However, a single miRNA can alter the expression of multiple target
genes. Moreover, several miRNAs can target the same target gene, resulting in a combina-
torial effect on gene expression regulation. These interactions form complex networks that
18
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during regular cell function confer robustness to gene expression programmes (Ebert and
Sharp, 2012; Nazarov et al., 2013; Stark et al., 2005). The exact miRNA expression pattern
varies between cell types and even between different cell activation states. This gives rise to
context-specific gene regulatory networks, which modulate gene expression programmes in
a spatially and temporally resolved manner.
The traditional approach to the discovery of novel miRNA targets involves the investi-
gation of predicted targets using computational tools, the characterisation of the interaction
of the miRNA and the targeted region of the gene, and typically an investigation into the
functional impact of the interaction described in a model biological system. Although some
temporal information is gathered in these experiments, the cost and limitations of molecular
biology techniques make it challenging to collect high resolution continuous data that would
give a comprehensive understanding of the dynamics of miRNA-mediated silencing.
Just over a decade ago, Kitano (2002) described the need for complex system approaches
for understanding biological systems: whilst individual studies focus on understanding key
functionalities of single biological components, the integration of vast amounts of high-
throughput data that supports a network of regulatory functions for those biological com-
ponents are, in fact, highly dynamic and intrinsically complex. The discovery of regulatory
patterns governing biological processes and their constituents, the study of system dynam-
ics, and in silico predictions through simulating biological systems can therefore be made
possible through a combined approach between computational modelling and wet-lab ex-
perimental approaches. Following these principles, we employ the traditional approach to
novel miRNA target discovery followed by an in-depth investigation of the regulatory mech-
anism by a miRNA on its targets. Through the use of modelling and simulation, we intend
to demonstrate that the development of a computational model capturing the miRNA-target
interaction furthers our understanding of the biological system. Notably, the information
gained from the simulation suggests further experiments to explain phenomena revealed
through simulating a biological system.
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1.2 Mammalian miRNA biology
MiRNAs are a class of highly-conserved short non-coding RNAs that regulate gene expres-
sion at the post-transcriptional level (Bartel, 2009). The ~23 nucleotides long miRNAs are
associated with Argonaute (AGO) family proteins. Nucleotides 2-7 of the 5’ region on a
miRNA, known as the ’seed’ site, determines the specificity for the mRNA transcript, com-
monly located at the 3’untranslated region (UTR). Following target recognition and binding,
AGO proteins recruit other factors in order to silence the target gene expression (Huntzinger
and Izaurralde, 2011). There are characteristic differences in the biogenesis, evolutionary
origin and structure of mammalian and plant miRNAs (Axtell et al., 2011), with only the
mammalian miRNA biology being covered in this chapter.
1.2.1 miRNA biogenesis
With over a half of the protein-coding genome subject to miRNA regulation (Friedman
et al., 2009), dysfunction in miRNA-mediated biogenesis and silencing components results
in embryonic developmental abnormalities and lethality (Bernstein et al., 2003; Chong et al.,
2010; Liu et al., 2004; Wang et al., 2007), indicating an essential role for miRNAs in cell
biology. This section describes the biogenesis (the canonical miRNA pathway summarised
in Figure 1.1) and function of miRNAs, the involved functional complexes and introduces
the relevant miRNAs investigated in this thesis.
The biogenesis of the majority of miRNAs follows a canonical pathway, although non-
canonical processing pathways have been identified (Babiarz et al., 2008; Cheloufi et al.,
2010; Chong et al., 2010). The canonical pathway involves primary miRNA (pri-miR)
transcription by RNA polymerase II (Lee et al., 2004) or III (Borchert et al., 2006), fol-
lowed by two main processing steps: first, the pri-miR is processed by the Microprocessor
complex in the nucleus comprised of DROSHA and DiGeorge Syndrome Critical Region 8
(DGCR8), and the produced precursor miRNA (pre-miR) is cleaved in the cytoplasm by the
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DICER-TAR RNA Binding Protein (TRBP) complex into a short RNA duplex, ready for
AGO loading. The transcription, processing, transport and function of miRNAs are subject
to context-dependent regulation.
Figure 1.1: Overview of the canonical pathway of miRNA biogenesis.
1.2.1.1 Transcriptional regulation of miRNAs
miRNAs have been found both in intergenic and intragenic regions of the genome. The
transcriptional start sites (TSSs) and the RNA polymerase responsible for the transcription
have been reported for a fraction of miRNAs (Ozsolak et al., 2008). RNA polymerase II is
suggested to be the predominant transcriber of the majority of miRNAs (Lee et al., 2004), but
the exact TSS positions for many miRNAs remains a complex issue with many features of
miRNA promoters being identified (Corcoran et al., 2009). Some miRNAs are transcribed
together with other miRNAs as part of a single polycistronic unit (Lee et al., 2002; Altuvia
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et al., 2005). Such miRNAs belong to the same cluster and are produced together (Nohata
et al., 2012; Remenyi et al., 2010), but can be post-transcriptionally regulated. The produced
pri-miRs are from several hundred base pairs to several kilobases in length (Saini et al.,
2007).
1.2.1.2 Nuclear processing
The pri-miR is typically processed by the DROSHA-DGCR8 Microprocessor complex into
a short-lived intermediate precursor, pre-miR. The pre-miR is ~65 nucleotides in length,
consisting of a single terminal loop structure with 5’ and 3’ overhangs. DROSHA is a
type III ribonuclease, which is able to cleave double-stranded RNAs in the nucleus (Lee
et al., 2003). For efficient nuclear processing DROSHA is translocated to the nucleus upon
its activation (Tang et al., 2011). DGCR8 has been shown to be essential for DROSHA-
mediated miRNA processing (Gregory et al., 2004), and both proteins are involved in an
autoregulatory loop with each other to control the Microprocessor activity in mammals (Han
et al., 2004, 2009). Interestingly, not all miRNAs require nuclear processing by DROSHA:
several groups of miRNAs have been shown to be products of intron splicing that produce
< 500 nucleotide long hairpins, known as ”mirtrons”, with shorter primary transcripts, not
suitable for DROSHA processing (Okamura et al., 2007; Ruby et al., 2007; Babiarz et al.,
2008); instead, they are processed as a result of splicing into DICER compatible substrates.
1.2.1.3 Transport
The pre-miR is exported from the nucleus by Exportin 5 (EXP5) in a guanosine triphos-
phate (GTP)-dependent manner (Bohnsack et al., 2004). Upon export, the EXP5-RanGTP
complex is hydrolysed allowing the release of the double-stranded pre-miR and causing
the disassembly of the EXP5-RanGTP nucleopore complex (Okada et al., 2009). A non-
canonical miRNA has been shown to be exported via an alternative route by Exportin 1
(EXP1) that recognises the 5’ m7G-cap on a pre-miR (Xie et al., 2013).
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1.2.1.4 Cytoplasmic processing
The exported pre-miR is recognised by DICER, another type III ribonuclease resident in
the cytoplasm. DICER processing requires the recognition of the terminal loop of the pre-
miR (Tsutsumi et al., 2011). The result of DICER processing is a miRNA duplex with
2-nucleotide 3’ overhangs, which in humans is loaded into AGO-family proteins without
preference (Siomi and Siomi, 2008; Su et al., 2009). Only one strand is selected during
AGO-loading, termed as the mature strand, whereas the other strand is rapidly degraded
(passenger strand, commonly marked with an asterisk after the miRNA name).
The human DICER1 mRNA is a target of the let-7 miRNA family and is subject to au-
toregulation due to DICER’s involvement in miRNA processing (Forman et al., 2008; Toku-
maru et al., 2008). Other genes, such as LIN28 are targeted by the let-7 miRNAs, where
LIN28 associates with the terminal loop of the pre-miR and prevents DICER-mediated pro-
cessing (Heo et al., 2008; Newman et al., 2008). Other proteins involved in pre-miR pro-
cessing have also been identified, such as TRBP and Protein Activator of PKR (PACT).
Both of the aforementioned proteins associate with DICER and have been shown to regu-
late pre-miR binding specificity and processing (Lee and Doudna, 2012; Lee et al., 2013).
TRBP has been shown to be actively regulated by phosphorylation at S142 and S152 (Pa-
roo et al., 2009; Nakamura et al., 2015), whilst PACT has been shown to be regulated at a
transcriptional level by Specificity Protein 1 (SP1) (Fasciano et al., 2007).
Alternative pathways that skip DICER-processing have been suggested in humans, where
DICER is unable to recognise a shorter miRNA precursor (Cifuentes et al., 2010). Instead,
AGO2 associates with the pre-miR, and processes and cleaves the pre-miR into the mature
miRNA with the aid of a poly-A specific ribonuclease (Yoda et al., 2013).
1.2.2 miRNA-mediated gene silencing
Processed mature miRNAs are loaded into AGO to form the RNA-induced silencing com-
plex (RISC). Many other proteins are involved in the formation, stabilisation and the func-
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tion of the RISC, with AGO playing a key role in small RNA-mediated gene silencing.
1.2.2.1 AGO-family proteins
There are four AGO family members in the mammalian genome, with AGO2 located on
the human chromosome 8q24.3 and the other 3 AGOs positioned together on the human
chromosome 1p34.3. The amino acid conservation between AGO1-4 is over 80% (Fig-
ure 1.2). Predominant expression of AGO1 and AGO2 has been found in HeLa and HEK
293T cells (Meister et al., 2004; Petri et al., 2011), with AGO3 and AGO4 being magni-
tudes lower in abundance; similar results were shown for Ago1 and Ago2 dominance over
Ago3 and Ago4 in different mouse tissues (Valdmanis et al., 2012). Unlike in mammals, 10
different AGO family protein have been reported in Arabidopsis thaliana (Qi et al., 2005)
and 2 in Drosophila melanogaster (Okamura et al., 2004), with distinct, context dependent
roles in small RNA mediated silencing.
Over the last few years, the crystal structures of human AGO2 (2.3A˚) (Schirle and
MacRae, 2012) and AGO1 (2.1A˚) (Faehnle et al., 2013) were obtained in complex with
miR-20a and let-7, respectively (Figure 1.3), displaying many structural similarities and
structural domain conservation of the 4 main regions (N-terminal, PAZ, PIWI and Mid do-
mains). Early in the millennium, of the 4 AGOs, only AGO2 was shown to function as
a catalytically active endonuclease (Liu et al., 2004; Meister et al., 2004). Moreover, re-
cent studies have suggested, that some of the AGO family proteins have overlapping roles
– AGO1 and AGO3 have been shown to play redundant role during small interfering RNA
(siRNA) mediated gene suppression in vivo, not requiring the participation of AGO2 to sup-
press gene expression (Ruda et al., 2014). To much surprise, Faehnle et al. (2013) demon-
strated that the cleavage activity of AGO2 can be transferred onto AGO1 and AGO3 by
making chimeric proteins – domain swaps of domain N and PIWI onto AGO1, a domain
swap of domain N onto AGO3, or 2 point mutations of AGO1 (alignment position 698 and
829 in Figure 1.2), indicated that slicer activity is possible in AGO1 and AGO3. This was
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proposed to be due to the interplay of the AGO domains to create a catalytic center similar to
that of the endogenous AGO2, mediated by the PL3 loop (Faehnle et al., 2013) (alignment
position 692-699 in Figure 1.2).
AGO proteins associate with miRNAs to perform their function in silencing target genes.
Due to the limited availability of AGO, miRNAs must compete for AGO-loading (Lund
et al., 2011; Janas et al., 2012). Several studies demonstrated that miRNAs, through their
interaction with AGO, have increased stability (Diederichs and Haber, 2007; O’Carroll et al.,
2007) and can also act to maintain the abundance of AGO protein expression (Elkayam
et al., 2012). The regulation of AGO2 activity has been demonstrated by post-transcriptional
modifications through:
hydroxylation required for Heat Shock Protein 90 (HSP90) binding for miRNA loading
onto AGO2 (Wu et al., 2011)
phosphorylation at S387 determining AGO2 localisation to processing bodies and its si-
lencing activity (Zeng et al., 2008)
phosphorylation at Y529 reducing affinity of miRNA binding to AGO2 (Ru¨del et al., 2011)
ubiquitylation targeting AGO2 for degradation (Gibbings et al., 2012)
Finally, AGO2 has been found to be upregulated by Epidermal Growth Factor Receptor
(EGFR) and Mitogen-Activated Protein Kinase (MAPK) signalling (Adams et al., 2009).
Therefore, many mechanisms exist in regulating AGO2 activity in mammals, with AGO2



















Figure 1.2: The alignment of the human AGO1-4 proteins. Highly conserved regions are highlighted in black.
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(a) human AGO1
(b) human AGO2
Figure 1.3: The crystal structures of the human AGO1 protein (4KRF) with superimposed
let-7 (black) and AGO2 protein (4F3T) with superimposed miR-20a (black). The domains
N, PAZ, Mid and PIWI are labelled and approximately highlighted based on the atom
colour scheme.
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1.2.2.2 RISC formation
The maturation of a functional RISC complex occurs in two distinguishable steps: the
adenosine triphosphate (ATP)-dependent loading of the miRNA and the ATP-independent
removal of the passenger strand (Kawamata et al., 2009; Yoda et al., 2010). The loading of
a miRNA duplex can occur in the presence or absence of DICER (Murchison et al., 2005).
The catalytically active AGO - AGO2 - has endonuclease activity and is able to cleave the
passenger strand that is perfectly complimentary to the guide strand (Rand et al., 2005).
However, most mammalian miRNAs contain kinks and mismatches. Moreover, other AGO
proteins do not possess catalytic activity (Liu et al., 2004; Meister et al., 2004), and gener-
ally act through the more common mechanism of passenger strand removal - unwinding of
the RNA duplex. Mismatches in the seed region and the 12-15 nucleotide region (Kawa-
mata et al., 2009) promotes the unwinding of the RNA duplex and thereby promotes RISC
maturation. The guide strand is typically selected favouring 5’ terminus, with a preference
for a uracil in position 1 of the mature miRNA sequence (Hu et al., 2009). The mature RISC
requires further recruitment of inhibitory factors to the miRNA:mRNA duplex to initiate
silencing.
1.2.2.3 Processing bodies
Processing bodies are cytoplasmic foci where a large concentration of translation inhibit-
ing proteins are localised, together with mRNA decapping complexes, exonucleases and
other constituents involved in miRNA-mediated decay (Kedersha and Anderson, 2007).
They are dynamic entities, that have been suggested to form as a consequence of miRNA-
mediated gene silencing (Eulalio et al., 2007), and can form as a result of mRNA deadeny-
lation (Zheng et al., 2008). They are identifiable by their protein composition (Kedersha and
Anderson, 2007) and are the sites for stalled and actively degraded mRNAs.
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1.2.2.4 Translational repression and target degradation
The binding partner of AGO2, GW182, is essential for efficient miRNA-mediated silenc-
ing (Eulalio et al., 2008) and is localised to processing bodies (Behm-Ansmant et al., 2006).
There has been mounting evidence that GW182 (3 paralogues in humans called TNRC6A-
C) functions as the key adaptor protein for recruitment and binding of translation inhibitory
factors, that facilitate the deadenylation of the poly-A tail (Braun et al., 2011; Piao et al.,
2010) and subsequent mRNA decapping (Rehwinkel et al., 2005). As a result, it is suggested
that through these mechanisms of destabilisation the mRNAs becomes a target for XRN1
driven mRNA degradation in a 5’ to 3’ manner. The proposed model for mRNA silencing
together with the participating proteins is described in Figure 1.4. Indeed, mRNA destabil-
isation has been proposed to play the dominant role miRNA mediated silencing in mam-
mals (Eichhorn et al., 2014) when the majority of target mRNA suppression is observed;
moreover, mRNA destabilisation by miRNAs is reflected in their overall role to act as fine-
tuners of gene regulation as measured by their mostly mild impact on the proteome (Baek
et al., 2008).
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Figure 1.4: A proposed model describing mRNA silencing by a miRNA-loaded RISC.
Upon miRISC binding to the miRNA target site, several adaptor proteins are recruited
necessary for the recruitment of mRNA deadenylation and decapping complexes.
(reviewed in (Fabian and Sonenberg, 2012)).
1.2.3 miRNA-mediated regulation
The post-transcriptional regulation of a miRNA target requires miRNA-target base-pairing
and site accessibility. The conservation of a the seed region of the miRNA demonstrated over
a third of human genes are targeted by miRNAs (Lewis et al., 2005; Friedman et al., 2009).
The direct association of the the miRNA with the target mRNA forms a miRNA-mRNA
duplex. The pairing of the seed site, nucleotides 2-8 of the miRNA, is necessary for target
binding and specificity, however mismatches at the 1st nucleotide position of the miRNA is
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tolerated to allow miRNA binding to the mRNA target site (Wee et al., 2012). Additional
mutants of the miRNA-target pair have been studied suggesting a model for miRNA asso-
ciation, where the seed region binds to the target mRNA first, with the additional binding
sequence at nucleotide positions 13-16 binding subsequently to increase the miRNA-mRNA
complex stability (Wee et al., 2012).
Initially, approaches for identifying miRNA targets have been largely based on seed re-
gion base pairing (Rehmsmeier et al., 2004; Krek et al., 2005; Miranda et al., 2006; Betel
et al., 2008). Other factors such as evolutionary conservation of the target sequence (Fried-
man et al., 2009; Obermayer and Levine, 2014) and target site accessibility were consid-
ered (Kertesz et al., 2007). Each of the aforementioned algorithms operate on independent
web servers providing users with the option to search for predicted targets, but yield a large
proportion of false-positive results (Yue et al., 2009). By comparing the expression pro-
files of miRNAs and their candidate mRNA targets using a microarray or sequencing data
sets, MirZ (Hausser et al., 2009) offered a way for reducing some of the false-positive re-
sults. The combined analysis from multiple algorithms can be used to predict miRNA-target
relations, however the accuracy of such predictions remain still limited. More accurate tar-
get identification would involve AGO2 immunoprecipitation, or a combined approach to
wide-scale protein expression and miRNA and mRNA gene expression analysis in order
to improve positive target discovery rates (Yue et al., 2009). The latter analysis technique
– utilising chromatography separation and tandem mass spectrometry for protein quantifi-
cation, sequencing of the miRNA and mRNA expression – has been used in more recent
studies by Clarke et al. (2012) and Li et al. (2015). Despite the involved expense of the com-
bined -omics techniques limiting the amount of studies published containing genome- and
proteome-wide data sets, such data sets yield results that are directly relevant to the studied
model system and are ideal for computational model development of miRNA-gene regula-
tory networks, with different techniques in molecular biology benefiting different stages of
data analysis, target identification (Yao et al., 2015) and understanding of miRNA-mediated
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gene regulation (Baek et al., 2008; Eichhorn et al., 2014).
1.2.4 miRNA networks
High-throughput data that is obtained from gene, miRNA and protein profiling experiments
provides essential information for the investigation of regulatory networks involved in the
studied biological system. The high quantity of gathered data from biological experiments
requires a computer-aided approach to process and analyse data. As a single miRNA can
negatively regulate multiple gene targets by complimentary binding, it affects multiple cel-
lular processes at once, linking it into a wider network of processes regulated through a
complex network of feed-back and feed-forward loops controlling mRNA and protein ex-
pression (Shalgi et al., 2007; Sengupta and Bandyopadhyay, 2013).
The perturbation of the miRNA-mediated silencing on gene expression has down-stream
effects: the direct target of the miRNA is perturbed, followed by the effect of initial target-
perturbation which may be involved in the regulation of multiple gene transcriptional events
leading to a phenotypic change in cell biology. For example, miR-132 regulates the tran-
scription of RASA1 (Anand et al., 2010), which in turn allows for the activation of Ras,
triggering the endothelial cells to form vessels. In such cases, miRNAs have temporally
separated effects on their targets, and simply considering direct miRNA-target impact on
differential gene expression would be insufficient to identify miRNA-target regulation pat-
terns. To address the propagation of miRNA-mediated regulation utilising genome-wide
studies, a network propagation based method has been proposed (Wang et al., 2014).
On the other hand, multiple miRNAs can potentially regulate 2 distinct regions of a
single mRNA target, giving rise to cooperative miRNA regulation. Through the use of
modelling and simulation of two miRNA binding to a single mRNA, Schmitz et al. (2014)
have proposed a model of potential miRNA-mRNA triplexes. The synergistic regulation of
miRNA targets would contribute to the idea that miRNAs act as fine-tuners of global gene
expression in the context of a gene regulatory network, and nearby miRNA target sites have
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been suggested to allow silencing complexes to interact in a cooperative manner (Sæ trom
et al., 2007).
The complex nature of disease development and progression involves a large set of in-
volved genes and miRNAs, and has been extensively used in understanding cancer regula-
tory networks (Zhang et al., 2014b; Ding et al., 2015). A lot of the aforementioned studies
investigating miRNA-gene regulatory networks utilise the power of web servers that contain
information about gene regulatory patterns (Kanehisa et al., 2014) and enable them to per-
form gene ontology enrichment analysis (Ashburner et al., 2000). The availability of online
tools provides multiple platforms for the identification and studying of miRNA targets and
their involvement in gene regulatory networks; modelling that aims to investigates the dy-
namics of such networks is described in the following section on Modelling and Simulation.
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1.2.5 miRNAs in LECs
Lymphatic Endothelial Cells (LECs) can be identified by their expressed lineage specific
markers – Lymphatic Vessel Endothelial Hyaluronan Receptor (LYVE1) (Banerji et al.,
1999), Podoplanin (PDPN) (Breiteneder-Geleff et al., 1999), Prospero Homeobox protein
1 (PROX1) (Wigle and Oliver, 1999) and Vascular Endothelial Growth Factor Receptor 3
(VEGFR3) (Veikkola et al., 2001) – and differentiate as a result of Vascular Endothelial
Growth Factor C (VEGFC) induced signalling (Karkkainen et al., 2004). They form an
extensive network of the lymphatic vasculature, lining the vessels with a single cell layer
that has loose junctions to allow fluid and cell uptake and trafficking in a unidirectional
manner. The lymphatic vasculature functions as a trafficking platform for immune cells and
a drainage system for collecting and diverting excess interstitial fluid (Karkkainen et al.,
2004). LECs play an important role in lymphangiogenesis and in the recruitment of immune
cells (Johnson and Jackson, 2010). From a disease perspective, the lymphatic vasculature
is exploited by cancers as a pathway for metastasis (Alitalo, 2011). The involvement of
miRNAs in the interactions of maintaining the normal function of LECs has been a focus of
recent studies and its implication in cell biology is summarised in this section.
1.2.5.1 miRNAs important for endothelial cell function
Many miRNAs have been described to function as regulators of gene expression programmes
in LECs. Studies have demonstrated the involvement of endothelial cell expressed miRNAs
in the positive (Anand et al., 2010; Chen and Gorski, 2008; Kuehbacher et al., 2007; Nicoli
et al., 2012) and negative (Poliseno et al., 2006; Sabatel et al., 2011) regulation of vascular
angiogenesis.
Other miRNAs, such as miR-126, are abundantly expressed in endothelial cells and also
play a pivotal role in controlling endothelial cell migration, proliferation and angiogene-
sis (Fish et al., 2008; Wang et al., 2008). Several miRNAs are involved in controlling LEC
phenotype by regulating the expression of lineage specific marker PROX1 (Kazenwadel
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et al., 2010; Pedrioli et al., 2010).
1.2.5.2 miRNAs expressed in LECs involved in tumour growth
The miRNAs present in endothelial cells are important for LEC function, and the dysregu-
lation of these miRNAs result in uncontrolled cell proliferation and vessel growth. Vascular
Endothelial Growth Factor (VEGF), a positive regulator of angiogenesis has been shown to
be under the regulation of miR-15b and miR-16 in cells subject to hypoxic environment dur-
ing tumour angiogenesis (Hua et al., 2006). The miR-17-92 cluster targets anti-angiogenic
factors to enhance neovascularisation and growth of vessels in tumours (Dews et al., 2006).
Interestingly, miR-126, also shown to suppress the expression of VEGF (Fish et al., 2008;
Zhu et al., 2011), has been a major focus for a large amount of cancer studies where it
was mostly found to be down regulated (Ebrahimi et al., 2014). The role of miR-221 in
endothelial cells has been shown to both oppose (Poliseno et al., 2006) and promote angio-
genesis (Nicoli et al., 2012), and in addition in cancer cell lines it has been found to target
p27, a cell cycle inhibitor, promoting the proliferation of tumour cells (le Sage et al., 2007),
suggesting a diverse role for miR-221 in context dependent regulation.
1.2.5.3 miR-132 biology
The miR-132/212 cluster is co-transcribed as a primary transcript from the intergenic region
of chromosome 17p13.3. The sequence of the 3’-arm of the miR-132 duplex (miR-132-3p)
has confirmed miRNA target sites for several genes described below. Although miR-212 is
co-transcribed with miR-132, sharing the seed sequence and potential predicted targets, its
expression is relatively low compared to miR-132 (Lagos et al., 2010).
The expression of miR-132 in LECs is low, compared to other miRNAs, such as miR-126
and miR-21 (Lagos et al., 2010). Vo et al. (2005) were first to note that miR-132 expression
can be induced by Brain-Derived Neutrophic Factor (BDNF). The upregulation of miR-
132 was shown to be a consequence of cAMP-Response Element Binding protein (CREB)
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phosphorylation at Ser-133 (Gonzalez and Montminy, 1989). The function of miR-132 was
demonstrated in neurons by Vo et al. (2005) by targeting Rho GTPase Activating Protein
32 (p250GAP). Subsequently, it was shown that miR-132, although important in neuronal
development and function (Impey et al., 2010; Wayman et al., 2008), was not critical for
development in mice (Remenyi et al., 2010). The latter authors also demonstrated that
phorbol myristate acetate (PMA) and lipopolysaccharide (LPS), just like BDNF are both
able to stimulate miR-132 expression.
Several other targets have been since demonstrated to be suppressed by miR-132 up-
regulation. The cycling of miR-132 expression was observed during light-exposure driven
regulation of CREB, which downstream activated miR-132 transcription (Vo et al., 2005),
where through the combined activity with miR-219 it functioned to regulate the circadian
rhythm in a light-dependent manner targeting Period Circadian Clock 1 (Per1) gene expres-
sion (Cheng et al., 2007). In addition, Alvarez-Saavedra et al. (2011) demonstrated that
in the mouse suprachiasmatic nucleus (SCN), miR-132 regulates chromatin remodelling
by direct targeting of Lysine (K)-Specific Demethylase 5A (Jarid1a), Methyl CpG Binding
Protein 2 (Mecp2), E1A-associated Protein p300 (Ep300) and modulates translation control
through its direct targeting of Polyadenylate-binding Protein-Interacting Protein 2 (Paip2)
and B-cell Translocation Gene 2 (Btg2). These studies revealed that miR-132 fine-tunes the
expression of many targets involved in pathways that govern mammalian circadian rhythms.
During cell activation, miR-132 has found its role as a regulator of EP300 (Lagos et al.,
2010), a transcriptional co-activator that binds the phosphorylated form of CREB to activate
miR-132 transcription. In the context of a viral infection, the inflammatory response genes
are regulated through the activity of the pCREB-EP300 transcription complex, where miR-
132 acts to modulate the innate immune response based on miR-132 abundance over its
time-course of expression (Lagos et al., 2010). In addition, Acetylcholinesterase (AChE)
has been demonstrated as a target of miR-132 (Shaked et al., 2009), with the ability to
attenuate inflammation during cell activation.
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The function of miR-132 has also been demonstrated in the regulation of heart func-
tion, where miR-132 suppression of Forkhead Box O3 (FOXO3) was necessary to modulate
recovery from cardiac hypertrophy (Ucar et al., 2012). In addition miR-21, miR-212 and
miR-129 have previously been demonstrated to be involved in cardiomyocyte function, sug-
gesting an important role for miRNA-mediated regulation (Thum et al., 2007). As miR-212
is co-expressed with miR-132, both miRNAs may play a role in cardiomyocyte function.
Finally, the development of vasculature has been shown to be under the control of miR-
132, where it targets RASA1 (encoding p120RasGap) and thereby enables Ras activity to
promote endothelial cell proliferation and angiogenesis (Anand et al., 2010).
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1.3 Modelling and Simulation
The interactions that exist between molecules in the cell take place from less than a second
time scale, are dynamic in nature, and result in complex systemic behaviour. The intracel-
lular molecular interactions that result in the non-linear behaviour can be best understood
using computational modelling (Wolkenhauer et al., 2005). Capturing regulation of molec-
ular processes at the subcellular level allows to identify the regulatory properties of the par-
ticipating molecular components, the impact of their interactions, and provides information
about the abundance of molecules that drive cellular responses.
1.3.1 Mathematical modelling
A biological system can be captured following a deterministic or a stochastic modelling ap-
proach (Gillespie, 1977). A deterministic component of a model can be described using an
Ordinary Differential Equation (ODE), or a Partial Differential Equation (PDE) where the
component needs to be spatially separated into discrete locations. In case of a subcellular
model, molecules can be described as a system of coupled ODEs or PDEs. These type of
approaches are useful for simulating system level dynamics where the abundance of partici-
pating components are present in a high abundance (Khan et al., 2003). However, in order to
better capture reactions where a low abundance of components can have system-wide effects
(such as miRNA-mediated control of a low-expressed mRNA translation resulting in magni-
tudes larger abundance of protein molecules), a stochastic approach needs to be considered
due to the random perturbations that can occur during these regulatory steps (Sreenath et al.,
2008). Kinetics of stochastic biochemical networks can be captured using Stochastic Dif-
ferential Equations (SDEs) (Alves et al., 2006), where each molecule can be considered as
an independent entity and separated in both time and space.
Models that utilise stochastic approaches require a deeper understanding of the under-
lying biology and assume that the numerous parameters that describe the model system of
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biology do not change during the simulation time. The power of stochastic simulations lies
in the more accurate representation of a biological system, with an increasing cost to com-
putational time with the increase in parameter and component count: a subcellular model
describing biochemical reaction networks can capture thousands of individual entities sim-
ulated over continuous time and space.
1.3.2 Agent-based modelling
Although mathematical models of complex biochemical networks have been used in mod-
elling biological phenomena, they require an large set of parameters determining each of the
kinetic reactions. Whilst this may be feasible for small-scale models of biological processes,
mathematical models are limited by the availability of kinetic information for large-scale
models (Acerbi et al., 2012). Moreover, the small abundance of some of the molecule com-
ponents, such as the abundance of miRNAs (Lee et al., 2008) and specifically – abundance
of miR-132 in LECs (Lagos et al., 2010), can significantly affect system dynamics (Pogson
et al., 2006).
In order to resolve some of the aforementioned issues with mathematical modelling,
an agent-based model (ABM) framework can be used. In ABMs, each entity, or agent,
is provided a set of simple rules which describe its behaviour in an environment. There
are several features to an agent that make ABMs a powerful tool for capturing biological
phenomena (An et al., 2009):
1. Each agent is an autonomously acting entity which responds to environmental cues
2. Each agent contains its own set of parameters allowing heterogeneity on the scale of
a single entity (e.g. no cell in biology is identical)
3. Some of the system parameters can be abstracted, allowing qualitative hypothesis
testing of a domain, where knowledge is incomplete
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4. The modularity of an ABM allows to build systems that span multiple scales of de-
tail, providing an appropriate abstraction for each organisational level of biology (e.g.
organ, cellular, molecular level) that are easily extensible (e.g. addition of a new type
of cell as an agent with its own behaviour)
5. The interactions between agents are inherently resolved in a spatio-temporal man-
ner (e.g. allowing for time-delayed effects) and the resulting behaviour is implicitly
stochastic
6. The heterogeneous distribution of entities and their individual properties as defined by
their parameters are more naturally resembling the heterogeneity present in biological
systems
ABMs have been successfully used in biology to capture complex biological phenomena
in immunology (Read et al., 2012; Alden et al., 2012; Moore et al., 2013), cancer develop-
ment (Pappalardo et al., 2011), mRNA transport (Azimi et al., 2014) and more recently in
molecular interaction networks (Williams, 2014). To date, only a single ABM has been de-
scribed by Ripoli et al. (2009) that involves two negative feedback loops between miR-221
and miR-222, and their target CD117 in endothelial cells.
1.3.3 Modelling miRNA regulatory networks
Whilst only a single example of a miRNA-regulatory network has been found using an ABM
approach (Ripoli et al., 2009), there has been a myriad of studies investigating the function
of miRNAs in cell biology. The methods involved in investigating miRNA-regulatory net-
works range from analytical methods that predict target regulation and infer networks (Gen-
narino et al., 2012; Sengupta and Bandyopadhyay, 2013; Weber et al., 2013; Aure et al.,
2015), study general miRNA role and function (Sæ trom et al., 2007; Zinovyev et al., 2013;
Obermayer and Levine, 2014; Schmitz et al., 2014) to specific miRNA-mRNA target mod-
elling (Schuetz et al., 2012).
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Most relevant to the work presented in this thesis, Schuetz et al. (2012) combine an
ABM approach with a set of 17 ODEs to describe a model of tumour growth. In Schuetz
et al. (2012) model, the molecular interaction network model of miR-451, Liver Kinase B1
(LBK1) and 5’-AMP-activated Protein Kinase Catalytic Subunit α-1 (AMPK1), previously
published by Godlewski et al. (2010), is incorporated into a cell-based agent system, where
the subcellular network interactions described by ODEs determine the function of the cell
agent. Whilst this is a novel model involving a miRNA in an ABM, the subcellular level
of interactions are not represented as a network, making the interactome subject to possible
system dynamics inaccuracies (Pogson et al., 2006). Moreover, their work has not pre-
sented a fully calibrated system, with no statistical evaluation of the model parameter space,
although conclusions from the in silico simulation were proposed. Additionally, no methods
describing the development rationale of the ABM were provided, highlighting the continued
need to establish good model development, validation and verification standard in the field
of computational biology.
1.3.4 Modelling process
Computational models that capture biology can only be as accurate as our understanding of
the biological system. Importantly, computational models should be used to aid the under-
standing of a specific biological process, integrated into a wet-lab and simulation coupled
approach. The need for such development life cycle in studying biological systems was
drawn attention to by Kitano (2002), who suggested that modelling and experimental work
should progress hand in hand, allowing models to be used as predictive tools for further
experimental studies in biology.
Designing a biological experiment involves several key stages: the understanding of the
problem domain and its constituents, the design of an experiment that would address a hy-
pothesis, the necessary tools required to perform the experiment, and the appreciation for
limitations of the experimental approach including the sources of error. Similar to this ap-
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proach, a computational model requires the understanding of the domain it is modelling,
driven by a defined hypothesis that the model is expected to address, which in turn is limited
by the constituents involved in the setup of the model, imposing limitations on what the
model can tell us about the biological system. In line with these principles, the Complex
Systems Modelling and Simulation (CoSMoS) process has been developed (Andrews et al.,
2010a), providing a framework for designing, developing and exploring complex systems.
The stages of the project development are described in detail under Modelling and simula-
tion of biological systems (Section 2.2). The CoSMoS modelling process has proven to be
an effective and transparent framework for the developing of several other complex biolog-
ical processes (Read et al., 2012; Alden et al., 2012; Moore et al., 2013), and has been used
to coordinate the research investigating miR-132 regulation of AGO2 and EP300 in LECs.
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1.4 Thesis aim
The aim of this work is to characterise the interaction between miR-132 and human AGO2
by perturbing the expression of miR-132 and AGO2 in Human Dermal Lymphatic Endothe-
lial Cells (HDLECs) (Chapter 3). The regulation of AGO2 and EP300 (Lagos et al., 2010),
both targets of miR-132, is captured in an ABM (Chapter 4) in order to understand the
emergent properties of this regulatory network (Chapter 5).
Chapter 2
Materials and methods
2.1 Cell and molecular biology approaches
2.1.1 Cell culture
Cells were cultured in a humid environment at 37°C, 5% CO2. Cryopreserved cells stored in
1:10 dimethyl sulfoxide (DMSO) (Sigma-Aldrich)-fetal calf serum (FCS) (Sigma-Aldrich)
were thawed in a water bath (37°C) and added to a Ø10 cm plate containing 8ml of appro-
priate pre-heated media. After 5 to 6 h the cells were washed with phosphate-buffered saline
(PBS) and the appropriate fresh media was replenished.
2.1.1.1 LECs
HDLECs were purchased from Promocell (C-12219), grown in Endothelial Cell Growth
Medium MV ready-to-use (Promocell, C-22020) and supplemented with 10 ngml−1 Re-
combinant Human VEGF-C (R&D Systems, 2179-VC-025). Supplemented media was
changed every 24 to 48 h.
A single vial containing ~5× 105 HDLECs were grown from passage 0 and cryopre-
served in liquid N2 at passages 2, 3, and 5 in a 1ml volume at 5× 105 cellsml−1. Cells were
frozen at -80°C, 24 h prior to cryopreservation. Passage 5 cells were used for all experi-
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ments. Passage 2 and 3 cells were expanded to passage 5 for later experiments when needed.
The HDLECs were tested for LYVE1 expression as a determinant of LEC lineage (Banerji
et al., 1999), showing that LYVE1 was highly expressed in HDLECs compared to Human
Foreskin Fibroblasts (HFFs) (Figure 2.1). The LEC marker confirmation was performed by
Daniel Yee (University of York, UK).
Figure 2.1: Comparison of the expression of LYVE1 mRNA in HFFs and LECs (n = 1).
Sub-confluent cells (80-90%) were split between 2-4 plates dependant on cell count.
The cells were washed with PBS, and incubated for 5min at 37°C with 4ml pre-warmed
1:5 trypsin-EDTA (Invitrogen) and PBS mix. Trypsin-EDTA was neutralised with 4ml
of media, and the cells were pelleted by centrifugation for 5min at 260 g. Resuspended
HDLECs were seeded at 5× 105 per Ø10 cm plate (BD Falcon™).
2.1.1.2 HeLa cell line
HeLa cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen),
supplemented with 10% FCS and 1% of 100 µgml−1 penicillin G and 100 µgml−1 strepto-
mycin (Invitrogen). Cells were split 1:4 every 48 to 72 h grown in Ø10 cm plates.
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2.1.2 Treatments
For all treatments cells were seeded in 6-well plates (BD Falcon™) at 6× 104 cells per well
and grown for 16 h before any treatment.
2.1.2.1 PMA
A 5mM stock of PMA (Sigma) was prepared in DMSO. Next, aliquots of 5 µM PMA diluted
in basal LEC media (without supplements) were stored. Aliquots of 1:1000 DMSO in basal
media were prepared as a control. HDLECs were treated with 25 nM PMA or the DMSO
control unless stated otherwise. Stand alone PMA treatments were done 16 h after plating,
and 48 h after transfections or transductions described below.
2.1.2.2 siRNA, mimics and inhibitors transfections
The transfection mix was prepared using Opti-MEM (Invitrogen), TransIT-siQUEST (Mirus)
and the respective nucleic acid (see Table 2.1), following the manufacturer’s instructions.
The final volume of the transfection mix in each well was 800 µl. 5 to 6 h post-transfection
1ml of LEC media was added. 24 h after the transfection the cells were washed with PBS
and replenished with fresh media.
Table 2.1: Transfected nucleic acid products and used concentrations.







mimic miRIDIAN microRNA mimic
NTC
miR-132
inhibitor 100 nM miRIDIAN microRNA hairpin inhibitor
NTC
miR-132
LNA inhibitor 50 nM miRCURY LNA™ microRNA inhibitor
NTC
miR-132
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2.1.2.3 Lentiviral transductions
The used lentiviral constructs were provided by Dimitris Lagos, produced as described
in Lagos et al. (2010). The miR-132/miR-212 cluster and AGO2−UTR were amplified from
genomic DNA and cDNA respectively and subcloned into the pSIN lentiviral vector using
the NotI and BamHI restriction enzymes. For lentiviral transduction, virions were produced
as described in Lagos et al. (2008).
Prepared lentiviral constructs were incubated with cells for 6 h in a total volume of 800 µl
per well. Unless stated otherwise, the amount of lentivirus added per well was 20 µl for
AGO2 and 400 µl for miR-132 overexpression experiments. Cells infected with miR-132
and AGO2−UTR constructs were harvested after 48 h or 30 h, respectively.
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2.1.3 Molecular biology techniques
2.1.3.1 Tissue homogenisation
Mouse brain and spleen tissue used for RNA and protein analysis were provided by Mark
Coles’ group (University of York, UK) from 6-8 weeks old C57BL/6 and miR-132 -/- KO
mice (Magill et al., 2010). The extracted brain tissue was supplied frozen in one piece.
Each brain tissue sample was cut over dry ice into similar sized chunks (<30mg) for RNA
and protein extraction. The prepared samples were homogenised on a TissueLyser LT (Qi-
agen) device for 3min at 50Hz in 1ml of appropriate solution using two beads per tube.
QIAzol Lysis Reagent (Qiagen) was used for homogenising tissue for RNA analysis and
radio-immunoprecipitation assay (RIPA) lysis buffer (for recipe see Protein extraction and
quantification Section below) was used for homogenising tissue for protein analysis.
2.1.3.2 RNA extraction
A dedicated RNA extraction workspace was used for all RNA extractions. RNaseZap RNase
(Ambion) was used to wipe down the workspace surfaces and pipettes prior to sample pro-
cessing. The miRNeasy Mini Kit (Qiagen) was used for all total RNA extractions. Extra
RNAse-free Microfuge tubes (Ambion) were purchased for carrying out the extraction pro-
tocol and storing the samples.
The cells in each well were lysed using 700 µl of QIAzol, collected into 1.5ml Eppendorf
tubes and frozen at -80°C for at least a few hours. The lysed cell samples were processed
according to the manufacturer’s instructions and eluted in 30 µl of RNAse-free H2O. The
DNAse I digestion step was only carried out for mouse tissue samples.
The extracted RNA quality was measured on the NanoDrop ND 1000 (Thermo) using
1 µl of eluted RNA. Samples with an absorbency measure of >2.0 for A260/A280 were
used for further analysis, suggesting that the sample contains a higher proportion of RNA
(purity). Most samples had a recommended A260/A230 value in the range of 1.8-2.0. Due to
low yield of RNA as a result of treatment conditions and cell viability, some samples showed
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lower A260/A230 values; this was the case with samples where the yield of nucleic acids
from extraction were very low (<20 ng µl−1 and the 230 peak which measures presence of
contaminants such as phenol gave a higher signal than the 260 peak (indicates nucleic acid
presence)). Subsequent to cDNA synthesis and quantitative reverse transcription polymerase
chain reaction (qRT-PCR) the results replicated previously collected experiments and could
be reliably used.
2.1.3.3 cDNA synthesis
The extracted RNA concentration used for polyadenylated and random hexamer cDNA syn-
thesis was typically ~100 ng µl−1. Mouse sample RNA was diluted to a similar concentration
range. For miRNA cDNA synthesis the RNA was further diluted to 1 to 5 ng µl−1.
The cDNA synthesis of polyadenylated RNA was done by incubating 1 µl of RNA for
6min at 70°C with 1 µl of 5 µM oligo(dt) and 1 µl of 10 µM dNTP made up to 12 µl of total
volume with ddH2O per reaction mix. Samples were chilled on ice before adding a mix of
4 µl of 5x First-Strand Buffer (Invitrogen), 2 µl of 0.1 M DTT (Invitrogen), 1 µl of RNase-
OUT (40 units, Invitrogen) and 1 µl of SuperScript II (200 units, Invitrogen). Samples were
incubated at 40°C for 1 h and finally heated at 70°C for 10min to inactivate SuperScript II.
To reverse transcribe primary miRNA transcripts, 1 µl of RNA was incubated at 65°C
for 6min with 1 µl of 50 ng µl−1 random hexamers and 1 µl of 10 µM dNTP made up to 10 µl
of total volume with ddH2O per reaction mix. Samples were chilled on ice before adding a
mix of 2 µl of 10x First-Strand Buffer (Invitrogen), 4 µl of 25mM MgCl2 (Invitrogen), 2 µl
of 0.1 M DTT (Invitrogen), 1 µl of RNaseOUT (40 units, Invitrogen) and 1 µl of SuperScript
III (200 units, Invitrogen). Samples were incubated at 25°C for 10min, 50°C for 50min
and finally heated at 85°C for 5min to inactivate SuperScript III.
miRNA cDNA synthesis was performed using the TaqMan® miRNA Reverse Transcrip-
tion Kit (Applied Biosystems). Following manufacturer’s instructions, a master mix was
prepared using the supplied 4.16 µl of ddH2O, 1.5 µl of cDNA synthesis buffer, 0.15 µl of
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dNTP mix, 0.19 µl of RNAse inhibitor and 1 µl of Reverse Transcriptase, giving a final vol-
ume of 7 µl per reaction. 5 µl of diluted RNA (1 to 5 ng µl−1) was mixed together with 2 µl of
miRNA specific reverse transcription primers. Samples were then chilled on ice for 5min,
followed by an incubation at 16°C for 30min, 42°C for 30min and finally heated at 85°C
for 5min to inactivate the reverse transcriptase.
Prepared cDNAs were chilled on ice and stored at -20°C.
2.1.3.4 Real-time qRT-PCR
Expression levels of target sequences were quantified by qRT-PCR press using SYBR Green
(Applied Biosystems) and TaqMan primers (Applied Biosystems), detailed in Table 2.2,
designed with the aid of the online service Universal ProbeLibrary Assay Design Center
(Roche). Primers were used at 300 nM final concentration with typically 1 µl of neat cDNA
in a final volume of 20 µl per reaction. The MicroAmp Optical 96-well Reaction and Mi-
croAmp Fast Optical 96-Well Reaction (Applied Biosystems) plates were used on the Ther-
mal Cycler 7500 System (Applied Biosystems) and the StepOnePlus™ Real-Time PCR
System (Applied Biosystems), respectively. The plates were sealed using the MicroAmp
Optical Adhesive Film (Applied Biosystems) and briefly pulsed to 300 g prior to the qRT-
PCR. The default program for 40 cycles of amplification was used. GAPDH was used as
a loading control for target gene mRNAs, pri-miR-126 and pri-miR-132. RNU6 was used
as a loading control for all mature miRNAs. The relative change in target expression was



























Table 2.2: Real-time qRT-PCR primers and assays. Asterisk (*) indicates that these are mouse-specific primers. TaqMan primer
sequences marked as not applicable (N/A) as they are supplied with the product data sheet.
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2.1.3.5 Protein extraction and quantification
RIPA lysis buffer was used for all protein extractions, supplemented with phosphatase and
protease inhibitor cocktails (Sigma) that were only added immediately before lysis. The
recipe is detailed below:
RIPA lysis buffer:
25mM Tris•HCl, pH 7.2
150mM NaCl
0.5% (w/v) Triton X-100 (Sigma)
1% (w/v) sodium deoxycholate
0.1% (w/v) sodium dodecyl sulphate (SDS)
0.1% (w/v) ethylenediaminetetraacetic acid (EDTA), pH 8.0
The cultured cells were washed with PBS (37°C) and all of the PBS was removed using
a P1000 pipette by tilting the plate under an small angle. The plate was transferred onto
ice. Typically, 30 µl of RIPA lysis buffer was added per well and spread using a cell scraper.
Next, the plate was placed under an angle and the cell scrapper was used to collect the cell
lysate at the bottom of the well. The lysate was then transferred to a 0.5ml Eppendorf tube
and kept on ice. The lysates were centrifuged at 10 000 g for 10min to pellet the cellular
debris. The supernatant was transferred to a new Eppendorf tube and stored at -80°C.
Mouse samples that were homogenised in RIPA lysis buffer (see the Tissue homogeni-
sation Section above) were centrifuged at 10 000 g for 10min two times. After the first
centrifugation the sample separated into three distinct phases: the upper white few mm
thick lipid layer, the middle predominantly aqueous protein lysate layer, and the bottom
layer containing intracellular and extracellular debris, and the two metal beads used during
homogenisation. 800 µl of the lysate was transferred to a new Eppendorf in order to avoid
carryover of debris and lipids. After the second centrifugation the remaining debris was
pelleted and a final volume of 700 µl of protein lysate was kept and stored at -80°C.
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Protein concentration was measured using the Pierce BCA Protein Assay kit (Thermo
Scientific). The standard curve was prepared by serial diluting (6 times) the Albumin Stan-
dard ampoules provided with the kit that contained 2mgml−1 of bovine serum albumin
(BSA). A 1:4 dilution of HDLEC and HeLa protein lysates and 1:40 dilution of mouse brain
protein lysates was prepared in ddH2O. The samples were pipetted into a 96-well Maxisorp
Multiwell plate (Sigma) in duplicate, and incubated at 37°C for 90min with 200 µl of BCA
reagent mix per well, prepared according to the manufacturer’s instructions. The absorp-
tion was measured at 562 nm and the protein concentrations calculated against the standard
curve.
2.1.3.6 Western blotting
Protein lysates were prepared in 4x SDS-polyacrylamide gel electrophoresis (SDS) sample
loading buffer (recipe below) and topped up with ddH2O to the same final volume. Cultured
cell lysates and mouse sample lysates were prepared at 1 µg µl−1 and 2 µg µl−1 of protein,
respectively.
SDS-PAGE sample loading buffer:




0.05% (w/v) bromophenol blue
The proteins were separated on 0.75mm thick 8% polyacrylamide gel in SDS-PAGE
running buffer (National Diagnostics) using the Mini-PROTEAN Tetra Handcast Systems
(Bio-Rad), typically for 1.5 h at 120V. The recipe for the stacking and the resolving gel is
detailed below:
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4% stacking gel:
3ml dH2O
0.67ml 30% (w/v) acrylimide
1.25ml 1.5 M Tris, pH 6.8
50ml 10% (w/v) SDS




2.13ml 30% (w/v) acrylimide
2ml 1.5 M Tris, pH 8.8
80ml 10% (w/v) SDS
80ml 10% (w/v) APS
8ml TEMED
Prepared protein samples for SDS-PAGE were denatured by heating at 95°C for 5min,
prior to loading. Empty lanes were loaded with 1x SDS-PAGE sample loading buffer. Fer-
mentas Protein Ladder Pageruler Plus Prestained (Thermo Scientific) was diluted 1:1 with
the 1x SDS-PAGE sample loading buffer. Each lane was loaded with 12 µl of sample.
Protein was transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore) at
0.2A and a maximum of 25V for 75min using a semi-dry transfer apparatus (Bio-Rad) and
transfer buffer (National Diagnostics). Prior to transfer the PVDF membrane was activated
by immersing in methanol for 1min, followed by dH2O for 1min and transfer buffer for
5min. Membranes were blocked in 5% (w/v) BSA-TBS/T (see TBS/T recipe below) for 1 h
at room temperature on a gently rocking platform.
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10x TBS, pH 8.0
87.65 g Tris
12.2 g NaCl
dissolved in final volume of 1 l dH2O




0.1% (v/v) Tween-20 (Sigma)
After blocking the PVDF membranes were placed in 50ml Falcon tubes and incubated
at 4°C with 10ml of 1° antibody (see Table 2.3 for used antibodies) overnight on a gen-
tle roller. Following the 1° antibody incubation the membranes were washed three times
for 5min each time in TBS/T on a gently rocking platform. Next, the membranes were
incubated at room temperature in the appropriate horse-radish peroxidase conjugated 2° an-
tibody for 1 h on a gently rocking platform, followed by the three TBS/T washes. Finally,
the membranes were incubated for 5min in the ECL Western Blotting reagent (GE Health-
care) in the dark. The chemiluminescence signal was detected on the Hyperfilm ECL (GE
Healthcare). After detection the membranes were washed three times as before and re-used
for more target detections: the membranes were blocked again in 5% (w/v) BSA-TBS/T
or, if necessary, stripped using a stripping buffer (Thermo Scientific) at 37°C for 30min on
a shaking platform. After stripping the membranes were washed several times with dH2O,
followed by three 5min washes with TBS/T. Used membranes were briefly placed on What-
man paper to soak up excess liquid, wrapped in cling film and stored flat at -20°C.
The films were scanned in at 600DPI and the signal of each band was quantified using
ImageJ. Each target band signal was normalised to the corresponding lane loading control
(β-actin or GAPDH).
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Table 2.3: Antibodies used for western blot detections.






87G3 phoshpo-CREB (Ser133) 1/1000
AB33 TIE2 1/500
4221S phoshpo-TIE2 (Tyr992) 1/500
Santa Cruz B4F8 RASA1 1/500







P0447 mouse IgG 1/5000
P0448 rabbit IgG 1/5000
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2.1.4 Cell viability assay
HDLECs were plated in 12-well plates (BD Falcon™) at 1.5× 104 cells per well and grown
for 16 h before any treatment. Cell viability was measured using the Colorimetric Cell
Viability Kit IV (PromoKine) at the desired time point after treatment. All of the media
from the wells was collected (per treatment condition) and used to prepare 40 µl of the
MTT reagent in 360 µl of media (37°C) per well. 400 µl of the MTT mix was returned to
each corresponding well and incubated at 37°C for 4 h. After the incubation with the MTT
reagent, 800 µl of DMSO was added per well and mixed by pipetting up and down several
times. After 5min 300 µl of the contents of each well was transferred in triplicate to a 96-
well Maxisorp Multiwell plate, and the absorbency was measured at 570 nm to obtain the
signal and at 630 nm to obtain the background readings. The normalised absorbency signal
was obtained by subtracting the background from the signal absorbency values.
2.1.5 Statistical analysis of biological data
Where applicable (sample n ≥ 3), the significance of the difference between experimental
conditions was determined by calculating the p-value using a two-tailed t-test. The differ-
ence was considered significant if p < 0.05 (indicated by *), p < 0.01 (indicated by **) or
p < 0.001 (indicated by ***).
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2.2 Modelling and simulation of biological systems
The tools and packages for developing, testing, and evaluating the models have been well-
established within the York Computational Immunology Lab (YCIL) group1. To ensure
good software development practices the standard protocols and applications have been doc-
umented by Dr. Kieran Alden (University of York, UK) and made available on the YCIL
intranet2. The steps involved and the software used in developing this model are outlined
within this section below.
2.2.1 Biological domain and simulation specification
”Essentially, all models are wrong, but some are useful.” ~ George E. P. Box
The biological domain in the context of the research question was explicitly defined
using the strategy described below. This allowed to establish the scope of the problem and
suggest possible hypothesis that could be tested by the model. The systematic approach for
developing models of biological systems was based on the CoSMoS process (Andrews et al.,
2010a,b), a conceptual framework for engineering complex systems. The CoSMoS process
schematic is described in Figure 2.2 which was used as a roadmap for model development.
2.2.1.1 Model specification
Once the problem domain, i.e. the biological context, was agreed upon with the domain
expert, it was captured in diagrams using the Unified Modeling Language (UML). The bi-
ological problem and the way system components3 interact was captured in pseudo-UML
expected behaviour diagram. This diagram represents the top-level mechanism and the
emergent behaviour that was expected of the model. The behaviour of each component was
1https://www.york.ac.uk/computational-immunology/
2https://www.york.ac.uk/computational-immunology/intranet/
3Defined as an abstracted object of the real world domain that is able to function based on input and output
information; e.g. a component in an ABM is an agent
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Figure 2.2: Model development cycle as defined by the CoSMoS process (Andrews et al.,
2010a).
then described in UML state diagrams. The actions and activities of the system compo-
nents were captured in UML activity diagrams. The diagrams allowed the representation of
concurrent actions that many components in biological systems often exhibit, such as when
several proteins need to interact before a product can be synthesised. The afore-mentioned
diagrams captured the necessary components to describe the biological domain within the
context of the scientific question and constitute the domain model.
The specifications for the implementation of an executable model were captured in the
platform model. Explicit parameter names and transitions conditions were used in the state
and activity diagrams for the platform model. Some concepts in the domain model were fur-
ther abstracted. Figure 2.2 suggests that the information flow is directed from the problem
domain towards the platform model, however decisions made when abstracting knowledge
from the domain model and appropriating it to the platform model suggested gaps in knowl-
edge in the domain model. This resulted in revisiting the problem domain and updating
the domain model and consequently the platform model. Although the workflow shown in
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Figure 2.2 is goal-oriented towards completing the full cycle of model development, the
Research Context interface allows the revision of earlier modelling steps when necessary.
2.2.1.2 Notation in state and activity diagrams
The state and activity diagrams are captured using standard UML notation. However, there
are some non-standard notations. For clarity, the full key to the diagrams is described below:
Rounded rectangle State diagrams: Contains the state of the component; an encapsulated
rounded rectangle within another state suggests a sub-state
Solid circle Starting point of the component - from a model perspective, this is where the
component is instantiated
Solid circle with an inner white line End point of the component - from a model perspec-
tive, this is where the component is removed
Arrow Displays the direction of the state or activity transition
Text next to an arrow Describes the condition for the state or activity transition (together
with the Arrow, it is commonly known as a ”guard”); text enclosed in ”[...]” refers
to specific conditions or parameters; text following a forward-slash ”/ ...” instructs a
parameter change upon the transition; text following ”& ...” suggests that the condi-
tion above within the same transition must be met simultaneously; ”>”, ”<”, ”==”,
”! =” refer to ”greater than”, ”smaller than”, ”equivalent to” and ”not equivalent to”,
respectively, and are used as part of a condition description
Diamond Activity diagrams: Arrows feeding into a diamond suggest a point where multiple
activities converge; Arrows pointing out of a diamond allow one of the activities to
take place depending on which transition condition is met
Thick solid line Activity diagrams: Arrows feeding into the thick solid line are prerequisite
conditions that need to be met for the emerging Arrow(s) activity to be triggered
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Dotted line Indicates that states on either side of the line act in parallel
2.2.1.3 Justification and model validation
The information gathered when studying the biological domain and performing wet-lab ex-
periments was used in justifying decisions made in the development of the domain and
platform models, and later also used part of validating the model against the real world
domain. Every component and interaction was documented and justifications were drawn
based on existing data from the lab and supporting evidence from literature.
2.2.1.4 Parametrisation
Finding values for each of the parameters in the model was done alongside the argumenta-
tion. Based on the platform model specification of parameters, a table was prepared with
approximate real world values and possible ranges using the sources in the argumentation
structure. Some of the parameters were chosen to form the baseline values against which
other model parameters would be calibrated (described under Statistical analysis and cali-
bration).
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2.2.2 Model development
The model was developed in the Java programming language using the latest JRE and JDK
(JVM version 1.7.0).
2.2.2.1 Modelling system
The model was developed using the Eclipse IDE (Kepler) which was supplied with Repast
Simphony (version 2.2) (North et al., 2013). Repast Simphony is an agent-based modelling
environment which was built based on its predecessor Repast 3 (North et al., 2006).
Based on the platform model specification a system architecture was developed and a
class structure was implemented (Figure B.1). Next, the model main class that builds the
simulation environment was implemented. The agent classes were developed sequentially
with basic functionality. Finally, more complex functionality with other agents was devel-
oped and refined. The model underwent several iterations to improve and refine readability,
and the code was appropriately documented. The Doxygen (van Heesch, 2012) tool was
used to compile the documentation.
2.2.2.2 Version control and distribution
Git (Torvalds and Hamano, 2005) was used as the version control system of choice, inte-
grated within the Eclipse IDE. During the model implementation at the end of each revision
cycle the state of the model was described in the commit notes, including known bugs and
suggested revisions. The source code was synchronised after each commit with the Bit-
Bucket repository4. The implemented model can be distributed as a stand-alone installer
and executed on any system with Java version 1.7 or later.
Due to many pitfalls discovered after developing a model using Repast Simphony (de-
scribed in detail in Section 4.6.2), the developed model has been packaged up5 for cluster
4https://bitbucket.org/gl524/mirnet.git
5https://bitbucket.org/gl524/mirnet/src/58bd98b6932968ffb83946dd36f5cad1aa7a7aaa/model package/
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execution together with necessary modifications to Repast Simphony and cluster execution
scripts. The Graphical User Interface (GUI) based installer supported on devices running
Java 7 or higher is also available in the same directory.
2.2.2.3 Code profiling and testing
The JVM Monitor (Eclipse Foundation, 2012) integrated with Eclipse IDE was used to
establish central processing unit (CPU) intensive parts of the model. The profiler was useful
at revealing other built-in Repast Simphony implementation pitfalls.
Exploratory testing was employed when developing the model. After every commit cycle
the updated and related code was reviewed and tested. The system components in the model
were loosely coupled allowing each of the individual components to be rigorously tested
during implementation. Effort was made to test individual system components as well as
perform integrated system testing. Although test-driven development was not employed in
the development of this model, the YCIL model development cycle should support effective
test-driven development in the future.
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2.2.3 Statistical analysis and calibration
Statistical analysis and evaluation of the model is a cyclic process that aims to understand
how the model behaves during various parameter perturbations. An overview of this pro-
cess is captured in Figure 2.3 The steps involved are described below using the Spartan
toolkit (Alden et al., 2013). Statistical analysis of the differences between treatments in sil-
ico was performed using the 2-sample Kolmogorov-Smirnov (K-S) test described in further
detail under Section C.6.
Figure 2.3: The work flow involved in calibrating a model to a baseline model subsequent
to domain, platform and executable model development. The calibration utilises two main
parameter space analysis techniques and the output is compared to a biological data set of
expected outcomes (also referred to as ”measures”), i.e. molecular abundance of miR-132.
The parameter set that matches all the measures can then be used as a baseline model to
drive hypothesis by performing in silico experimentation and further develop the model.
2.2.3.1 Simulation output
Stochastic simulations produce different output under the same starting conditions and using
the same parameter values. In computational simulations the stochastic nature of the model
output is defined by a Random Number Generator (RNG). In order to obtain exact replicate
simulation output the RNG must make the same choices each time it is used. Within a
simulation this can be set using a seed value that the RNG uses to compute the next value
for a function call. The simulation seed value in Repast Simphony is computed using the
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Mersenne Twister algorithm (Matsumoto and Nishimura, 1998). The seed must be set at
the start of the simulation by explicitly defining a static environment variable. This ensures
that the same seed value can be supplied in the parameter file when the exact simulation
run needs to be reproduced or tested. Simulations that differ by the seed parameter can be
statistically evaluated.
2.2.3.2 Aleatory uncertainty analysis
The impact of stochastic behaviour in a simulation needs to be understood before any further
analysis can be performed. As mentioned earlier, the output of any two non-deterministic
simulations that only differ by a seed will produce different output, creating uncertainty
in the simulation response outcome (Helton, 2008). In order to reduce uncertainty that
is due to the RNG alone, many simulation runs need to be performed. The method for
estimating the minimum amount of simulation runs required to reduce the uncertainty of
the simulation output, also known as aleatory analysis, has been previously described (Read
et al., 2012). Aleatory analysis is done by evaluating the uncertainty in an increasing amount
of simulation runs, measuring the output variation of having a specific amount of simulation
runs using the A-Test score (Vargha and Delaney, 2000). The simulation can enter the
calibration cycle after completing the aleatory analysis, where each new combination of
simulation parameters will be used to execute a simulation with a different seed the amount
of times required to keep the uncertainty of simulation output to an accepted minimum.
2.2.3.3 Calibration
Depending on the amount of parameters that need to be calibrated and the complexity of the
model, calibration of a stochastic simulation is currently one of the most time-consuming
processes in computational modelling. The parameters that are specified in the model are
derived from two main sources:
• parameter values based on published or unpublished experimental data
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• parameter values introduced at the platform model development stage that represent
an element of the real-world domain or an abstraction
Some parameters of the model are considered to be exact values that should not be al-
tered by calibration, whilst others, especially the parameters introduced during the platform
model development, need to calibrated within a predefined range. Having parameter values
that are considered to be closely representing the real-world domain can reduce the time re-
quired to establish the less known parameter values, as each parameter requiring calibration
adds another level of complexity to the calibration process.
During calibration the simulation output is matched against the experimental data that
the model is aiming to reproduce. The parameter set combination that produces a simulation
outcome that qualitatively resembles the experimental data formulates the baseline. The
baseline parameter values that result in the expected experimental system behaviour can
further be used for in silico experimentation. The two techniques described below are used
to achieve the behaviour of the model system that resembles real world phenomena by
studying the effect of altering parameters under controlled conditions.
2.2.3.4 Single parameter exploration
Perturbation of a single parameter at a time is needed to understand the magnitude effect
that each parameter has on the system outcome. This is done using the one-at-a-time (OAT)
analysis technique.
By choosing a large range of values for each parameter of interest it is possible to iden-
tify the parameter settings that significantly affect the simulation outcome as measured by
the A-Test score. Small changes to a single parameter that result in big differences in the
simulation outcome indicate that the parameter is highly sensitive to change. Such infor-
mation can suggest that the value of the parameter needs to be accurately measured, or that
the value range where the parameter is perturbed destabilises the system, changing the be-
haviour of the model. Further rounds of OAT sampling can be used to establish the turning
CHAPTER 2. MATERIALS AND METHODS 67
point for the sensitive parameters using narrower ranges with tighter increments to evaluate
the effect on the simulation outcome.
The gathered information from OAT analysis is useful for redefining some of the param-
eter baseline values for the following calibration and analysis rounds. The final round of
OAT sampling, where most of the baseline parameter values have been established, can be
used to understand how the resulting model behaviour compares to the real-world system.
2.2.3.5 Global exploration of parameter space
Subsequent to the OAT analysis, the sensitivity of the simulation in response to multiple pa-
rameter perturbations can be studied using the Latin Hypercube (LHC) sampling technique.
The LHC analysis produces a correlation coefficient between the tested parameter and the
resulting outcome measure. Highly correlated or anti-correlated parameter-measure pairs
indicates that during the LHC sampling and analysis the effect that resulted in the outcome
measure was predominantly caused by the single parameter alone; other parameters, al-
though varied in a specified range, are unlikely to be the cause for the observable outcome.
The LHC sampling technique is useful in aiding the calibration process by indicating which
parameters are most likely to cause large perturbations to the simulation response. Some
of these finding may also suggest the driving forces that regulate or maintain specific real-
world phenomena. Each correlation coefficient is assigned a p-value to indicate significance
of the correlation.
Chapter 3
Direct regulation of AGO2 by miR-132 –
in vitro and ex vivo investigation
In LECs the expression of miR-132 is relatively low (Lagos et al., 2010), however it has
been shown to play a role in the anti-inflammatory response during KSHV infection (Lagos
et al., 2010) by targeting EP300 and by mediating angiogenesis through the regulation of
p120RasGap (RASA1) (Anand et al., 2010). In both aforementioned studies, miR-132 was
upregulated up to 10-fold, sufficient for miR-132 mediated functional regulation in activated
LECs. Therefore, LEC activation was required in order to investigate endogenous miR-132
regulation of AGO2. In this chapter I demonstrate the direct targeting of AGO2 by miR-132
through the overexpression of miR-132 and induction of the miRNA endogenously. Fur-
thermore, I aim to investigate how miR-132 and AGO2 modulation affects other functions
within LECs in the context of cell activation.
3.1 miRNA target prediction
The pilot study for identifying the potential novel targets for miR-132 was carried out by
Dimitris Lagos (University of York, UK) by performing an overexpression of miR-132 us-
ing a lentiviral construct (see Figure 3.1). The targets were chosen based on the EIMMO
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prediction analysis tool (Gaidatzis et al., 2007) which suggested that RNA-binding proteins
(RBPs) were among the highly correlated miR-132 targets (see Table 3.1). I identified that
several of the RBPs were predicted by multiple online target prediction tools (see Table 3.2)
as potential targets of miR-132. The mature miR-132 sequence was then aligned against
one of the selected candidate targets, AGO2 (see Figure 3.2).
Figure 3.1: RBP target screen after 48 h of miR-132 or miR-132 mutant (M) lentiviral
overexpression (n = 2, mean ± standard error margin (S.E.M.)).
Table 3.1: Predicted miR-132 targets using the EIMMO prediction analysis tool showing
enriched Gene Ontologies (GOs) (Gaidatzis et al., 2007).
GO Term (Molecular Process) Bonferonni corrected p-value
DNA binding 1.23× 10−5
transcription factor activity 1.63× 10−5
DNA (cytosine-5-)-methyltransferase activity 2.92× 10−4
RNA binding 2.39× 10−3
protein serine/threonine kinase activity 6.93× 10−3
voltage-gated sodium channel activity 1.54× 10−2
AF-2 domain binding 3.16× 10−2
transferase activity 4.46× 10−2
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Table 3.2: RBPs predicted by multiple online algorithms as targets of miR-132.
Gene Symbol
Prediction algorithm
miRanda miRDB PICTAR PITA Targetscan MiRZ
AGO1 Yes No No Yes Yes Yes
AGO2 Yes No Yes Yes Yes Yes
ATXN1 Yes No No No Yes Yes
CUGBP2 Yes No No Yes Yes Yes
FXR1 No No No Yes Yes Yes
HNRNPM Yes No No Yes Yes Yes
HNRNPU No Yes Yes Yes Yes No
LSM11 Yes No No Yes Yes Yes
NOVA1 Yes Yes Yes Yes Yes Yes
PAPOLA Yes No Yes Yes Yes Yes
PTBP2 Yes Yes Yes Yes Yes Yes
QKI Yes No Yes Yes Yes Yes
SFRS1 Yes No No Yes Yes Yes
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Figure 3.2: AGO2 sequence alignment with miR-132 across different species. Seed
sequence is highlighted in bold.
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3.2 miR-132/AGO2 binding and silencing activity
Based on target prediction and miR-132/AGO2 alignment (Figure 3.2), miR-132-3p was
predicted to target only one sequence in the 3’UTR of AGO2. In order to demonstrate that
miR-132 indeed binds the specific 3’UTR site of AGO2, the AGO2 miR-132 binding site at
positions 2-4 of miR-132 was mutated from GUU to AAA:
WT: 5’-GUACAAUCCUUUUUCACUGUUU-3’
Mut: 5’-GUACAAUCCUUUUUCACUAAAU-3’
The concentration of miR-132 mimics appropriate for miR-132 mediated AGO2 reg-
ulation were determined by titration and presented later in Section 3.3.2. The wild-type
AGO2 full length 3’UTR, the mutated AGO2 3’UTR and a positive control EP300 full
length 3’UTR were expressed (40 nM) as part of a luciferase gene construct in HeLas. The
introduction of miR-132 mimics (20 nM) suppressed the activity of the luciferase reporter in
wild type AGO2 3’UTR and wild type EP300 3’UTR reporters, but not when AGO2 3’UTR
was mutated (Figure 3.3). The level of luciferase signal suppression was approximately
35% for AGO2 and 45% for EP300. These experiments in HeLas were performed by Kunal
Shah (Barts Cancer Institute, UK).
In order to determine if the suppression of AGO2 would alter the silencing activity of
AGO2, Kunal Shah (Barts Cancer Institute, UK) also performed a silencing activity assay.
In this experiment, a constitutively active luciferase promoter is regulated by either a single
fully complementary let-7 binding site located in the 3’UTR of the luciferase gene (si),
or 7 times repeat of mismatched let-7 binding sites (mi7). If AGO2 is regulated by miR-
132, the activity of AGO2 to silence the luciferase gene by miRNA-mediated silencing
should decrease. This was observed both when knocking down AGO2 directly, or by miR-
132 overexpression (Figure 3.4), confirming that miR-132 targets AGO2, affecting miRNA
mediated silencing.
The results showed that miR-132 suppresses the predicted region on the AGO2 3’UTR,
allowing to investigate miR-132 regulation of AGO2 in HDLECs.
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Figure 3.3: Luciferase activity assay in HeLas demonstrating that miR-132 overexpression
reduces luciferase activity by suppressing EP300 3’UTR and AGO2 3’UTR, but not a
mutated AGO2 3’UTR (n = 3, mean ± S.E.M.).
Figure 3.4: Silencing activity reporter assay demonstrating the let-7 target site silencing
activity in HeLas (n = 3, mean ± S.E.M.).
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3.3 miR-132 overexpression
Several approaches were taken to demonstrate the regulation of AGO2 by miR-132 in LECs:
the transduction of lentiviral vector with a constitutively active promoter expressing pri-
miR-132, the transfection of miR-132 mimics (miRIDIAN) and the endogenous activation
of miR-132 through the activation of LECs. In this section the first two methods of exoge-
nous miR-132 introduction are presented.
3.3.1 pri-miR-132 lentiviral transduction
The transduction of lentiviral expression vectors differs from the mimics transfection – the
constitutively active promoter produces a full length primary miR-132 transcript, which is
subject to processing steps, that require miRNA biogenesis machinery within the cell, prior
to its loading onto AGO. Following the initial screen that looked at potential miR-132 pre-
dicted targets at the mRNA level (Figure 3.1), the protein expression was determined using
lentiviral overexpression of a wild type pri-miR-132 and a mutated pri-miR-132 (Lagos
et al., 2010). After processing, the mutated miR-132 was unable to suppress AGO2 protein
expression compared to the wild type miR-132 (Figure 3.5).
Figure 3.5: Lentiviral overexpression of pri-miR-132 (132) and mutated pri-miR-132
(132M) in LECs for 72 hours: effect on AGO2 protein expression (n = 2,
mean ± S.E.M.)..
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3.3.2 miRIDIAN mimics transfection
During miR-132 mimics transfection the mimics are taken up by the cell, with only a small
fraction of it loaded onto AGO to form functional RISC (Thomson et al., 2013). HeLa
cells were used for the initial miR-132 mimics transfections, in order to investigate the level
of AGO2 suppression. As a result of miR-132 overexpression, AGO2 was significantly
downregulated at the mRNA level (Figure 3.6a). As a consequence of the loss of AGO2
mRNA, the protein output was also decreased for AGO2 (Figure 3.6b), but not AGO1.
(a) (b)
Figure 3.6: Overexpression of miR-132 miRIDIAN mimics in HeLas for 48 hours: relative
levels of AGO2 mRNA, AGO1 protein and AGO2 protein (n = 3, mean ± S.E.M.; 1
replicate for (b)).
For LECs, the aim was to choose a concentration of miR-132 mimics to be used for
further experiments where AGO2 and a positive control were suppressed, without using an
excess amount of transfected miR-132 in order to reduce off-target effects and cut costs.
Thereby, miR-132 mimics were transfected into LECs across a range of concentrations in
order to determine the effective range of miR-132-induced regulation of its targets. Both
AGO2 and the previously published target RASA1 (Anand et al., 2010) were downregulated
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when using > 12.5 nM concentration of transfected miR-132 mimics (Figure 3.7). The
concentration of 25 nM was chosen for further experiments performed in LECs.
(a)
(b)
Figure 3.7: Titration of miR-132 mimics in LECs for 48 hours (n = 1).
Similar to the results of miR-132 overexpression in HeLas (Figure 3.6), the LECs showed
a similar downregulation of AGO2 mRNA and protein (Figures 3.8a-3.8b). EP300 and
RASA1 served as positive controls, however only 2 successful replicates were completed to
this stage for EP300 protein detection, with a large deviation from the mean in the measured
response, making it an unreliable control. The optimisation to improve EP300 detection in
LECs is presented in section A.1 – EP300 antibody optimisation.
Indeed, the transfection of miR-132 into LECs resulted in a large abundance of de-
tectable miR-132 (Figure 3.8c). Since miR-132 overexpression decreased the amount of
AGO2 in LECs, it was expected that the loss of AGO2 would globally affect the abun-
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dance of other miRNAs (Winter and Diederichs, 2011) and result in decreased process-
ing (Diederichs and Haber, 2007). The measured expression of two miRNAs, miR-126 and
miR-221 – both highly expressed (Lagos et al., 2010) and essential for LECs role in an-
giogenesis (Fish et al., 2008; Zhu et al., 2011; Nicoli et al., 2012; Poliseno et al., 2006) –
showed a decrease (Figure 3.8c), most likely due to the decrease in AGO2 protein expres-
sion. Additionally, the expression of the primary miR-126 transcript remained unchanged
(Figure 3.8d), resulting in a drop of the mature to primary miR-126 ratio. Notably, this con-
firms that miR-132 mediated loss of AGO2 does not affect the transcription of the primary
miR-126, but rather reduces the abundance of the mature miR-126 through the mechanism
of miRNA loaded RISC complex associated stability or AGO2-related miRNA processing.
The overexpression of miR-132 in LECs demonstrated that AGO2 expression can be
regulated to a similar extent as the already confirmed targets EP300 (Lagos et al., 2010) and
RASA1 (Anand et al., 2010), and that the regulation of AGO2 impacts on the abundance
of other miRNAs, miR-126 and miR-221. To further our understanding of endothelial cell
function during this regulation the following section describes the effect of endogenous
miR-132 induction in the context of LEC activation.
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(a) (b)
(c) (d)
Figure 3.8: Overexpression of miR-132 mimics in LECs for 48 hours: relative levels of
AGO2 mRNA and protein, and RASA1 and EP300 protein (a, b), miR-126, miR-132 and
miR-221 expression (c), with pri-miR-126 expression and mature:primary miR-126 ratio
(d) (n = 3, mean ± S.E.M.; 2 replicates for EP300 protein (b) and pri-miR-126 (d); 5
replicates for AGO2 protein (b)).
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3.4 Endogenous miR-132 activation
The activation of endogenous miR-132 expression can be achieved by PMA in neurons (Re-
menyi et al., 2010; Vo et al., 2005). PMA is a small molecule drug that potently activates
protein kinase C signalling, which results in cell activation and promotes angiogenesis in
LECs (Montesano and Orci, 1987). In order to determine the PMA concentration neces-
sary to activate miR-132 transcription in LECs, a titration of PMA was performed over a
time period of 48 hours. LECs, when exposed to 10 to 200 nM concentration of PMA, ex-
press a similar amount of miR-132 over the 48 hour period (Figure 3.9). For all following
experiments 25 nM concentration was used to induce miR-132 expression in LECs.
Figure 3.9: The level of mature miR-132 in LECs over a 48 hour period across different
PMA concentrations (n = 1).
As a result of PMA treatment in LECs, Figure 3.10 shows that the resulting CREB phos-
phorylation is rapid (peak 30 min), with pCREB levels returned to baseline by 24 hours. The
phosphorylation of CREB is necessary for the induction of miR-132 (Remenyi et al., 2010),
and the recruitment of EP300 (Mayr and Montminy, 2001). The activation of LECs by
PMA increase mature miR-132 expression and sustains it over the course of 24 hours (Fig-
ure 3.11a). Mature miR-132 is upregulated 5-fold, however the transcriptionally activated
pri-miR-132 expression returns to baseline at the 24 hour time point (Figure 3.11b). The rel-
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ative expression profile of pri-miR-132 fits the expression profile of pCREB (Figure 3.10),
supporting Remenyi et al. (2010); Vo et al. (2005) findings that miR-132 is upregulated by
PMA through transcriptional activation.
In addition, AGO2 mRNA is significantly upregulated in the first 6 hours after PMA
treatment (Figure 3.11c), with no change in EP300 mRNA (Figure 3.11d). This results in




Figure 3.10: PMA triggered activation of CREB phosphorylation over 24 hours in LECs
(immunoblot (a) and densitometry (b)) (n = 1).
The fact that PMA activation of LECs affects the expression of AGO2 mRNA as well as
miR-132 creates a regulatory feedback loop, assuming miR-132 levels reach high enough
expression to impact on AGO2 protein expression. In order to further understand this regu-
lation, miR-132 would need to be inhibited to compare the effect of PMA activation during
miR-132 upregulation and inhibition.




Figure 3.11: PMA triggered activation of LECs: relative levels of mature (a) and primary
miR-132 (b), AGO2 (c) and EP300 mRNA (d), and AGO2 protein (immunoblot (e),
densitometry (f)) 24 and 48 hours post-treatment (n = 3, mean ± S.E.M.).
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3.5 miR-132 inhibition in activated LECs
The activation of LECs results in the simultaneous upregulation of miR-132 and AGO2. In
order to distinguish the effect of miR-132 induced regulation on AGO2 expression during
LEC activation, miR-132 was inhibited using 2 different miR-132 inhibitors - hairpin based
miRIDIAN inhibitors and LNA-based inhibitors.
3.5.1 miRIDIAN inhibitors transfection
The hairpin miRIDIAN inhibitors of miR-132 significantly reduced the miR-132 expression
in LECs, but failed to reduce miR-132 expression in activated LECs (Figure 3.12a). As
recorded previously in Figure 3.11c, the level of AGO2 mRNA upregulation 24 hours after
PMA treatment was not significant. There was no regulation occurring during any treatment
condition at the mRNA level for EP300 (Figure 3.12c). The expression of AGO2 protein 24
hours post-PMA treatment remained significantly increased (Figure 3.12d-3.12e).
Since the expression of miR-132 could not be effectively suppressed by miR-132 hairpin
inhibitors, none of the miR-132-linked regulatory effects could be observed nor interpreted.
Therefore, a more stable form of inhibitors needed to be tested for the same treatment con-
ditions.




Figure 3.12: Inhibition (miRIDIAN) of miR-132 in PMA-activated LECs: relative levels of
mature miR-132 (a), AGO2 (b) and EP300 mRNA (c), and AGO2 protein (immunoblot (d),
densitometry (e)) 24 hours post-treatment(n = 3, mean ± S.E.M.; only 2 replicates for (c)).
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3.5.2 LNA-based inhibitors transfection
Using the LNA-based miR-132 inhibitors it was possible to suppress miR-132 expression in
both PMA-activated LECs as well as the untreated (DMSO) control LECs (Figure 3.13a).
Inhibiting miR-132 without activation resulted in a mild but significant upregulation of
AGO2 mRNA, and the activation of LECs maintained above baseline expression of AGO2
mRNA 24 hours post-PMA treatment (Figure 3.13b). Similar to previous findings, AGO2
protein expression was increased as a result of PMA 24 hours post-treatment, however the
inhibition of miR-132 in PMA-activated LECs did not reach significant change compared
to the effects of the PMA alone (Figure 3.13d). Nevertheless, AGO2 protein expression
followed a trend where miR-132 inhibition in activated LECs derepressed AGO2 protein
expression in each individual replicate condition (Figure A.3).
The aim of miR-132 inhibition was to observe and record the effect of miR-132 during
PMA-activation of LECs, however PMA-activation was the bigger contributing factor to
modulating the expression levels of miR-132 targets. Therefore, it was difficult to observe
small differences between replicate conditions, which can be attributed to two observations:
1. PMA induced upregulation of miR-132 had high variance (variance σ2 = 2.39, mean
µ = 4.95) between the replicate conditions (Figure 3.13a)
2. AGO2 protein expression was significantly affected by PMA treatment, with increased
variance (variance σ2 = 0.43, mean µ = 1.96) when miR-132 was inhibited
Based on the observed trend on AGO2 expression (Figure 3.13d), we tested the expres-
sion of miR-126, miR-221 and miR-146a (Taganov et al., 2006), miRNAs important for
LEC function as described in section 1.2.5.1. Since AGO2 regulation was not observed to a
significant extent during miR-132 inhibition in activated LECs, it was expected that most of
the impact on other miRNAs will be due to the effects of PMA: miR-126 expression did not
change significantly (Figure 3.14a), miR-146a was significantly upregulated (Figure 3.14b)
and miR-221 was significantly downregulated (Figure 3.14c) in response to PMA. Unex-
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pectedly, the transcription of primary miR-126 was decreased in response to the combined
effect of miR-132 inhibition and PMA treatment.
Since the positive control (RASA1) which should have been affected by miR-132 inhi-
bition in activated LECs did not reach significance between 2 treatment conditions in PMA
activated LECs, it did not refute the hypothesis that endogenously upregulated miR-132 reg-
ulates AGO2 expression in LECs, suggesting that an alternative experimental approach is
needed to further investigate miR-132 mediated regulation of its targets in LECs.




Figure 3.13: Inhibition (LNA) of miR-132 in PMA-activated LECs: relative levels of
mature miR-132 (a), AGO2 mRNA (b), AGO2 (c) and RASA1 protein (d) 24 hours
post-treatment (n = 4, mean ± S.E.M.; only 2 replicates for (e)).




Figure 3.14: Inhibition (LNA) of miR-132 in PMA-activated LECs: relative levels of
mature miR-126 (a), miR-146a (b), miR-221 (c) and pri-miR-126 (d), and the
mature:primary miR-126 relative expression (e) 24 hours post-treatment (n = 3,
mean ± S.E.M.; 2 replicates for (d and e); 4 replicates for (a)).
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3.6 Effect of AGO2 regulation
Keeping in mind that miR-132 overexpression demonstrated that AGO2 can be regulated by
miR-132, the functional role of AGO2 was the focus of the next set of experiments. The aim
was to demonstrate that small changes in AGO2 expression affected its function to modulate
miRNA abundance.
3.6.1 siRNA-mediated knockdown
Downregulation of AGO2 can be achieved by siRNA-mediated knockdown, which should
results in a significant loss of AGO2 protein and thereby reduce miRNA abundance in re-
sponse to AGO2 depletion (Winter and Diederichs, 2011). The addition of siAGO2 for 48
hours resulted in a loss of AGO2 mRNA and protein without affecting RASA1 protein ex-
pression (Figure 3.15a-3.15b. Consequently, the depletion of AGO2 negatively impacted on
miR-126, miR-132 and miR-221 abundance. These results confirmed that AGO2 is needed
to maintain high levels of miRNA abundance (Winter and Diederichs, 2011).
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(a) (b)
(c)
Figure 3.15: Knockdown of AGO2 in LECs for 48 hours: relative levels of AGO2 mRNA
and protein, and RASA1 protein (a, b), and miR-126, miR-132 and miR-221 expression (c)
(n = 4, mean ± S.E.M.; only 2 replicates for (a, b)).
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3.6.2 AGO2−UTR lentiviral overexpression in activated LECs
Knowing that loss of AGO2 was sufficient to reduce miRNA abundance in LECs, the re-
verse had to be tested: does upregulating AGO2 increase miRNA abundance? Importantly,
assuming that miR-132 expression during cell activation could impact on AGO2 expression
(presented in a representative immunoblot in Figure 3.13c), AGO2 protein expression would
need to be modulated by less than 5-fold. By accurately but mildly overexpressing AGO2
using a lentiviral construct with the full length AGO2 protein fused with M2-FLAG and
lacking AGO2 3’UTR (cannot be targeted by miR-132), I aimed to investigate the effect of
AGO2 upregulation in the context of activated endothelial cells and during overexpression
miR-132.
Figure 3.16: Titration of AGO2 lentiviral overexpression in LECs for 48 hours (n = 1).
The titration of the AGO2 lentiviral mix used to transduce LECs suggested that 20 µl is
sufficient to give a mild overexpression of AGO2 protein (Figure 3.16) and was used for all
following AGO2−UTR overexpression experiments.
The overexpression of AGO2 mRNA was successful (Figure 3.17a), resulting in a mild
upregulation of AGO2 protein expression in activated and DMSO control conditions where
AGO2 lentivirus was expressed (Figure 3.17b-3.17c). Interestingly, AGO2 overexpression
or PMA alone also resulted in an increased expression of RASA1 protein expression (Fig-
ure 3.17d).
From the 4 miRNAs that were measured, miR-132, miR-126 and miR-146a were pos-
itively regulated by PMA, but not by AGO2−UTR overexpression (Figure 3.18). On the
other hand, miR-221 showed an increase in miR-221 levels in response to AGO2−UTR over-
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(a) (b)
(c) (d)
Figure 3.17: Overexpression of AGO2−UTR for 30 hours followed by LEC activation for
24 hours: relative levels of AGO2 mRNA (a), and AGO2 and RASA1 protein (immunoblot
(b), densitometry (c and d, respectively)) (n = 3, mean ± S.E.M.; 4 replicates for (a)).
expression and a decrease in response to PMA treatment (Figure 3.18d). Previously, PMA
treatment did not reach a significant increase in inducing miR-126 expression (Figure 3.14a).
This may be explained by the fact that PMA induced regulation was stronger in these sets
of experiments: miR-132 was induced almost 8-fold (Figure 3.18a) compared to the LNA-
inhibition experiments (Figure 3.13a).
The overexpression of AGO2−UTR by ~2.5-fold (Figure 3.17c) did not show any con-
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(a) (b)
(c) (d)
Figure 3.18: Overexpression of AGO2−UTR for 30 hours followed by LEC activation for
24 hours: relative levels of miR-132 (a), miR-126 (b), miR-146a (c) and miR-221 (d)
(n = 4, mean ± S.E.M.).
sistent noticeable regulatory effects on miRNA expression other than on miR-126 (Fig-
ure 3.18b). However, PMA induced effects on miRNA expression was significant in all
cases (Figure 3.18). In order to determine if AGO2−UTR overexpression and PMA had
any effect on LEC gene expression, several mRNA candidates were chosen: Angiopoi-
etin 2 (ANG2), Tyrosine kinase with Ig and EGF homology domains-2 (TIE2), Vascular
Endothelial Growth Factor Receptor 1 (VEGFR1) and VEGFR3 (associated with LEC lin-
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eage differentiation and function (Zheng et al., 2014; Hamaguchi et al., 2006; Olsson et al.,
2006; Pan et al., 2009)), Interleukin 6 (IL6) (under the regulation of miR-132/EP300 feed-
back loop (Vanden Berghe et al., 1999)) and Sprouty-Related, EVH1 Domain Containing 1
(SPRED1) (a target of miR-126 and essential for LEC function (Fish et al., 2008)). In all
cases PMA-induced LEC activation lead to an upregulation of all aforementioned mRNAs
(Figure 3.19). Interestingly, AGO2 overexpression significantly affected TIE2 expression
(Figure 3.19d). PMA induced LEC activation during AGO2−UTR overexpression found that
miR-221 and TIE2 are both responsive to AGO2 abundance. The regulation of TIE2 in the
context of AGO2 regulation by miR-132 was further investigated (section 3.7.1).




Figure 3.19: Overexpression of AGO2−UTR for 30 hours followed by LEC activation for
24 hours: relative levels of ANG2 (a), IL6 (b), SPRED1 (c), TIE2 (d), VEGFR1 (e) and
VEGFR3 (f) mRNA (n = 3, mean ± S.E.M.; 2 replicates for (a, b, e, f)).
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3.6.3 AGO2−UTR lentiviral overexpression in miR-132 overexpressing
LECs
Another way of demonstrating that AGO2 regulation affects miRNA abundance is to use an
AGO2 that cannot be targeted by miR-132, such as the lentiviral overexpression vector with
AGO2−UTR. The overexpression AGO2−UTR in this set of experiments resulted in a much
larger variance (variance σ2 = 57.79, mean µ = 9.02) of the overexpressed AGO2 mRNA
(Figure 3.20a) and protein (Figure 3.20d,3.20c). This meant that statistical significance
could not be achieved for AGO2 expression, although the lowest relative fold overexpres-
sion of AGO2 mRNA was 3.52 and highest 19.77. Despite the variance in the data, AGO2
was overexpressed. There was no notable change found in SPRED1 mRNA expression
(Figure 3.20b). RASA1 protein expression was downregulated by miR-132 overexpression
as expected (Anand et al., 2010). Importantly, as seen in Figure 3.20c, the overexpressed
AGO−UTR (indicated by FLAG row) did not change, however there was a loss in total AGO2
protein expression (indicated by AGO2 row) as a result of miR-132 overexpression. Since
the overexpressed AGO2 levels did not change in response to miR-132 overexpression, the
loss of total AGO2 expression must be due to the endogenous AGO2 protein expression
downregulation by miR-132. This effect could be observed in each replicate condition (Fig-
ure A.4).




Figure 3.20: Overexpression of miR-132 mimics for 30 hours followed by AGO2−UTR
lentiviral overexpression for 24 hours: relative levels of AGO2 (a) and SPRED1 (b) mRNA,
AGO2 and RASA1 protein (immunoblot (c), densitometry (d and e, respectively)) (n = 3,
mean ± S.E.M.; only 2 replicates for (b and e)).
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Unexpectedly, AGO2−UTR overexpression resulted in a drop of mature miR-132 expres-
sion (Figure 3.21a), whereas no such drop was observed in miR-126 or miR-221 expression
(Figures 3.21b-3.21c). For miR-126, the overexpression of miR-132 resulted in a drop of
miR-126 abundance, which was partially rescued by overexpressing a non-targeted form
of AGO2 (Figure 3.21b). It was only a partial recovery of miR-126 abundance, since the
level of AGO2−UTR overexpression was not sufficient to overcome the effect of miR-132
overexpression on miR-126 abundance.
The overexpression of AGO2, despite its large variance between experimental replicates,
resulted in more tightly controlled responses in miRNA abundance. This suggests that de-
spite the large differences in AGO2 overexpression, the overexpression of AGO2 protein
elicits small effects on miRNA abundance in these AGO2−UTR experimental conditions
(Figures 3.18d, 3.21b).
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(a)
(b) (c)
Figure 3.21: Overexpression of miR-132 mimics for 30 hours followed by AGO2−UTR
lentiviral overexpression for 24 hours: relative levels of miR-132 (a), miR-126 (b) and
miR-221 (c) (n = 3, mean ± S.E.M.).
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3.7 TIE2 regulation in activated LECs
Based on the finding that TIE2 was significantly upregulated by an increased abundance
of AGO2 protein (Figure 3.19d), as well as positively regulated by PMA induced LEC
activation, the previously collected results were revisited and tested for TIE2 expression.
Online miRNA prediction tools such as TargetScan could not identify TIE2 as a potential
miR-132 target. The aim was to determine if there was a link between TIE2 expression,
AGO2 abundance and its regulation by miR-132, rather than TIE2 being a direct target of
miR-132.
3.7.1 miR-132 overexpression affects TIE2
In compliance with AGO2 upregulation resulting in an increased expression of TIE2 mRNA
(Figure 3.19d), the downregulation of AGO2 by miR-132 mimics also resulted in a drop of
both TIE2 mRNA and TIE2 protein expression (Figure 3.22).
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(a) (b)
Figure 3.22: Overexpression of miR-132 mimics in LECs for 48 hours: relative levels of
TIE2 mRNA and protein (a - mRNA and densitometry, b - immunoblot comparing TIE2
downregulation by miR-132 mimics relative to other miR-132 targets) (n = 3, mean ±
S.E.M.).
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3.7.2 miR-132 inhibition effect on TIE2
The activation of LECs by PMA did not show a significant effect on TIE2 mRNA (Fig-
ure 3.23a), but reduced the expression of TIE2 protein in response to LEC activation (Fig-
ures 3.23b-3.23c). Since AGO2 was upregulated by PMA induced LEC activation (Fig-
ure 3.13d), it was expected that TIE2 protein expression would also increase as noted during
AGO2 overexpression (Figure 3.19d). However, PMA induced LEC activation seemed to
have a predominant effect on TIE2 expression and the increase in TIE2 due to the increase
in AGO2 could not be observed. This meant that AGO2 had to be overexpressed using a
lentiviral transduction in order to avoid the side effect of PMA on TIE2 protein abundance.
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(a) (b)
(c)
Figure 3.23: Inhibition (LNA) of miR-132 in PMA-activated LECs: relative levels of TIE2
mRNA (a) and protein (b - immunoblot comparing TIE2 regulation to AGO2 and RASA1,
c - densitometry) (n = 3, mean ± S.E.M.).
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3.7.3 TIE2 rescue by AGO2−UTR overexpression
Up until now it was established that AGO2 overexpression increase TIE2 protein expression
(Figure 3.19d), and miR-132 mediated downregulation of AGO2 decreases TIE2 expres-
sion (Figure 3.22). The aim was to see if the overexpression of AGO2 could rescue TIE2
expression in both activated LECs and during miR-132 overexpression.
It was unclear what occured during PMA induced LEC activation in regards to TIE2
mRNA levels due to the differences in TIE2 mRNA expression between Figure 3.19d and
Figure 3.23a. As previously found in Figure 3.23c, PMA negatively affected TIE2 protein
abundance, which was reproduced again in Figures 3.24a-3.24b. No significant effect was
consistently observed on TIE2 protein expression as a result of AGO2−UTR overexpression,
although as evident from the immunoblot (Figure 3.24a), TIE2 can potentially be upregu-
lated during AGO2 overexpression in activated LECs.
The attempt to rescue TIE2 protein expression using AGO2−UTR lentiviral overexpres-
sion resulted in more unexpected outcomes: TIE2 protein expression was upregulated as a
result of miR-132 mimics alone, and further downregulated by the introduction of AGO2−UTR
in miR-132 overexpressing LECs (Figures 3.24c-3.24d). This is contradictory to previous
results where AGO2 overexpression was found to increase TIE2 abundance at the mRNA
level (Figure 3.19d), and that loss of AGO2 would result in loss of TIE protein abundance
(Figure 3.22).
Based on the conflicting results observed during AGO2 overexpression experiments
when measuring TIE2 expression, it was only possible to conclude that increase in AGO2
abundance did not result in increased TIE2 protein expression. However, the loss of AGO2
alone significantly impacted on TIE2 mRNA and protein abundance (Figure 3.22). This con-
curs with the idea that the increase in AGO2 abundance has less profound effects in LECs
compared to the loss of AGO2 abundance.
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(a) (b)
(c) (d)
Figure 3.24: Overexpression of AGO2−UTR for 30 hours followed by LEC activation for
24 hours: relative expression of TIE2 protein (a - immunoblot, b - densitometry) (n = 3,
mean ± S.E.M.). Overexpression of miR-132 mimics for 30 hours followed by
AGO2−UTR lentiviral overexpression for 24 hours: relative expression of TIE2 protein (c -
immunoblot, d - densitometry) (n = 3, mean ± S.E.M.).
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3.8 LEC viability during miR-132/AGO2 regulation
It has been long known that LEC activation by PMA leads to increased growth and prolif-
eration (Montesano and Orci, 1987), and the increase in miR-132 expression could be the
facilitator of angiogenesis through its ability to downregulate RASA1 (Anand et al., 2010).
Here I aimed to reproduce these findings in LECs to shed light on how the AGO2 and
miR-132 regulation observed in Chapter 3 could affect LEC viability during the different
treatment conditions. MTT assays were performed to determine the relative level of live
cells present between treatment conditions.
First, PMA treatment did not show any effect on cell viability after 24 or 54 hours
of PMA treatment (Figure 3.25a). It was clear, however, that LECs appeared healthier
over the period of 24-54 hours (Figure 3.25a). Following these results, the inhibition of
the low abundantly expressed miR-132 in LECs (Lagos et al., 2010) did not result in an
increase in cell viability (Figure 3.25b). Only the overexpression of miR-132 increased
LEC viability (Figure 3.25c), and this was not due to the result of AGO2 downregultion
(Figure 3.25d), but most likely due to miR-132 downregulating RASA1 to activate LEC
angiogenic function (Anand et al., 2010).
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(a) (b)
(c) (d)
Figure 3.25: MTT assay showing LEC viability during PMA activation (a), miR-132
inhibition in PMA-activated (b), miR-132 overexpression (c) and AGO2 knockdown
during miR-132 overexpression (d) (n = 3, mean ± S.E.M.; 6 replicates for (c)).
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3.9 miR-132 -/- knockout mice
Following the in vitro investigations, it was interesting to determine if miR-132 has regula-
tory functions in vivo. First, the expression of miR-132 was compared between spleen and
brain, where it was found that C57BL/6 (WT) mice express 2 magnitudes higher level of
miR-132 in the brain than in the spleen (Figure 3.26a). There was no significant difference in
the expression of AGO2 mRNA (Figure 3.26b), AGO2 protein (Figures 3.26c, 3.27a, 3.27c,
3.27d), or RASA1 (Figures 3.26d, 3.27a) between WT and miR-132 KO mouse samples in
their corresponding tissues.
Considering that the low expression of miR-132 in the spleen would be unlikely to con-
tribute significantly to target regulation, it was expected that miR-132 would at least show a
difference in AGO2 or RASA protein expression between the WT and miR-132 KO mice,
however this was not observed.
There was also an attempt made to compare the expression of AGO2 between the spleen
and brain tissue where miR-132 levels in wild type mice drastically differ (Figure 3.26a),
but this lead to more experiments in search for a normalisation control for protein loading
between tissues. Of the three tested loading controls – α-tubulin, β-actin and GAPDH –
none of them showed an equal loading distribution when comparing brain and spleen sample
lanes (Figure 3.27b) and could only be used to normalise WT vs miR-132 KO conditions
within each tissue.
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(a) (b)
(c) (d)
Figure 3.26: The levels of miR-132 (a), AGO2 mRNA (b), AGO2 protein (c) and RASA1
protein (d) in wild type (C57BL/6) and miR-132 double genomic knockout mice (age 6-8
weeks), in spleen and brain tissues (n = 8, mean ± S.E.M.; 3 replicates for (b), 5 replicates




































Figure 3.27: Immunoblots comparing C57BL/6 and miR-132 -/- KO mouse brain samples - AGO2 and RASA1 protein in brain (a),
AGO2 protein in brain (c) and spleen (d), and different loading controls (b).
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3.10 Summary and Discussion
The work presented in this chapter focused around validating the interaction of miR-132
with a potential candidate target – AGO2. Having confirmed miR-132 direct binding to
the predicted miR-132 site on the AGO2 3’UTR (Figure 3.3), the following experiments
demonstrated:
• AGO2 is downregulated by miR-132 overexpression in HeLas and LECs (Section 3.3)
• miR-132 mediated regulation of AGO2 affects miRNA-mediated silencing (Figure 3.4)
• miR-132 overexpression affects AGO2 function in LECs by affecting miR-126 and
miR-221 abundance (Figure 3.8)
• miR-132 is transcriptionally induced by PMA in LECs through the phosphorylation
of CREB (Figure 3.10)
• endogenous induction of miR-132 by PMA can be inhibited using LNA-based in-
hibitors (Figure 3.13a)
– but not miRIDIAN hairpin based inhibitors (Figure 3.12a)
– which relieves AGO2 protein suppression by miR-132 (Figure 3.13d)
• AGO2−UTR (cannot be targeted by miR-132) overexpression
– upregulates miR-221 abundance (Figure 3.18d)
– can recover miR-132 overexpression induced loss of miR-126 (Figure 3.21b)
• TIE2 protein and mRNA levels indirectly affected by miR-132 overexpression (Fig-
ure 3.22)
• AGO2 and RASA1 (miR-132 positive control (Anand et al., 2010)) protein expression
is unchanged between miR-132 -/- KO and C57BL/6 mice (Figure 3.26)
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3.10.1 Role for miR-132 mediated suppression of AGO2
In the work presented here, a low expressed miRNA in LECs (~102 copies per cell), miR-
132 (Lagos et al., 2010), was shown to directly target AGO2 and was able to mediate AGO2
regulation during LEC activation. However, this is not the first miRNA that has been shown
to target AGO2: miR-99a, a regulator of AGO2 in hepatocellular carcinoma cell line, was
found to be downregulated in several liver cancers (Zhang et al., 2014a). The downregu-
lation of miRNAs has been previously reported as a common feature among liver cancer.
Zhang et al. (2014a) show that the loss of AGO2 leads to a drop in miR-21, a miRNA tar-
geting a tumour suppressor, Phosphatase and Tensin Homolog (PTEN) (Meng et al., 2007).
The downregulation of miR-21 expression is associated with cancer progression and in-
creased proliferation (Zhang et al., 2014a). In this context, loss of miR-99a regulation of
AGO2 resulted in increased AGO2 protein expression, enabling miR-21 to suppress PTEN
and enhance carcinogenesis, and demonstrating that miR-99a mediated AGO2 regulation
was necessary to reduce cell proliferation and thereby oncogenesis. Moreover, the regu-
lation of AGO2 by miR-184 epidermal keratinocytes during cell activation by Interleukin
22 (IL22) was shown by Roberts et al. (2013). Shortly after, a publication by Tattikota
et al. (2014) confirmed miR-184 mediated regulation of AGO2 in pancreatic β cells, where
AGO2 regulation was positively correlated with cell proliferation, complementing the pos-
sible function for AGO2 in the control of cell proliferation Zhang et al. (2014a).
Conversely, Anand et al. (2010) demonstrated that miR-132 positively controls cell pro-
liferation and angiogenesis in endothelial cells by regulating Ras activity through the sup-
pression of RASA1. Based on the finding that miR-132 is a direct target of AGO2 (Chap-
ter 3), the loss of AGO2 in endothelial cells would result in decreased proliferation of cells,
contrary to the findings made by Tattikota et al. (2014); Zhang et al. (2014a). This suggests
a possibility of context-dependent regulation of cell proliferation by AGO2. Moreover, it is
important to consider the expression profiles of the miRNAs that regulate AGO2: based on
Lagos et al. (2010), the estimated abundance of miR-99a and miR-184 in LECs is > 104
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and < 101 copies per cell, respectively. Interestingly, the target sites on AGO2 for miR-184,
miR-99a and miR-132 are non-overlapping. Should all three miRNAs operate to suppress
AGO2 in LECs, this would create a complex regulatory network modulating AGO2 ex-
pression. A study investigating the engagement of these differentially expressed miRNAs
in the regulation of AGO2 would expand our understanding of context-dependent miRNA-
mediated target regulation.
3.10.2 Loss of function experiments using antisense miRNAs
MiRNA hairpin based inhibitors used to inhibit miR-132 levels showed different efficien-
cies between untreated and PMA-activated LECs (Figure 3.12a). It was unexpected that
PMA induced miR-132 expression would not be suppressed below baseline level. Sten-
vang et al. (2012) assessed the inhibition of miRNAs using hairpin inhibitors and LNA-
based inhibitors, demonstrating that LNA-based inhibitors (Petersen and Wengel, 2003)
provide higher efficiency for miRNA inhibition, with increased specificity for on-target
effects (Obad et al., 2011). By inhibiting miR-132 in PMA activated LECs, we indeed
observed a significant loss of miR-132 (Figure 3.13a), allowing to proceed with the loss of
function experiments.
The alternative to the LNA and hairpin based inhibitors would be to test miRNA sponges,
which instead of blocking miRNA loaded RISC, create a decoy site for endogenous miRNA
binding (Ebert et al., 2007). As such, it would be interesting to use sponge technology, for
example, to sequester multiple miRNAs that could potentially bind and target other AGO2
miRNA binding sites (Meng et al., 2007; Roberts et al., 2013), reducing any possible off
target effects.
3.10.3 miR-132 activity controlled by its targets AGO2 and EP300
The expression of miR-132 is negatively regulated during its activation by downregulating
EP300 (Lagos et al., 2010), however the final product, mir-132-3p, remains expressed above
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steady-state levels after activation. This implies that miR-132 abundance is stabilised, most
likely as a result of the ability of AGO2 to stabilise miRNAs (Diederichs and Haber, 2007;
Winter and Diederichs, 2011); AGO loading of this low-expressed miRNA must occur soon
after its synthesis following a canonical biogenesis pathway (Meister, 2013) in order for the
stability of the miRNA to be increased.
Although miR-132 was observed to be inducible as a result of LEC activation by PMA,
several other miRNAs were affected – miR-146a was significantly upregulated whilst miR-
221 was significantly downregulated. Considering that only 1 in 10 miRNAs could be loaded
onto an AGO2 protein at any given moment (Janas et al., 2012), the cell would need to
accommodate the change in miRNA abundance in response to transcriptional activation due
to LEC activation. PMA-induced activation of AGO2 transcription can function to allow
newly synthesised miRNAs to be incorporated into functional complexes. This way the
accelerated synthesis of miRNAs that are upregulated during LEC activation can elicit their
function by binding and being stabilised by AGO2 – suggesting a coupled activation of both
the functional regulators, miRNAs, and the effector complex, AGO2.
Unlike AGO2 mRNA (Figure 3.11c), EP300 mRNA (Figure 3.11d) was not transcrip-
tionally induced during LEC activation by PMA. EP300 acts as a co-activator to facilitate
miR-132 transcriptional induction, and therefore the transcription of EP300 should remain
unaffected by LEC activation to allow for miR-132 to post-transcriptionally regulate the
protein required for its own biogenesis. As a consequence, EP300 downregulation by miR-
132 reduces its function to activate cytokine production during LEC activation (Lagos et al.,
2010). The increased sustained expression of miR-132 even 24 hours after LEC activation is
potentially able to both maintain EP300 expression at a steady-state level of expression (La-
gos et al., 2010), as well as control the silencing activity of AGO2 that was induced to
accommodate the increase in LEC activation responsive miRNAs.
In other systems, such as neurons, miR-132 is highly expressed and its regulatory func-
tion is necessary to maintain neuron cell identity and function (Vo et al., 2005; Remenyi
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et al., 2010). However the gene expression programmes active in neurons will be vastly
different from cells of the lymphatic endothelium, with different targets and miRNA:target
ratios available to miR-132. The relative abundance of miR-132 to its targets will determine
miR-132 activity as it will be competing for its targets, eliciting different effects on different
targets depending on miRNA:target ratio (Mukherji et al., 2011; Bosson et al., 2014). The
additional targets of miR-132, such as AGO2, will decrease this ratio. However, the level of
AGO2 expression present in brain cannot be depleted, as its silencing function is necessary
for miRNA function; since miR-132 is able to directly target AGO2, this suggests that the
broad range of targets that have been discovered for miR-132 (Cheng et al., 2007; Lagos
et al., 2010; Anand et al., 2010; Alvarez-Saavedra et al., 2011; Ucar et al., 2012; Mehta
et al., 2015b) titrate the effect of miR-132 impact on AGO2 in a context-dependent manner.
In LECs, EP300 and AGO2 act together in an enclosed regulatory loop with miR-132
during endothelial cells activation to control miRNA mediated silencing, effects which are
unlikely to occur in unstimulated LECs, where miR-132 expression is naturally low. Al-
though an attempt was made to compare high and low miR-132 expressing tissues in vivo
using C57BL/6 mice (Figure 3.9), it was not possible to use standard loading controls to
normalise and compare AGO2 expression between spleen and brain tissues (Figure 3.27b),
where the expression of miR-132 in WT mice differs by two magnitudes (Figure 3.26a).
de Kok et al. (2005) demonstrated that Hypoxanthine Phosphoribosyltransferase (HPRT)
may be yet the best control between different types of tissue samples, however their esti-
mated error of up to 2-fold differences in expression from HPRT normalisation would leave
many miRNA-target regulatory comparisons inconclusive, as miRNA effect on target regu-
lation is often within a 2-fold range; a different method – using multiple loading controls or
normalising to total protein expression (Eaton et al., 2013), cell count based or total RNA
normalisation – comparing cell types with large differences in miR-132 expression, could
benefit this approach. AGO2, necessary for miRNA-mediated silencing, is present in cells
with both high and low miR-132 expression, and therefore it would be interesting to see how
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miR-132 activity and ability to silence AGO2 is managed considering the large difference
in gene expression programmes between different cell types.
3.10.4 AGO2 loss, not upregulation, affects miRNA abundance
It has been shown that miRNAs are stabilised by the presence of AGO1-4 (Winter and
Diederichs, 2011). Winter and Diederichs (2011) demonstrated that by overexpressing a
AGO1, AGO2 or AGO3 and let-7 simultaneously they could stabilise the overexpressed
let-7 miRNA pool. During the AGO2 overexpression performed in LECs, where AGO2 is
overexpressed only by a few fold above its steady state, it was difficult to detect noticeable
changes even in the highly expressed miRNAs in LECs, such miR-126 and miR-221 (Fig-
ures 3.18, 3.21), although some cases were observed. Based on the experiments performed
in LECs, the loss of AGO2 below the steady state expression level had profound effects on
miRNA abundance (Figures 3.15c, 3.8c). These findings suggested, that AGO2 is present in
cells at an optimal expression level, where the decrease, rather than the increase in AGO2
would cause several changes to cell function. Because AGO2 is the limiting factor in stabil-
ising miRNAs in cells (Janas et al., 2012), it should effect low and high expressed miRNAs
to a different extent. Although miR-132 is a low expressed miRNA in LECs, its function be-
comes apparent during LEC activation regulating RASA1 to promote angiogenesis (Anand
et al., 2010). In contrast, miR-126 is a highly expressed miRNA in LECs, responsible for
regulating SPRED1 expression in order to maintain the LEC phenotype (Fish et al., 2008).
However, in both cases AGO2 expression is required to maintain miRNA regulatory func-
tionality, whereas the increase in AGO2 expression would only attenuate the potential for
miRNA mediated regulation if no change in miRNA transcription follows AGO2 upregu-
lation. An interesting study would be to investigate (1) the threshold level when chang-
ing miRNA abundance affects its target expression and (2) identify what proportion of the
miRNA is loaded onto RISC, importantly distinguishing between low and high expressed
miRNAs in LECs.
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3.10.5 TIE2 expression regulated by AGO2 abundance?
During several experiments where AGO2 abundance was regulated either through cell acti-
vation, miR-132 or AGO2 overexpression, TIE2 was sensitive to the changes that correlated
with AGO2 expression. TIE2 is a receptor that can positively regulate angiogenesis by be-
ing activated via its extracellular domain through Angiopoietin 1 (ANG1) ligand binding,
or negatively regulated during ANG2 association (Maisonpierre et al., 1997). In this study,
PMA-induced activation of LECs resulted in the upregulation of the competitive antagonist
of ANG1 for TIE2 signalling (Figure 3.19a), and downregulation of TIE2 protein expression
(Figure 3.23c). The drop in TIE2 protein expression can be explained by TIE2 endodomain
cleavage (Reusch et al., 2001) in response to PMA induced ANG2 upregulation (Singh et al.,
2012). However, it remains unclear why AGO2 abundance positively correlated with TIE2
protein abundance. AGO2 overexpression alone was sufficient to upregulate TIE2 expres-
sion only at the mRNA level (Figure 3.19d), but without any effect on miR-132 expression
(Figure 3.18a) or TIE2 protein abundance (Figure 3.24b), suggesting that miR-132 may not
be involved in regulating TIE2 abundance directly acting through an unknown mechanism.
Furthermore, miR-132 overexpression indicated an increase in cell viability (Figure 3.25),
which would contradict the role of TIE2 in regulating LEC proliferation and blood vessel
formation Morisada et al. (2005). Therefore the regulation of TIE2 by miR-132 may be
coincidental and the mechanism of indirect TIE2 regulation by miR-132 remains unclear.
Chapter 4
Development of an in silico model of
miR-132 mediated silencing
The impact of miRNA-mediated gene regulation on target gene expression is typically small,
with each miRNA predicted to target multiple target mRNAs within a cell. As a result,
miRNAs have become predominantly viewed as fine-tuners of gene expression. However,
despite the small changes in gene expression elicited by miRNAs, they have been shown
to have important functional roles described previously in Section 1.2.5.3. The regulatory
potential of miRNAs within gene regulatory networks (described in detail in Section 1.2.4)
becomes evident when we consider the abundance of miRNAs and their candidate target
mRNAs: whilst the majority of mRNAs are present in the low 2-digit range of molecular
abundance (Schwanha¨usser et al., 2011), the abundance of functional miRNAs can exceed
median mRNA copy number by a factor of 10, such as in the case of miR-132 (Lagos et al.,
2010). Given this stoichiometry, each miRNA-mediated silencing event can contribute to
moderating the protein output in a temporally resolved manner.
Using the strengths of agent-based modelling to our advantage (see Section 1.3.2) we
aim to gain insight into the dynamic regulation of miR-132 target genes based on the avail-
able in vitro LEC data presented in Chapter 3 complemented by available published litera-
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ture. The development of the model is described within this Chapter, following the CoSMoS
process (described in Section 2.2).
4.1 Domain model
The purpose of the domain model is to capture the information relevant to the biological
problem (Andrews et al., 2010a,b): biological processes and actors are captured at appro-
priate levels of abstraction, in order to help scope the purpose, and subsequent development
of, a computer based model or equations.
Based on the work presented in Chapter 3, AGO2 was identified as one of the targets
of miR-132 in LECs. AGO2 is one of the proteins required for effective miRNA-mediated
silencing. EP300, another miR-132 target previously identified by Lagos et al. (2010), is a
co-transcriptional activator; when bound to an active form of CREB during LEC activation
(described in Section 3.4), EP300 is able to activate the transcription of miR-132. Therefore,
two negative feedback loops are regulated through the function of a single entity - miR-132 -
targeting AGO2 and EP300 mRNA, preventing ribosomes from translating the mRNAs into
functional proteins. In order to determine the functional impact of miR-132 suppression on
AGO2, in Chapter 3, the expression of another miRNA, miR-221, was measured. It is known
that loss of AGO2 results in a loss of global miRNA expression (Winter and Diederichs,
2011), therefore miR-221 was included as part of the problem domain for developing the
miR-132 silencing model.
The interactions between these components1 form the regulatory network to describe
miR-132 function in the context of miRNA-mediated gene silencing of AGO2 and EP300.
The expected behaviour diagram (Figure 4.1) describes how these components interact, and
how their behaviour changes over a period of 48 hours based on the available data from
Chapter 3. The rationale for the inclusion of each of the components described above and
1Defined as an abstracted object of the real world domain that is able to function based on input and output
information; e.g. a component in an ABM is an agent
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included in Figure 4.1 is summarised below:
AGO2 protein Functions as a mediator of miRNA-mediated silencing when associated
with a miRNA.
EP300 protein Functions as a co-activator of miR-132 transcription after its association
with activated CREB protein.
CREB protein Upon cell activation, the phosphorylation of CREB (pCREB) is necessary
for its translocation to the nucleus, where after the association with EP300, will func-
tion as an activator of miR-132 transcription.
RISC The RISC comprises of an AGO2 protein associated with a miRNA and necessary
co-factors that drive miRNA-mediated silencing.
miR-132 The key regulator of the interaction network. When in complex with the AGO2
protein, it determines target specificity for the AGO2 protein to bind to the EP300
mRNA or AGO2 mRNA.
miR-221 A secondary miRNA in the model, that acts as a competitor with miR-132 for
AGO2 protein loading. This miRNA does not have target mRNAs in this model.
AGO2 mRNA The mRNA that is a direct target of miR-132-associated RISC. It is a pre-
requisite for AGO2 protein synthesis.
EP300 mRNA The mRNA that is a direct target of miR-132-associated RISC. It is a pre-
requisite for EP300 protein synthesis.
Promoter A transcription start site for mRNA and miRNAs production. Although consti-
tutively active, it requires the pCREB-EP300 complex localisation to the nucleus and
the binding to the promoter to drive miR-132 transcription. Based on information in
Chapter 3, AGO2 mRNA and miR-221 transcription is also affected by cell activation.
Different genes have different transcription rates, which in case of mRNAs may affect
the dynamics of miR-132 mediated regulation.
Ribosome Requires the association with an mRNA. Produces the corresponding protein,
releasing the mRNA after protein synthesis. Longer mRNAs take longer to translate























Figure 4.1: Expected behaviour diagram of the domain model. The mechanism describes the regulatory functionality of the interaction
network. The cell activation event is a network perturbation which is described by the observed phenomena as recorded in Chapter 3
(relevant figures in italics under each phenomena), and the propagation of this event is explained by the expected behaviour under the
timeline. The colours of the expected behaviour boxes are linked to the mechanistic components through which these events manifest.
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The documentation and specification of the functional role of the abovementioned com-
ponents was captured in the domain model state and activity diagrams. The key to the Nota-
tion in state and activity diagrams is described in Section 2.2.1.2. The evidence supporting
transitions is provided either from literature, supporting data from Chapter 3 or based on
assumptions made in collaboration with the domain expert. The diagrams below present the
domain model state and activity diagrams; the sequence of presented diagrams (Figures 4.2-
4.6) are supported by a table of evidence following each diagram figure, with the captions
in the figures detailing the purpose of each of the model components. The activity diagram
following the state diagrams combines the activity of the components into an integrated























(a) ribosome state diagram (b) promoter state diagram
Figure 4.2: State diagrams of the domain model for ribosome and promoter with supporting evidence in Tables 4.1 and 4.2, respectively.
The ribosome exists in 2 states – the mRNA bound and unbound state, where the mRNA associates with a free ribosome, and upon the
completion of translation is dissociated, freeing up the ribosome for the next mRNA. The promoter is part of the DNA, and in the























Table 4.1: Evidence supporting the domain state diagram for Ribosome
Domain model – state diagram – Ribosome
State Associated transition Evidence
free assembly Lafontaine and Tollervey (2001)
disassembly
mRNA released [translation rate] Reid and Nicchitta (2015)
bound mRNA [proximity]
Table 4.2: Evidence supporting the domain state diagram for Promoter
Domain model – state diagram – Promoter
State Associated transition Evidence
free available Domain expert assumption
unavailable
EP300-pCREB complex [dissociation rate] Zhang et al. (2005)
bound EP300-pCREB complex [association rate]
CHAPTER 4. MIR-132 SILENCING MODEL 124
(a) AGO2 mRNA state diagram
(b) EP300 mRNA state diagram
Figure 4.3: State diagrams of the domain model for AGO2 mRNA and EP300 mRNA with
supporting evidence in Tables 4.3 and 4.4, respectively. Both mRNAs have 3 states – free,
bound by ribosome or bound by a RISC complex with the complimentary miRNA
(miR-132). Following translation the mRNA is free of that ribosome. Following RISC
binding, the mRNA can be silenced and degraded with a certain probability, otherwise it is
released into its free form. Although both mRNAs are transcribed at a certain rate, AGO2
mRNA transcription is affected by PMA activation.
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Table 4.3: Evidence supporting the domain state diagram for AGO2 mRNA
Domain model – state diagram – AGO2 mRNA
State Associated transition Evidence
free transcription Schwanha¨usser et al. (2011)
upregulation [PMA] Figure 3.11c
degradation Schwanha¨usser et al. (2011)
[translation rate] Lackner et al. (2007)
silencing [probability] Figure 3.3
boundRISC RISC [complementarity] Figure 3.2
silencing [rate] Domain expert assumption
boundribo ribosome [proximity] Reid and Nicchitta (2015)
Table 4.4: Evidence supporting the domain state diagram for EP300 mRNA
Domain model – state diagram – EP300 mRNA
State Associated transition Evidence
free transcription Schwanha¨usser et al. (2011)
degradation Schwanha¨usser et al. (2011)
[translation rate] Lackner et al. (2007)
silencing [probability] Figure 3.3
boundRISC RISC [complementarity] Lagos et al. (2010)
silencing [rate] Domain expert assumption























(a) miR-132 state diagram (b) miR-221 state diagram
Figure 4.4: State diagrams of the domain model for miR-132 and miR-221 with supporting evidence in Tables 4.5 and 4.6, respectively.
Both miRNAs are transcribed as primary transcripts in the unprocessed state, which will mature and become available for AGO2
binding. Based on the mature miRNA state – free or bound – it will have different stability affecting its lifespan. Although both
miRNAs are transcribed from the promoter, miR-221 transcription is affected by PMA activation.
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Table 4.5: Evidence supporting the domain state diagram for miR-132
Domain model – state diagram – miR-132
State Associated transition Evidence
primary – unprocessed transcription Vo et al. (2005)
mature – free maturation [rate] Faller et al. (2010); Ota et al. (2013)
degradation Winter and Diederichs (2011)
AGO2 released [stability]
mature – bound AGO2 [stability]
Table 4.6: Evidence supporting the domain state diagram for miR-221
Domain model – state diagram – miR-221
State Associated transition Evidence
primary – unprocessed transcription Schwanha¨usser et al. (2011)
downregulation [PMA] Figure 3.14c
mature – free maturation [rate] Faller et al. (2010); Ota et al. (2013)
degradation Winter and Diederichs (2011)
AGO2 released [stability]
mature – bound AGO2 [stability]
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Figure 4.5: State diagram of the domain model for AGO2 protein with supporting evidence
in Table 4.7. AGO2 is translated as a free protein and is able to bind a miRNA. The
association is potentially reversible. Upon miRNA binding, additional cofactors will
contribute to the function of the AGO2-miRNA complex, which will allow it to bind a
potential mRNA based on miRNA-mRNA complementarity and silence it. The complex
may potentially be re-used to suppress another mRNA target. AGO2, has a limited lifespan
and may degrade upon its lifespan expiration. The activity of AGO2 is positively controlled
by a post-translational modification and could occur at any time during its lifetime.
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Table 4.7: Evidence supporting the domain state diagram for AGO2 protein
Domain model – state diagram – AGO2 protein
State Associated transition Evidence
free translation Lackner et al. (2007)
degradation Weinmann et al. (2009)
− miRNA [stability] Domain expert assumption
boundmiRNA + miRNA [proximity] Section 1.2
RISCfree miRNA released [silencing] Stalder et al. (2013)
+ cofactors [probability] Domain expert assumption
degradation Weinmann et al. (2009)
RISCbound mRNA binds [complementarity] Section 1.2.3
























(a) Protein EP300 state diagram (b) Protein CREB state diagram
Figure 4.6: State diagrams of the domain model for EP300 and CREB protein with supporting evidence in Tables 4.8 and 4.9,
respectively. Upon the activation of CREB phosphorylation, it is translocated to the nucleus where it can bind EP300 in order for them
to elicit their function as a EP300-pCREB complex by binding to the promoter. After a transcriptional event is triggered, the complex is























Table 4.8: Evidence supporting the domain state diagram for EP300 protein
Domain model – state diagram – EP300 protein
State Associated transition Evidence
free translation Lackner et al. (2007)
degradation Schwanha¨usser et al. (2011)
boundCREB binds pCREB [proximity] Mayr and Montminy (2001)
boundpromoter binds promoter [probability] Vo et al. (2005)
degradation Schwanha¨usser et al. (2011)
Table 4.9: Evidence supporting the domain state diagram for CREB protein
Domain model – state diagram – CREB protein
State Associated transition Evidence
unphosphorylated translation Lackner et al. (2007)
degradation Schwanha¨usser et al. (2011)
− [Pi] Bito et al. (1996)
phosphorylated – boundEP300 + [Pi] Mayr and Montminy (2001)
phosphorylated – boundpromoter binds promoter [probability] Vo et al. (2005)
degradation Schwanha¨usser et al. (2011)
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Figure 4.7: Combined activity diagram of the domain model for all interacting components
in the model. The aim of the combined activity diagram was to demonstrate how the
activities of the domain model components propagate, capturing the activity localisation to
either the nucleus or the cytoplasm. Asterisks indicate a continuation point of an activity at
another location with the equivalent number of asterisks. The evidence for the activities is
already explained and presented in the above domain state diagrams; additional evidence of
all molecular movement is justified within Section 4.2.1. Part 1 (next page extends figure to
the right).
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Figure 4.8: Combined activity diagram of the domain model for all interacting components
in the model. Part 2 (next page extends figure to the right, previous page extends the figure
to the left).
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Figure 4.9: Combined activity diagram of the domain model for all interacting components
in the model. Part 3 (previous page extends figure to the left).
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4.2 Platform model
The domain model determined the scope of the model, capturing the necessary compo-
nents and their behaviour for describing miR-132 mediated silencing of AGO2 and EP300.
However, the domain model does not provide the specification for creating an executable
model. Instead, the developed platform model builds on the domain model specifying the
implementation strategy for each of the components within the domain model (development
process described in Section 2.2). The state (Figures 4.10-4.13) and activity (Figures 4.14-
4.20) diagrams detail the implemented states of each of the components and their activities.
The differences between the domain and platform model assumption as reflected by the
state and activity diagrams are summarised in Table 4.10. Additional justifications for the























Table 4.10: Summary of changes made from the domain to the platform model (continued on the next page).








[Domain expert assumption] The post-translational modification
affecting AGO2 activity adds unnecessary complexity to the model






complex can also be
degraded subsequently
after mRNA silencing
[Domain expert assumption] The AGO2-miRNA complex, from a
simulation perspective, does not need to enter an mRNA free state in










[Domain expert assumption; Janas et al. (2012)] The limited
abundance of AGO2 in the cells is scaled down in the model
proportionally to the miR-132/221 fraction of the total miRNA pool in









[Wanet et al. (2012)] Many targets have been identified for miR-132,
therefore only a proportion of these can target the 2 simulated targets
captured in the model.
EP300
protein
All of EP300 is
available to bind
pCREB
A small proportion of
EP300 is available to
bind pCREB
[Franceschini et al. (2013), STRING database] In cells, although full
populations of both EP300 and CREB are present, only a fraction of
those associate together into a complex. The proportion has been
estimated and scaled down to reduce EP300 proteins explicitly
simulated in the model.
CREB
protein






[Domain expert assumption] CREB protein abundance is estimated to
not be limiting (Schwanha¨usser et al., 2011), therefore to reduce































instantiated at the start
of the simulation and
not removed
[Domain expert assumption; Duncan and Hershey (1983)] The amount
of ribosomes in the model is sufficient to allow for noncompetitve
mRNA association with the ribosomes, which would be the case in
proliferating cells for most protein coding genes. Decay/synthesis of












[Zhang et al. (2005)] EP300-pCREB complexes activate transcription
of many other genes, and therefore the abundance of these complexes









where they can enter
translation
[Takahashi et al. (2011)] Overlooked in the planning of the domain
model, to incorporate a time delay on the silencing of mRNAs and
allow possible localisation of silencing activity, cytoplasmic foci were






of silencing for AGO2
and EP300
[Domain expert assumption] Although the silencing efficiency of
AGO2 and EP300 by miR-132 are not exactly measured, it is assumed
based on energy of the miRNA-target duplex and luciferase activity
reporter assay (Section 3.3), the model implements the possibility of







when bound or not
bound by AGO2
[Domain expert assumption] miRNAs not bound to AGO2 have a
shortened lifespan, however the lifespan of a miRNA is dependent on
its association with AGO2 for a limited period of time; the increased
stability of miRNA is implemented as function of its association with
AGO2, a calibrated stability constant, and its unbound lifespan. Decay
of the miRNA can therefore occur even when bound to AGO2 for a
prolonged period of time to avoid persistent miRNA accumulation.
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(a) ribosome platform state diagram
(b) promoter platform state diagram
Figure 4.10: State diagrams of the platform model for ribosome and promoter.
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(a) mRNAs state diagram
(b) miRNAs platform state diagram.














































(a) Protein EP300 platform state diagram (b) Protein CREB platform state diagram
Figure 4.13: State diagrams of the platform model for EP300 protein and CREB protein.
CHAPTER 4. MIR-132 SILENCING MODEL 142
Figure 4.14: Activity diagram of the platform model for ribosome. The ribosome functions
to translate mRNA into protein, as evident from its main activity. It is a stationary agent























Figure 4.15: Activity diagram of the platform model for promoter. The promoter, a unique stationary agent resident in the nucleus, it
functions to produce AGO2 and EP300 mRNA, and miR-221; miR-132 is produced in response to pCREB-EP300 complex binding with
a certain probability (in Table 4.10, under Promoter). The transcriptional activity for AGO2 and miR-221 is directly affected during
PMA activation.
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Figure 4.16: Activity diagrams of the platform model for AGO2 mRNA and EP300
mRNA. The mRNAs are both actively translocated to the cytoplasm after transcription,
where they will move towards a location in the cytoplasm; there, at the cytoplasmic foci, a
decision is made to either enter translation or remain stored at that location (in Table 4.10,
under mRNA). Translating mRNAs cannot be targeted by miR-132 in this model, as most
























Figure 4.17: Activity diagrams of the platform model for miR-132 and miR-221. Both miRNAs have the same functional activity,
however only miR-132 can participate in silencing targets in this model. Both miRNAs are produces as part of a canonical miRNA
biogenesis process, and are loaded onto available AGO2 proteins as soon as possible.
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Figure 4.18: Activity diagram of the platform model for AGO2 protein. AGO2 functions as
the silencing unit in the model – in complex with miR-132 it is will locate and bind a
non-translating mRNA in order to attempt silencing, depending on the mRNA target
(differential silencing efficiency).
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Figure 4.19: Activity diagram of the platform model for EP300 protein. EP300 main
activity is to act as a co-transcriptional activator in the model by binding the active form of
CREB, pCREB, and triggering miR-132 transcription upon the association with the
promoter. It is translated into a protein in the cytoplasm, after which is is actively
transported to the nucleus, where the majority of EP300 resides.
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Figure 4.20: Activity diagram of the platform model for CREB protein. CREB is the only
protein in the model that is not produced as a result of translation, but rather used as a
recycled functional unit - upon its function as part of the EP300-pCREB complex triggering
miR-132 transcription, it is removed from the simulation and replaced in the cytoplasm in
its native, inactive form. The active, phosphorylated form of CREB, is targeted to the
nucleus. A cell activated by PMA promotes the phosphorylation of CREB, increasing the
potential for EP300 association in the nucleus to activate miR-132 transcription.
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4.2.1 Supporting evidence
The assumptions that are made during the domain model planning propagate to the platform
model, where more assumptions and implementation decisions are executed. In order to
ensure that the model is representative of the problem domain, the documentation of each
relevant model development step and decision is vital, and must be captured in a traceable
explicit manner. In addition to the Parametrisation section and evidence provided to sup-
port the domain and platform models, some of the model specific justifications could not
be categorised and presented under class and activity diagrams. This additional evidence
supporting implementation decisions for the miR-132 silencing model is presented below:
space dimensionality The model is implemented in 2-D space. Although the LECs in the
in vitro model system have a third axis, it makes up <10% of the cell diameter (see
Table 4.11, cytoplasmDiameter). We consider 2-D space as a sufficient representation
of the molecular motion without the implementation of collision dynamics.
space compartmentalisation The model implements a cell with borders that contains a cy-
toplasm and a nucleus. There is a 3rd type of compartment, cytoplasmic foci, which
are single-point coordinate locations within the cytoplasm. The involved mobile com-
ponents do not require a more complex compartmentalisation structure of the cell in
this model.
space shape The space environment is implemented as a square. The implication of the
space shape is unknown. The LECs have a stretched out cell shape with several pro-
trusions around the cell.
molecule size The molecules have no size measure in the model, as we are not considering
collision or any other function that is relevant to molecular size or shape.
nucleus size The size of the cell nucleus has been estimated with a nucleus to cytoplasm
ratio approximately 1:3 for LECs (Podgrabinska et al., 2002).
movement direction Some components undergo random movement unless following a canon-
ical process such activation or transport, in which case they will perform random-
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directed movement (with a 180°random vector).
movement velocity The represented molecules cover a range of molecular weights, how-
ever most of the movement in the cell will occur in a random-directed fashion. In
order to not lose the emergence of molecular interactions, the model simulates every
second of real time, where large molecular components will travel at a similar slow
rate (Wang et al., 2000).
simulation resolution As mentioned above, each step of the simulation represents one sec-
ond of real time. This is sufficient resolution to capture the emergence of silencing
events which occur on a longer time scale than 1 second.
ribosome mobility Ribosomes mobility is abstracted - the ribosomes are stationary units
that mRNAs will travel to in a semi-directional manner.
mRNA storage Transcribed and spliced mRNAs would normally enter the cycle of trans-
lation, get stored or silenced. The model abstracts the storage by keeping the newly
synthesised mRNAs at a cytoplasmic focus, where the mRNA will spend a set amount
of time (waitingTimeAtFoci). Entry into translation is given by the probabilityToEnter-
Translation parameter which is based on the translating mRNA percentage estimated
for cells (Lackner et al., 2007).
translation rate Translation of a single mRNA occurs faster than the maximum synthesis
rate in the model. However, the common translation in polysomes allows for trans-
lation rates to be much higher, assuming multiple ribosomes available to translate
the mRNA molecule. Additionally, the model translation rates and transcription rates
for the mRNAs have been calibrated to match the protein production rate per mRNA
molecule during its lifespan.
cytoplasmic foci Cytoplasmic foci serve the purpose of mRNA storage and localisation.
These abstract locations in space given by two coordinates allow for mRNAs to be
kept in a region where mRNA silencing can occur. There are approximately 10 large
cytosplasmic foci visible in the cell (Takahashi et al., 2011).
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transcription rate The rate at which mRNAs and miRNAs are transcribed have been esti-
mated directly through calibration. The transcription rate must ensure that the level of
mRNA molecules present in the simulation is representative of the low mRNA copy
numbers recorded by Schwanha¨usser et al. (2011), given the appropriate lifespan, bal-
anced by the effect of silencing.
silencing efficiency The binding of a miRNA to its target mRNA is not a fully efficient
process, therefore the model implements a probability of silencing a single mRNA
(AGO2ProbabilityToBeSilenced, EP300ProbabilityToBeSilenced). This probability
represents the sum effect of a miRNA-mRNA association and dissociation and has
been estimated based on Figure 3.3 and subsequent calibration.
miRNA maturation Determined by DroshaProcessingTime and DICERProcessingTime,
the maturation of a miRNA follows the canonical pathway (Figure 1.1). The model
allows for increasing the time delay between miRNA transcription and maturation,
however for the purpose of the model the rate is considered to be negligable.
mRNA silencing time Upon miRNA-mRNA association, several proteins need to be re-
cruited to perform silencing (Figure 1.4). The duration of this process has not been
estimated, but this model incorporates this as an additional parameter mRNASilenc-
ingTime to investigate this value and its impact on the model system.
RISC recycling It has been suggested that RISC complexes (miRNA-AGO2 protein bound
complexes) could be potentially recycled to perform silencing of more than one mRNA
molecule. The exact stoichiometry has not been determined to our knowledge, and
this model incorporates this additional parameter silencingCountLimit with the aim to
investigate its impact on the model system.
phosphorylation and dephosphorylation CREB is phosphorylated in the cytoplasm, which
signals its translocation to the nucleus, where it has a chance to encounter a phospho-
tase, lose its phosphorylated state and be exported to the cytoplasm. During normal
cell function the level of phosphorylated CREB is low. The two parameters that gov-
ern CREB phosphorylation are basalPhosphorylationProbability and basalDephos-
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phorylationProbability - both abstracted values estimated based on calibration – de-
termine the chance of a single CREB molecule to undergo phosphorylation or dephos-
phorylation depending on its state and location.
4.2.2 Parametrisation
Every computational model requires a set of parameters that represent the biological system
and can be used to make in silico predictions. The parameters displayed in the tables below
are included in the simulation with presented evidence. The information sources combine
inputs from data presented in Chapter 3 and published literature, pointing out parameters
for which data is unavailable and the parameter values that are abstracted representations
of biological phenomena. In some instances of Tables 4.11-4.12 the ”Source” is provided,
but ”N/A” (i.e. Not Available) estimate is given – this indicates that the source was used
in the calibration process but does not provide direct evidence for the estimate. The cali-
























Table 4.11: Parameter values for the current calibrated model baseline (as measured at 48 hours from the start of the simulation), the
estimated biological range and source of information. (*) denotes that the value has been scaled according to the requirements of the
platform model
Parameter Unit Calibrated value Estimated value Source / Note
cytoplasmDiameter 10−1 µm 300 250 x 150 x 20 estimated from Fig A.2
nucleusToCytoplasmRatio a.u. 4 3 Podgrabinska et al. (2002)
ribosomeCount a.u. 300* surplus Duncan and Hershey (1983)
minFociCount a.u. 5
approx. 10 Takahashi et al. (2011)
maxFociCount a.u. 10
proteinCREBCount a.u. 100* >50000 Schwanha¨usser et al. (2011)
miR132Count a.u. 90 80-120
Lagos et al. (2010)
miR221Count a.u. 5100 4500-6000
mRNAEP300Count a.u. 38 ~20 Schwanha¨usser et al. (2011)
mRNAAGO2Count a.u. 39 ~20 Schwanha¨usser et al. (2011)
proteinEP300Count a.u. 1050* 8000-15000 Schwanha¨usser et al. (2011)
proteinAGO2Count a.u. 420* 15000-30000 Janas et al. (2012)
miR132RISCCount a.u. 40* N/A
no estimate available
miR221RISCCount a.u. 380* N/A
pCREBCount a.u. 3* <5% estimated from Fig 3.10a
pCREB EP300AvailableForMiR132Transcription a.u. 100 (out of 1000) <10% Zhang et al. (2005)
miRNATranscriptionTime s 20
100 nt s−1
Saini et al. (2007)
mRNATranscriptionTime s 500 Ardehali and Lis (2009)
miR221TranscriptionInterval s 5 N/A Schwanha¨usser et al. (2011)
EP300TranscriptionInterval s 250 N/A Schwanha¨usser et al. (2011)
AGO2TranscriptionInterval s 500 N/A Schwanha¨usser et al. (2011)























Table 4.12: Parameter values for the calibrated model baseline (as measured at 48 hours from the start of the simulation), the estimated
biological range and source of information
Parameter Unit Calibrated value Biological value Source / Note
AGO2TranslationTime s 50
10 to 20 aa s−1 Lackner et al. (2007)
EP300TranslationTime s 50
EP300AvailableForCREBBinding a.u. 100 (out of 1000) ~10% Franceschini et al. (2013)
AGO2AvailableForMiR132AndMiR221 a.u. 15 (out of 1000) <2% Janas et al. (2012)
miRNAMovementRate 10−1 µms−1 10 <20 Wang et al. (2000)
DroshaProcessingTime s 1 1 Ota et al. (2013)
DICERProcessingTime s 1 1 Faller et al. (2010)
miRNAMeanLifeSpan sec 36000 <86400
Winter and Diederichs (2011)
boundAGO2LifeSpanMultiplier a.u. 2.0 >1.0
mRNAMovementRate 10−1 µms−1 10 <20 Wang et al. (2000)
waitingTimeAtFoci s 60 N/A no estimate available
probabilityToEnterTranslation a.u. 60 (out of 100) 60-80% Lackner et al. (2007)
AGO2ProbabilityToBeSilenced a.u. 60 40% estimated from Figure 3.3
AGO2mRNAMeanLifeSpan s 21600 <25200 Schwanha¨usser et al. (2011)
EP300ProbabilityToBeSilenced a.u. 80 60% estimated from Figure 3.3
EP300mRNAMeanLifeSpan s 10800 <18000 Schwanha¨usser et al. (2011)
proteinMovementRate 10−1 µms−1 10 <20 Wang et al. (2000)
AGO2ProteinMeanLifeSpan s 54000 46800-93600 Weinmann et al. (2009)
miR132RISCAvailableToMRNAs a.u. 100 (out of 1000) <10% Wanet et al. (2012)
coFactorBindingTime s 15 N/A
no estimate available
mRNASilencingTime s 20 N/A
silencingCountLimit a.u. 3 N/A Stalder et al. (2013)
EP300ProteinMeanLifeSpan s 25200 54000-144000 Schwanha¨usser et al. (2011)
basalPhosphorylationProbability a.u. 3 (out of 10000) N/A
abstracted value
basalDephosphorylationProbability a.u. 40 (out of 10000) N/A
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4.3 Executable model
The components described in the platform model were implemented using and ABM en-
vironment, where each component was defined as an agent class (inheritance diagram in
Figure B.1). Agents like miRNAs and mRNAs share a lot of common parameters and
functionality in this model: the mRNA and miRNA class were made as abstract classes,
with specific miRNAs (miR-132, miR-221) and mRNAs (AGO2 and EP300 mRNA) im-
plemented as independent agent classes inheriting from the parent classes, sharing much of
the functionality. Proteins, on the other hand, share little common functionality and most of
the movement and binding behaviour was implemented for each protein agent class (CREB,
EP300, AGO2 proteins). The implementation and testing of the model is described under
Section 2.2.2. Example outputs are available in the appendix
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4.4 Calibration
The process of manual model calibration has been previously described by Read (2011). The
rationale behind calibration is described in Section 2.2.3.3. The initial parameters used in the
model prior to calibration do not necessarily give the appropriate outcome for all simulation
measures. The model contains a range of implemented biological features and functionality
required for the minimal representation of miR-132 mediated silencing of AGO2 and EP300,
however it does not incorporate all known functionality of the miR-132 silencing network.
Therefore, abstracted values that have not been biologically determined have been used as
part of the model, and need to be calibrated alongside biological parameters in order to
provide simulation outcomes as close to the supported measured biological data as possible.
The molecular abundances were used to calibrate the model (Table 4.11, -Count suffix
parameters), with the biggest focus on miR-132 expression and abundance. The model, once
calibrated, should be able to function as a silencing network where miR-132 in complex with
AGO2 protein should be able to regulate the expression of EP300 and AGO2 through the
suppression of their corresponding mRNA molecules (Figure 4.1).
4.4.1 Aleatory uncertainty analysis
Every simulation run of a stochastic simulation is different, provided that the seed value
passed to the RNG is different (see Section 2.2.3 for more details). There are two types
of uncertainty that can be considered in a simulation: aleatory and epistemic (Kiureghian
and Ditlevsen, 2009). Epistemic uncertainty arises due to the lack of available data or un-
considered knowledge; following the CoSMoS process (Section 2.2), the development of
the domain and platform model explicitly considers any gaps in knowledge and data, min-
imising the impact from epistemic uncertainty. Aleatory uncertainty which arises due to
the implicit randomness of the stochastic behaviour as a result of agent-agent interactions
in an ABM can be estimated by performing an aleatory uncertainty analysis of the model
CHAPTER 4. MIR-132 SILENCING MODEL 157
(described in Section 2.2.3).
The first analysis method provided by spartan is the aleatory analysis (Alden et al.,
2013), which essentially determines the number of simulation runs necessary to reduce the
noise of the model output that is due to the stochastic nature of the simulation. For a bi-
ologist, this value (number of replicate simulations) would be equivalent to the amount of
replicates needed to be performed of the same experiment given the same experimental setup
and methodology, which would yield results with a certain error range. Until enough exper-
imental replicates are performed, it is not possible to perform rigorous statistical analysis of
the data set to determine the significance of the biological outcomes.
The aleatory analysis of miR-132 silencing model has been performed (Figure 4.21),
showing the deviation (or in other words the uncertainty) of the measures given a certain
number of simulation replicates. The measures presented are the agent counts of each of
the molecules (e.g. AGO2 protein) and some of the complexes (e.g. RISC-miR-132). The
Vargha-Delaney A-test was used to demonstrate the magnitude of the effect, which deter-
mined that after 100 simulation runs, the overall difference between the simulation outcomes
would be approximately 5% (Figure 4.21). It is possible to reduce the uncertainty of the sim-
ulation by performing additional runs - with 200 replicates per simulation parameter set the
difference between each outcome is consistently less than 5%. However, increased amount
of runs requires increased execution time on a computing cluster, which is not always pos-
sible as mentioned in the following two techniques. Therefore, 100 replicate runs was used























Figure 4.21: The aleatory analysis of the miR-132 silencing model displaying the uncertainty of each of the measures depending on the
simulation runs performed for a single parameter set.
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4.4.2 Single parameter perturbation
Single parameter perturbation effect is determined using the OAT analysis technique. The
technique was used as one of the first analysis methods to investigate how dozens of pa-
rameters, when altered individually within a specified range, would affect the outcome of
molecular abundance. Several rounds of OAT analysis was performed to look at different
parameters and investigate the differences in outcome measures after readjusting some of
the parameters as a result of the first OAT analysis.
The model contains over 50 parameters of which 25 were considered in the final round
of calibration that showed higher sensitivity in response to change within its biologically
accepted range of values (Table 4.11-4.12), each producing a summary graph demonstrating
the magnitude effect of changing each individual parameter (Figure 4.22) and the individual
breakdown of how each measure was affected as a result of this perturbation (Figure 4.23).
Given 10 measures per a single parameter perturbation summary graph and approximately
25 parameters the final OAT analysis run, the included examples demonstrate the principle
involved in the use of this analysis method to investigate system perturbation by a single
parameter. Overall, 3 rounds of OAT analysis were performed in order to understand the
sensitivity of each parameter in the simulation to an increasingly higher level of detail,
narrowing down the range of parameter values that would create a baseline behaviour as
described in the expected behaviours diagram (Figure 4.1).
One of the key parameters governing miR-132 transcription is the pCREB-EP300 com-
plex availability. This parameter is an abstracted value, indicating how many pCREB-EP300
complexes are used up to produce a transcript of miR-132. Upon binding the promoter, each
complex has a 10% chance to produce a miR-132. The stoichiometry of how many miR-132
transcriptional events occur as a result of a single complex binding is not known and there-
fore the abstracted value can incorporate that for investigating this biological question. As
an example, increasing pCREB-EP300 availability to produce miR-132, as a net effect in-
creases miR-132 abundance (Figure 4.23a and mildly impacts on miR-221 abundance (Fig-
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ure 4.23b). The change in miRNA expression has downstream effects on how many each of
the miRNAs is loaded onto AGO2 protein to form the functional RISC (Figure 4.23). Each
of the outcome measures needed to be considered when calibrating the model as changing
some parameters within certain ranges had a different magnitude of effect on the molecule
abundance – changing pCREB-EP300 complex availability affects miR-132 abundance to
a greater extent than the abundance of miR-221. These and hundreds of other graphs pro-
























Figure 4.22: An example OAT analysis plot displaying how the pCREB-EP300 complex availability affects the outcome of several other
parameters during the early stages of model calibration. The parameter value is a fraction of the complexes measured out of 1000 (i.e.
parameter value 100 is equivalent to 10% of pCREB-EP300 availble for miR-132 transcription).
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(a) miR-132 expression when altering
pCREB-EP300 complex availability to
transcribe miR-132
(b) miR-221 expression when altering
pCREB-EP300 complex availability to
transcribe miR-132
(c) Abundance of AGO2 protein loaded with
miR-132 when altering pCREB-EP300
complex availability to transcribe miR-132
(d) Abundance of AGO2 protein loaded with
miR-221 when altering pCREB-EP300
complex availability to transcribe miR-132
Figure 4.23: Increasing the transcription complex availability to transcribe miR-132
increases miR-132 loaded RISC count and decrease the RISC count loaded with miR-221,
altering the abundance of individual miRNAs in a similar manner.
4.4.3 Global analysis of parameter space
Unlike the OAT analysis, the global analysis of parameter space allows for the identification
of the affect of each parameter on the outcome measures during multiple system pertur-
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bations. Global analysis was performed using the LHC sampling technique (Alden et al.,
2013), during which 200 parameter files were generated, each with altered parameter values.
The LHC sampling method alters multiple parameters simultaneously in order to cover most
of the parameter space within the 200 parameter sample files. As pointed out earlier in the
Aleatory uncertainty analysis section above, 100 replicate runs needed to be used for each
parameter set. This meant that the LHC analysis technique required a grand total of 20 000
simulation runs. Depending on the parameter file setup of the analysis run, each individ-
ual simulation run can take up anything between minutes to hours of CPU time. Therefore
a LHC involving 100 replicates across 200 different parameter files can only be achieved
within a reasonable time scale through distributed computing.
The miR-132 silencing model global parameter analysis was conducted on the C2D2
cluster at York University with a sum CPU time of approximately 60 000 hours, distributed
across 320 nodes, completed in just over a week of real time. The summary of the LHC
analysis for the miR-132 silencing model is provided in Tables 4.13-4.14. The results of the
LHC display the partial rank correlation coefficient (PRCC) for each parameter-outcome
measure pair, showing both positive and negative effects of each parameter on the outcome
measures. Parameters that are more likely to affect the outcome measure have a higher
absolute value PRCC. The LHC analysis was most useful for investigating and appreciating
























Table 4.13: LHC results summary (part 1). Values are displayed for p-value <0.05 threshold and for PRCC absolute value 0.3 or above.















































Table 4.14: LHC results summary (part 2). Values are displayed for p-value <0.05 threshold and for PRCC absolute value 0.3 or above.
Parameter / Agent Count RISC-miR-132 RISC-miR-221 EP300 protein AGO2 protein
AGO2AvailableForMiR132AndMiR221 0.58 0.88 0.89





















silencingCountLimit -0.35 -0.34 -0.37
waitingTimeAtFoci
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4.5 Baseline model
The result of calibration is an established baseline model which is considered representa-
tive of the biological phenomena as described by the domain model. Figures 4.24 and 4.25
present the first 72 hours of the baseline model compared to an enhanced miR-132 expres-
sion model2, displaying the mean abundance of agents (or agent complexes) as recorded
every 10 seconds of the simulation.
The abundance of the agents reaches a steady-state like behaviour by 48 hours of the
simulation. The 48 hour time point is used to estimate the abundance of molecules in the
model presented in the parametrisation Tables 4.11-4.12. Whilst some agents such as miR-
221 and AGO2 mRNA have a small deviation from the mean, most of the measures display
approximately a 10% deviation from the mean value, which is comparable to the variation
that can be measured by molecular biology techniques for a population of cells (such as
demonstrated in Chapter 3). Here, we can consider each simulation replicate an independent
cell with its unique profile of expression, where most of the cells will exhibit a regular
pattern of expression closest to the mean.
As mentioned above, Figures 4.24 and 4.25 compare how molecular abundance differs
between a baseline model (red line, blue area) and a system where pCREB-EP300 complex
availability for miR-132 transcription has been enhanced 4-fold (teal line, green area). The
baseline model is representative of a LEC, whereas the expression of miR-132 in some cells
may be elevated (e.g. neurons); even the 4-fold change in miR-132 expression (Figure 4.24a)
has global systemic effects, most prominently on RISC loading (Figures 4.24c and 4.24d)
and consequently on AGO2 and EP300 mRNA and protein abundance (Figure 4.25). The
increased deviation from the mean suggests that net effect of increased miR-132 abundance
disrupts the regular protein expression and ”patterns” the protein synthesis and abundance
by intercepting mRNAs through the action of miRNA mediated silencing. These effects
2a simulation, where the parameter governing miR-132 expression as a result of pCREB-EP300 transcrip-
tional activation is changed to allow for increased miR-132 expression
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propagate to functional transcription (pCREB-EP300) and silencing (RISC-132) complexes
and could feed back on the miR-132 function. The increase in RISC loading with increased
miR-132 expression (Figure 4.24a) despite the decrease in EP300 and AGO2 mRNA and
protein abundance (Figure 4.25) suggests that the silencing efficiency of miR-132 targets
is increased in an enhanced model of miR-132 expression, where miR-132 increases its
competitiveness for AGO2 loading (Figure 4.24c) by outcompeting miR-221 (Figure 4.24d).
The current baseline model adequately represents the biological problem domain allow-
ing to investigate the impact of miR-132 driven regulation of AGO2 and EP300, and the























(a) expression of miR-132 (b) expression of miR-221
(c) abundance of miR-132 loaded RISC (d) abundance of miR-221 loaded RISC
Figure 4.24: Baseline expression of agents (mean - red line, standard deviation - blue area) compared to miR-132 enhanced expression
























(a) expression of AGO2 mRNA (b) expression of EP300 mRNA
(c) abundance of AGO2 protein available to miRNA (d) abundance of EP300 protein available to pCREB
Figure 4.25: Baseline expression of agents (mean - red line, standard deviation - blue area) compared to miR-132 enhanced expression
effect on the expression system due to enhanced pCREB-EP300 complex availability (mean - teal line, standard deviation - green area)
over 72 hours.
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4.6 Discussion – the miR-132 silencing model development
Aside from the work mentioned by Pedrioli et al. (2010), the miR-132 silencing model is the
first miRNA-regulatory network model developed as an ABM. In addition to the benefits of
capturing the regulatory network as an ABM (described in Section 1.3.2), the model ABM
offers several novel perspectives of investigating miRNA-mediated gene regulation:
1. Captures the activity of low abundance entities (i.e. miR-132, AGO2 and EP300 mR-
NAs) and the dynamics of miR-132 self-regulation through a double-feedback loop
with AGO2 and EP300
2. Implements 2D space, providing the potential to investigate role of AGO2 localisation
and its contribution to miRNA-mediated silencing
3. Implements two explicit miRNA-mediated silencing control points: the recycling of
RISC (re-use of a RISC for silencing several miRNAs) and the differential target
mRNA silencing potential (probability to be silenced specific to each mRNA)
The model represents a regulatory feedback loop where miR-132 is the key regulator of
its own transcription and required for controlling the level of silencing by targeting AGO2
mRNA. This model is built based on LEC expression data, however, the principles devel-
oped for capturing miRNA mediated gene silencing can apply to other miRNA-mRNA reg-
ulatory circuits.
4.6.1 Reflecting on the development process
The model development process employed the CoSMoS process (Andrews et al., 2010a,b) as
a framework for developing a model of biology, in this case the miR-132 mediated silencing
network in LECs. The process offered two main useful elements: (1) the separation of
the biological domain, the domain to be modelled, the implementation strategy, and the
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interpretation and analysis of the in silico simulation results and (2) the transparency of
capturing and presenting the model at each stage.
As the first stage of this thesis involved hands-on molecular biology approaches investi-
gating the biological system captured in the model, the initial stages of domain development
were the least time consuming. Since the problem domain was also well-established within
the wet-lab experimental period investigating miR-132 regulation of AGO2, the develop-
ment of the platform model also took up a little amount of time. Most effort was required in
understanding how to capture the domain and platform diagrams using a formalised UML,
and the calibration of the model. The process of implementation of the model is discussed
in the section below.
4.6.2 Reflecting on Repast Simphony
Repast Simphony (North et al., 2013) was developed as an agent-based modelling environ-
ment in Java, but also offers a High Performance Computing framework in C. The Repast
Simphony offered a much smaller learning curve and a wide variety of built-in functional-
ity that was useful and common in agent-based systems. The application itself has several
interfaces to other popular packages, like SPSS or R, offers live-rendered graphs without
impacting on execution speeds, with all functionality available via the GUI.
Despite its appeal as a highly integrated ABM environment with top-level functionality,
there were several drawbacks with this system design. Several features were counter intu-
itive and the batch submission system did not function properly. Here is a list of problems
that were encountered with Repast Simphony prior to any modifications:
1. Repast Simphony is tightly linked to the GUI
2. The GUI is the only access point for starting a Batch run
3. The Batch run setup GUI is intuitive, but lacks a way of customising the number of
replicates
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4. The Batch run deployment system did not correctly use/identify the Sun Grid Engine
on the remote machine when given the remote address
5. The Batch run setup GUI lacks a way of setting a random seed explicitly in the simu-
lation (see next point)
6. The seed is provided within the parameter XML file and specified to produce a random
seed each time a simulation is started. However, a new seed is generated and used by
the RNG within the simulation when a RandomHelper module is invoked
7. The online documentation provides no supporting information for executing a single
run of a Repast Simphony model without the GUI
8. Repast Simphony is ”bulky” - there are over 30 jar libraries packaged (over 50 MB)
when compiling the simulation into an executable, most of them not used by the model
but checked for on Repast Simphony runtime
9. Repast Simphony’s produced executable is an installer, not an executable simulation
file. There is no documentation or instructions of building an executable jar of the
simulation
10. Repast Simphony’s simulation trigger module RepastMain or RepastBatchMain only
takes 2 parameters: the optional parameter input file location and the required sce-
nario directory location. The output is managed by a separate module and an XML
configuration file
11. Repast Simphony has poor backwards and forwards compatibility. Repast Simphony
model created in version 2.1 does not compile into an executable jar due to several
packages merged/made obsolete from version 2.1 to 2.2. Similar problem occurs
when trying to build an executable of a model created in Repast Simphony version
2.2 in a version 2.1 environment
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All of the aforementioned problems encountered when developing using Repast Sim-
phony have been worked around for the purpose of this thesis and the miR-132 silencing
model. However, the Repast Simphony framework can currently be considered as an unsuit-
able choice for scientific development of ABMs, with the GUI providing little to no support
for creating reproducible simulation runs.
4.6.3 Reflecting on the baseline model
The current miR-132 silencing model is considered to be calibrated to a baseline behaviour.
Although all the calibrated parameter values are within or close to their biological values
(Tables 4.11-4.12), it is likely that several calibrated baselines with similar behaviour ex-
ist. The caveat of manual calibration means that only one of several solutions can be ob-
served and established. Calibrating the simulation to a baseline model behaviour remains
a laborious task, with an automatic calibration methodology in high demand. An attempt
has been made to address the issues and possibilities of automatic calibration of biological
ABMs (Read et al., 2013), but has not been easily adoptable to any other model to date.
There are several parameters such as PMAEffectModifiers, which determine the propa-
gation of PMA-activity in the simulation on various agents, that have not been calibrated
as part of the baseline model. Instead, the PMA activation of the cells is implemented and
presented in the following chapter - Explorative simulation of miR-132 activity and function
in silico.
Chapter 5
Explorative simulation of miR-132
activity and function in silico
The miR-132 silencing model (Chapter 4) was developed in order to investigate the miR-
132 mediated regulation of AGO2 and EP300 in cultured LECs (Chapter 3). The model was
calibrated to achieve a steady-state like behaviour of LECs in vitro (Section 4.4). In order
to investigate how miR-132 mediated regulation propagates its effects on AGO2 and EP300
abundance and function in the model, the following Chapter describes the implementation
of LEC activation. In vitro, the activating agent was PMA (Section 3.4), which drove several
processes as depicted in the expected behaviour diagram (Figure 4.1). The activation of the
LECs in silico was carried out 48 hours (172800 iterations) from the start of the simula-
tion once the baseline behaviour had been achieved, simulating the activated state and the
regulation of the model components during 48 hours of PMA activation (Section 5.2). In a
cell, the increased expression of miR-132 during LEC activation by PMA acts as a constant
regulator of its targets. Two of these are investigated in a closed regulatory network – EP300
and AGO2. But are both of them necessary to allow the cell to function? This raises the
problem of importance of miR-132 mediated regulation, which is later explored in silico by
making AGO2 a non-targeted mRNA molecule (Sections 5.2.3 and 5.2.4).
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5.1 PMA activation
PMA induced activation of LECs showed an effect on multiple measures (Section 3.11).
The function of PMA in the miR-132 silencing model was to induce CREB phosphorylation
as seen in Figure 3.10, and account for the additional PMA induced regulatory effects on
AGO2 mRNA and miR-221 levels. PMA itself cannot directly bind to any of the aforemen-
tioned agents to elicit an agent-agent interaction and response. Instead, it is implemented as
a model-wide state parameter, activatedByPMA, which results in the increased phosphoryla-
tion probability of the CREB protein and changes to transcription rates of AGO2 mRNA and
miR-221. The abstraction of PMA to a model-wide state parameter is justified for several
reasons: its effect of inducing miR-132 across a wide range of concentrations (Figure 3.9)
is saturated at the concentration (25 nM) used for all experimental conditions, and the up-
stream protein kinase cascades that result in PMA induced effects are not implemented and
therefore its concentration distribution in space within the context of this model would not
be relevant.
The gathered biological data (Section 3.4) was used as the determinant of how the PMA
treatment of LECs affects CREB protein phosphorylation and AGO2 mRNA and miR-221
abundance over a course of 24 hours. Unlike biological data, which has data available
at discrete time points of LEC activation, the model simulates continuous data recording
absolute quantities of molecules every 10 seconds of real time. This means that the PMA-
driven activation of the agents in the simulation needed to be approximated using a suitable
function that would fit the agents’ expression and activation profiles as found in the in vitro
data. Moreover, several assumptions had to be made regarding the effect of PMA and how
it affected AGO2 mRNA and miR-221 abundance, and CREB phosphorylation:
CREB protein During PMA activation, the CREB protein phosphorylation is rapidly in-
creased as a consequence of upstream kinase activity (Figure 3.10). The model aims
to identify if by altering the phosphorylation probability parameter of the agent, phos-
phorylationProbability, it is possible to achieve a CREB phosphorylation profile com-
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parable to that in LECs during PMA activation.
miR-221 During PMA activation, the transcription rate of other genes is downregulated, in-
cluding miR-221, resulting in an decreased expression of the miR-221. The model ab-
stracts this observation by altering the promoter agent basal transcription rate parame-
ter, miR221TranscriptionInterval, predicting that it is possible to achieve the miR-221
abundance comparable that in LECs during PMA activation.
AGO2 mRNA During PMA activation, the transcription rate of many genes is upregulated,
including AGO2, resulting in an increased expression of the AGO2 mRNA and pro-
tein. The model abstracts this observation by altering the promoter agent basal tran-
scription rate, AGO2TranscriptionInterval, predicting that it is possible to achieve the
mRNA and protein abundances comparable to those in LECs during PMA activation.
In vitro the activation of LECs by PMA can be observed within 15 minutes from the
treatment start: the phosphorylation of CREB rapidly escalates, with modest up- and down-
regulation of AGO2 mRNA and miR-221 expression. PMA has longer lasting effects, re-
sulting in a gradual decline in the activation profile. This activation can be approximated by
a function with a positively (right) skewed distribution. The Gompertz probability density1
function was taken as the basis for the PMA activation function used in the simulation. The
PMA activation function was used to compute the parameter-altering modification y neces-





where b > 0 determines the scale and η > 0 determines the shape of the function, and
e refers to the Euler’s number. The purpose of the activation function was to mimic the
resulting relative activity and abundance of the above mentioned molecules. The activation
1continuous probability distribution, more commonly applied in risk assessment and demography
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functions variables b and η were adjusted manually (Table 5.1) to give an approximate fit to
the available data points in Figure 5.1.
Table 5.1: Variable values b and η used for generating the profile of the PMA activation
functions for each of the affected parameters.
Altered parameter b η Plot
phosphorylationProbability 0.32 3.75 Figure 5.1a
miR221TranscriptionInterval 0.32 2.1 Figure 5.1b
AGO2TranscriptionInterval 0.13 3.7 Figure 5.1c
The activation function was implemented to modify the transcription rates of miR-221
and AGO2 mRNA, as well as CREB phosphorylation. Provided the assumptions regard-
ing the PMA effects in the simulation were correct, the relative activation function should
provide in silico experimental data comparable to the in vitro biological data.
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(a) The activation function altering the pCREB
phosphorylation probability parameter
phosphorylationProbability.
(b) The activation function altering the miR-221
transcription interval parameter
miR221TranscriptionInterval.
(c) The activation function altering the AGO2
mRNA transcription interval parameter
AGO2TranscriptionInterval.
Figure 5.1: Implemented PMA treatment activation functions for CREB phosphorylation,
miR-221 and AGO2 mRNA (dashed continuous line) following the in vitro LEC data
(single averaged data points) over a 24 hour time course.
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5.2 Experimentation in silico during PMA-activity
The in vitro effect of PMA on most components included in the simulation was only mea-
sured up to 24 hours from the treatment, with few experimental data points recorded at
earlier time points. The simulation of PMA activation presented in this section demon-
strates how miR-132 is able to regulate EP300 and AGO2 in LECs with baseline miR-132
expression compared to enhanced expression of miR-132 (Figure 4.24a) and explores how
PMA induced perturbation of the miR-132 regulatory network alters miRNA-mediated tar-
get regulation, namely AGO2 and EP300.
5.2.1 Baseline LEC stimulation
During regular LEC activity, untreated cells maintain a low level of CREB phosphoryla-
tion. In this in silico experiment, PMA functionality is activated at 48 hours, resulting
in an increased CREB phosphorylation level (Figure 5.2a). The increased pCREB level
allows for more miR-132 to be produced (Figure 5.2b), transcriptionally activated by the
the pCREB-EP300 complex association. The increase in CREB phosphorylation together
with the increase in miR-132 regulatory activity on EP300 mRNA (Figure 5.2c) results in a
rapid decline of EP300 protein (Figure 5.2e). Since PMA activation results in an increased
AGO2 mRNA expression (Figure 5.1c) by ~3 fold, the mRNA copy number for AGO2 is
increased during the early hours of PMA activation (Figure 5.2d) from ~40 molecules to
~100 molecules during the peak of PMA activation (2.5 fold change). The increase in
AGO2 mRNA is closely followed by the increase in AGO2 protein (Figure 5.2f) from ~420
molecules to ~1000 molecules during the peak of PMA activation (2.5 fold change).
AGO2 mRNA and protein levels return to baseline abundance after 48 hours of PMA
treatment – ~40 and ~420 molecules, respectively. However, miR-132 abundance (~1.2 fold
above pre-treatment level) remains at an elevated level of expression, up from 40 molecules
pre-treatment to 60 molecules post-treatment (Figure 5.2b). This coincides with an in-
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creased miR-132 bound AGO2 count, ~1.2 fold above pre-treatment level (Figure C.2c).
Both miR-132 and miR-221 are competitors for AGO2 protein loading to form a RISC
complex (AGO2 protein scaled proportionally to miRNA abundance in the cell, based on
the 1:10 ratio; see evidence in Table 4.10). Since miR-221 expression is reduced during
PMA activation by ~60% (Figure C.2b), and miR-221 loaded RISC baseline abundance
is restored after 48 hours of PMA treatment to the baseline value of 380 molecules (Fig-
ure C.2d), it is likely that increased miR-132 bound AGO2 count is due to the drop in the
expression of its competitor – miR-221. RISC-loaded miR-132 has an increased lifespan
(given by the boundAGO2LifeSpanMultiplier) and therefore the abundance of miR-132 can
remain above baseline for a prolonged period of time, keeping EP300 mRNA and protein
expression below baseline (Figures 5.2c and 5.2e).
Overall, the simulation results of PMA activation qualitatively reproduce the behaviour
presented in the Domain model - expected behaviour diagram and the PMA activation data
recorded for in vitro LECs (Figure 3.11). However, the miR-132 relative abundance during
PMA activation in silico is only ~3 fold upregulated, compared to the ~5 fold upregulation
recorded in vitro data (Figure 3.11a). Moreover, the relative increased abundance level of
miR-132 after 24 hours of PMA treatment in silico is upregulated by ~1.2 fold, lower than
in the in vitro data where miR-132 levels are maintained over 4 fold after 24 hours of PMA
treatment. Based on this result, and the work that demonstrated that at least a 4 fold miR-132
induction in LECs is necessary to show a small but significant change in miR-132 mediated
AGO2 regulation of activated LECs (Figure 3.13d), the following in silico experiments use
an enhanced miR-132 transcription rate (enhanced miR-132 expression baseline of ~380
molecules, up from ~100 molecules at LEC baseline (Lagos et al., 2010)). The model
parameters have been previously calibrated to the baseline behaviour of the regulatory net-
work, where the molecular abundances qualitatively resemble the abundances seen in LECs
(Tables 4.11 and 4.12). Increasing the amount of miR-132 in the model by altering the
pCREB EP300AvailableForMiR132Transcription parameter, the new miR-132 expression
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profile represents a scenario where higher miR-132 expression would regulate its molecular
targets consistent with the expected behaviours diagram (Figure 4.1). This allows the model
to explore the regulatory outcomes on the miR-132/AGO2/EP300 regulatory network when
the activated cell miR-132 abundance reaches a higher level of expression necessary for
target regulation.
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(a) % of phosphorylated CREB (b) absolute miR-132 count
(c) absolute EP300 mRNA count (d) absolute AGO2 mRNA count
(e) absolute EP300 protein count (f) absolute AGO2 protein count
Figure 5.2: Simulation of miR-132 mediated silencing of AGO2 and EP300 in LECs
during PMA-activation, presenting the molecular abundance baseline in LECs and baseline
perturbation during PMA treatment. The treatment is initiated at 48 hours after the
simulation start time. The mean (green line) and standard deviation (blue area) is
calculated based on 100 replicate simulation runs.
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5.2.2 miR-132 enhanced transcription
The initial model baseline was calibrated to the molecular abundances recorded in LECs.
Since the PMA treatment did not result in a miR-132 induction that was observed in vitro,
an enhanced miR-132 expression regime was proposed to study the regulatory effects of
miR-132 mediated target regulation. In order to determine the systemic effect of altering the
pCREB EP300AvailableForMiR132Transcription parameter, the baseline miR-132 model
and miR-132 enhanced expression model needed to be compared.
The increased miR-132 transcriptional activity showed no effect on the CREB phos-
phorylation profile (Figure 5.3a). The new miR-132 baseline expression was enhanced by
~4-fold (Figure 5.3b). Both mRNAs and protein in the enhanced miR-132 transcriptional
activity experiment have a lowered baseline expression, reduced by ~10% for AGO2 and
~20% for EP300 levels (Figure 5.3). Finally, EP300 protein levels recover slower: ~80% of
the original baseline is restored by 48 hours after PMA treatment in miR-132 enhanced ex-
pression model, compared to 24 hours after PMA treatment in the miR-132 baseline model
(Figure 5.2e).
Despite the 4-fold increase in miR-132 baseline in the enhanced miR-132 transcription
model, the qualitative results represented the behaviour described in Domain model - ex-
pected behaviour diagram; miR-132 upregulation peaked at 900 molecules (Figure 5.3b) – 9
fold higher than the original untreated miR-132 baseline molecule abundance (Figure 4.24a),
and remained at 500 molecules after 24 hours of PMA treatment – 5 fold higher than the
original untreated miR-132 baseline molecule abundance. At this level of miR-132 abun-
dance, it is expected to have functionally significant effects on target regulation and cell
biology as demonstrated in Figure 3.13d and Lagos et al. (2010); Anand et al. (2010). The
following sections explore the role of functional levels of miR-132 abundance on the regu-
lation of AGO2 and EP300 using the miR-132 enhanced expression model.
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(a) % of phosphorylated CREB (b) absolute miR-132 count
(c) absolute EP300 mRNA count (d) absolute AGO2 mRNA count
(e) absolute EP300 protein count (f) absolute AGO2 protein count
Figure 5.3: Simulation of miR-132 mediated silencing of AGO2 and EP300 in LECs
during PMA-activation with enhanced miR-132 transcription activity (mean - teal line,
standard deviation - green area) compared to baseline PMA-activation (mean - red line,
standard deviation - blue area), calculated based on 100 replicate simulation runs. The
treatment is initiated at 48 hours after the simulation start time. The impact of the
differences is measured by the K-S test in Table C.1.
CHAPTER 5. SILENCING OF MIR-132 TARGETS IN SILICO 185
5.2.3 Non-regulated AGO2 mRNA
Using the enhanced miR-132 expression baseline model, AGO2 mRNA is hypothesised to
not be a target of miR-132. The implications of the loss of a miR-132 target, AGO2, is
explored further in the in silico model.
Similar to previous in silico experiments, the CREB phosphorylation profile remained
mostly unchanged, with a strong activation curve during the first hour of PMA activation
and a gradual decline in phosphorylation levels (Figure 5.4a). However, the expression
of miR-132 during PMA activation differed in shape and the deviation from the mean (Fig-
ure 5.4b). This effect could be linked to the fluctuating levels of EP300 mRNA (Figure 5.4c)
and protein (Figure 5.4e) expression – the former under the regulation of miR-132 and the
latter required for miR-132 production. The pre-treatment baseline of the EP300 protein
(Figure 5.4e) was highly unstable, and the EP300 protein levels could not be restored within
48 hours after PMA treatment.
By disrupting the regulatory function of miR-132 to target AGO2 mRNA, the regulatory
profile of miR-132 changed, leading to unstable regulation of EP300. This suggests that
there is a balance between miRNA-mRNA ratios which are necessary to maintain a stable
steady state for a robust miRNA-mediated regulatory response. Similar functionality would
be expected if the other miR-132 target in the model, EP300, was not targeted by miR-132,
explored further in the following section.
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(a) % of phosphorylated CREB (b) absolute miR-132 count
(c) absolute EP300 mRNA count (d) absolute AGO2 mRNA count
(e) absolute EP300 protein count (f) absolute AGO2 protein count
Figure 5.4: Simulation of miR-132 mediated silencing of AGO2 and EP300 in LECs
during PMA-activation with enhanced miR-132 transcription activity comparing a
condition where AGO2 can (mean - red line, standard deviation - blue area) or cannot
(mean - teal line, standard deviation - green area) be targeted by miR-132, calculated based
on 100 replicate simulation runs. The treatment is initiated at 48 hours after the simulation
start time. The impact of the differences is measured by the K-S test in Table C.2.
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5.2.4 Non-regulated EP300 mRNA
Similar to the experiment where AGO2 could not be target by miR-132, the next step was
to investigate why EP300 would be an important target for miR-132, allowing to appreci-
ate its role in this regulatory network. Unlike the non-regulated AGO2 experiment, in the
non-regulated EP300 experiment the phosphorylation of CREB was upregulated 2-3 fold
(Figure 5.5a). Since the pCREB-EP300 is necessary for the transcriptional activation of
miR-132 production, the non-targeted EP300 mRNA resulted in a ~50% higher abundance
of the EP300 mRNA and protein (Figures 5.5c). The ~50% increased abundance of EP300
protein did not increase the baseline expression of miR-132 (Figure 5.5b), however during
stimulation with PMA the expression of miR-132 was upregulated ~4-fold during the peak
of its expression, up from ~3-fold compared to the control. Interestingly, AGO2 mRNA
(Figure 5.5d) and protein (Figure 5.5f) abundance was downregulated ~40%, possibly due
to the increased amount of miR-132 to AGO2 mRNA ratio, despite the ~20% reduced AGO2
bound miR-132 count (Figure C.5c).
Like previous results where AGO2 was not targeted by miR-132, by making EP300
not a target of miR-132, the regulation of both EP300 and AGO2 are disrupted. Impor-
tantly, the baseline of miR-132 during non-stimulated conditions were unaffected during
this mode of regulation, however during PMA-induced LEC activation this resulted in an
increase in miR-132 abundance. Although AGO2 is involved in the regulation of miRNA
abundance (Diederichs and Haber, 2007), the reduced AGO2 mRNA and protein expres-
sion when EP300 could not be targeted by miR-132 did not lead to a reduced pre- and 24h
post-PMA treatment abundance of miR-132 (Figure C.5a) or miR-221 (Figure C.5b).
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(a) % of phosphorylated CREB (b) absolute miR-132 count
(c) absolute EP300 mRNA count (d) absolute AGO2 mRNA count
(e) absolute EP300 protein count (f) absolute AGO2 protein count
Figure 5.5: Simulation of miR-132 mediated silencing of AGO2 and EP300 in LECs
during PMA-activation with enhanced miR-132 transcription activity comparing a
condition where EP300 can (mean - red line, standard deviation - blue area) or cannot
(mean - teal line, standard deviation - green area) be targeted by miR-132, calculated based
on 100 replicate simulation runs. The treatment is initiated at 48 hours after the simulation
start time. The impact of the differences is measured by the K-S test in Table C.3.
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5.3 Discussion
5.3.1 Simulating miR-132 expression in response to PMA treatment
The activation of miR-132 transcription in the model was abstracted, allowing a single
pCREB-EP300 complex association event to trigger a single miR-132 transcriptional event.
In the case of the LEC baseline with PMA treatment (Figure 5.2), miR-132 expression
reached only a ~3-fold upregulation of miR-132 abundance. Since the level of miR-132 re-
mained above the PMA activation baseline, the abundance of EP300 protein was maintained
below the PMA activation baseline. Although this was an expected outcome, the regulatory
potential of miR-132 would have been higher given a stronger miR-132 relative expression
increase in response to PMA activation, leading to a more gradual recovery of EP300 protein
expression. The smaller than expected (Figure 4.1; supporting data Figure 3.11a) increase in
miR-132 expression suggests that some element of the domain model needs re-evaluation.
The smaller than expected relative change in miR-132 abundance may be due to a miss-
ing component in the domain model, most likely to do with how transcriptional activation
operates upon transcription factor binding. For example, it is possible that miR-132 pro-
duction should be more enhanced upon pCREB-EP300 complex binding to the promoter.
The stoichiometry of pCREB-EP300 to produced miR-132 transcriptional events is unde-
termined with no available data to date, and would be necessary to adjust this parameter
of the simulation. However, in a recent attempt to investigate transcription factor driven
promoter activation, Rybakova et al. (2015) predicted that the burst-transcription of mRNAs
could be as fast as 10 mRNAs per a single transcriptional activation cycle2. During this time,
covalent modifications to chromatin components and DNA occur that regulate progression
of transcription (Reid et al., 2009). Therefore, it is likely that the pCREB-EP300 potential to
activate miR-132 transcription could be reviewed in the domain model. Since the aim of the
model was not to address how transcription is activated for miR-132, but rather investigate
2in this context, a cycle consists of transcription factor binding, complex maturation, possible chromatin
remodelling (e.g. acetylation by EP300) and eventually, complex disassembly
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how CREB activation in complex with EP300 can regulate miR-132 mediated regulation of
gene expression, it would be sufficient to abstract the activation mechanism by calibrating
the parameter (pCREB EP300AvailableForMiR132Transcription) responsible for miR-132
transcription upon the binding of the pCREB-EP300 complex. It is also possible, that dur-
ing cell activation by PMA, EP300 activity is redistributed (together with Polymerase II) to
potently activate transcription of other genes (Byun et al., 2009), such as the miR-132/212
locus. On the other hand, by performing native chromatin immunoprecipitation (Cosseau
and Grunau, 2011) at various time points of miR-132 activation collecting information about
pCREB-EP300 association with the promoter region, and comparing it to the resulting pri-
miR-132 levels, it would be possible to better estimate this parameter to benefit the miR-132
silencing model.
5.3.2 miR-132 controlled recovery of EP300 activity
The low expression of miR-132 as found in LECs can be considered as functionally inactive.
During cell activation in LECs, miR-132 has been shown to mediate the innate immune
response (Lagos et al., 2010), where miR-132 expression was upregulated ~10-fold. The
phosphorylation of CREB occurs in response to the PMA treatment, and the EP300 protein
in complex with phosphorylated CREB protein is needed for the transcriptional activation of
miR-132. From the presented explorative simulations (section 5.2), it is evident that EP300
protein abundance is depleted during the first hours of PMA-induced cell activation, and
that the recovery of EP300 protein abundance depends on the miR-132 expression profile
and abundance. The drop in EP300 protein expression has been previously demonstrated
to be a result of signalling through the MAPK signalling cascade (Sa´nchez-Molina et al.,
2006; Jeong et al., 2013), which is also activated during PMA stimulation, targeting EP300
for degradation.
In the miR-132 silencing model, the initial depletion of EP300 may be attributed to its
co-activatory role to initiate transcription, including the transcription of pri-miR-132 (Vo
CHAPTER 5. SILENCING OF MIR-132 TARGETS IN SILICO 191
et al., 2005), and the recovery of EP300 protein to baseline abundance is halted by the pres-
ence of miR-132 loaded RISC, as demonstrated in the loss of miR-132 function experiment
to regulate EP300 recovery in Figure 5.5. Although there is no EP300 that is degraded in the
model, only a fraction of it is used to bind CREB, a proportion of which is used to transcribe
pri-miR-132 transcription (exact parameters available in Tables 4.11 and 4.12; rationale for
implementation in Table 4.10). Overall, the effect of EP300 regulation during cell activation
can function as a temporal switch to prevent the subsequent reactivation of EP300 activ-
ity whilst the pCREB abundance is still high during the several hours after PMA treatment
(Figure 3.10). From the immunological perspective, limiting pCREB-EP300 re-activation
of EP300 after the initial cell activation through miR-132 modulates the strength of the im-
mune response (Lagos et al., 2010), and would in general impact on EP300 function, e.g.
lymphocyte development (Kasper et al., 2006).
5.3.3 AGO2 regulation by miR-132 during cell activation
In the explorative simulation (Figure 5.4) it was demonstrated that when miR-132 is unable
to target AGO2, this impacts on EP300 protein abundance and miR-132 expression profile
during activation. The silencing potential of miR-132 measured as the abundance of miR-
132 RISC, was unaffected (Figure C.4c). However, the impact of miR-132 RISC silencing
was fully directed at EP300 mRNA due to the lack of an additional miR-132 target. Since
miR-132 and EP300 are controlling each other through a negative feedback loop, by remov-
ing the ability of miR-132 to regulate AGO2 (a positive regulator of miR-132), this created
an unstable regulation between miR-132 and EP300. These results can be attributed to the
combined effect of several observations:
1. Lack of AGO2 regulation by miR-132 results in an increased AGO2 mRNA and pro-
tein abundance
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2. Increased AGO2 protein abundance allows for more miR-132 to bind and form func-
tional RISC to target EP300 mRNA
3. miR-132 bound AGO2 count is sustained overall (peaks at ~300 molecules, sustains
~150 molecules at 48 hours after PMA treatment) during the PMA activation (Fig-
ure C.3c) compared to the enhanced miR-132 expression baseline (Figure C.4c), sug-
gesting that miR-132 silencing activity is unchanged but more effective at silencing
EP300
The latter, third observation, is likely due to the increased ratio of miR-132 and EP300
mRNA, which is a consequence of the second observation. A similar effect has been previ-
ously observed that the miRNA-mRNA ratio would affect protein expression, where increas-
ing abundance of miRNA target sites for the same proportion of the miRNA would dilute
the suppressive effect of the miRNA (Poliseno et al., 2010). Complementing this princi-
ple, where overexpression of miRNA target sites can act as an effective inhibitor of miRNA
function has been previously demonstrated as a novel technology for miRNA functional
inhibition, termed ”miRNA sponges” (Ebert et al., 2007).
Simulating miR-132 mediated gene regulation without additional miR-132 target mR-
NAs (AGO2−UTR), miR-132 was unable to control and maintain a steady expression level
of EP300, causing the expression of EP300 to remain below 200 molecules after 48 hours
of PMA treatment, down by 60% from the pre-PMA treatment abundance (Figure 5.4). Al-
though only two miR-132 targets – AGO2 and EP300 – are represented in this model, this
poses regulatory constraints on the miRNA network: miR-132 functions to maintain steady
state expression levels of several targets (including others mentioned in Section 1.2.5.3),
requiring the presence of two or more targets in order to avoid an unstable regulatory in-
teraction. In addition, many miRNAs form self-regulatory feedback loops with their tar-
gets (Bosia et al., 2012). Therefore, during cell activation – the established steady state
expression of EP300 and AGO2 under the control of miR-132 may be an essential feature
for LECs: at steady-state when miR-132 expression is low, the targets of miR-132 are be-
CHAPTER 5. SILENCING OF MIR-132 TARGETS IN SILICO 193
low miR-132 regulatory threshold, however, during perturbation when miR-132 abundance
is increased above its regulatory threshold, it is able to restore the steady state levels of its
targets over a 2 day time scale. This way, miR-132 confers robustness on the biological
system during normal and changing gene expression by regulating AGO2 and EP300 simul-
taneously. Such regulation is necessary for normal physiological functioning of biological
processes, where miRNAs buffer noise of target regulation (Herranz and Cohen, 2010) by
being involved in the regulation of multiple targets. Expanding the model to incorporate
several other targets of miR-132 would allow to investigate the different thresholds dur-
ing which miR-132, in activated cells, would function to control a broader gene regulatory
network.
Chapter 6
Discussion and future work
6.1 Summary
The work presented in this thesis identified AGO2 as a novel target of miR-132, and de-
scribed several experimental designs investigating AGO2 and miR-132 regulation in the
context of a negative feedback loop. Based on these findings, we developed an ABM cap-
turing the regulatory feedback between two miR-132 targets - AGO2 and EP300 - allowing
to further investigate the dynamics of miR-132 mediated regulation in activated LECs. The
key findings of this work are:
1. Established that mammalian AGO2 is a conserved miR-132 target (Chapter 3)
• miR-132 directly interacts with AGO2 3’UTR (Section 3.2)
• miR-132 seed sequence determines the specificity for AGO2 association and
suppression (Section 3.2)
• AGO2 is regulated at mRNA and protein level by miR-132 (Section 3.3)
• The regulation of miR-132 in vivo does not show apparent effects on its tar-
gets’ abundances: AGO2 and RASA1 show no difference in protein expression
between wild type and miR-132 double knockout mice (Section 3.9)
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2. Demonstrated that miR-132 can be transcriptionally induced in LECs by PMA
through the activation of pCREB (Chapter 3)
• PMA rapidly induces the phosphorylation of CREB within the first 2 hours after
treatment (Section 3.4)
• pCREB binds the promoter to induce pri-miR-132 transcription, which is sus-
tained around 24 hours, dependent on levels of available pCREB (Section 3.4)
• Inhibition of the endogenously induced miR-132 increases AGO2 protein ex-
pression (Section 3.5.2)
3. Demonstrated that AGO2 protein abundance regulated by miR-132 affects the
abundance of other miRNAs in LECs (Chapter 3)
• The loss of AGO2 during miR-132 overexpression leads to a loss in mature
miRNA levels (Section 3.3)
• The loss of mature miR-126 during miR-132 overexpression can be partially
rescued by AGO2−UTR overexpression (Section 3.6.3)
4. Showed that an ABM model describing miR-132 regulation in a two-target feed-
back loop qualitatively reproduces the expected behaviour of the captured prob-
lem domain (Chapter 4)
5. Demonstrated that the effect of LEC activation by PMA perturbs the function of
miR-132 mediated silencing of AGO2 and EP300 regulation in silico (Chapter 5)
• The simulation of LEC activation suggested that other mechanisms may be at
play in the induction of miR-132 transcription (Section 5.2)
• Simulation during miR-132 enhanced expression during PMA-induced LEC ac-
tivation suggested a function for miR-132 in the stable recovery of EP300 protein
expression (Section 5.2.2)
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• Target (dis-)regulation experiments revealed a possible role for miR-132 targets
during LEC activation in maintaining a robust miRNA-mediated target regula-
tory response (Section 5.2.3-5.2.4)
The regulatory capacity of miR-132 during LEC activation by PMA appeared as mild,
with several other effects (rapid depletion of EP300 during CREB activation, AGO2 tran-
scriptional upregulation by PMA, miR-221 abundance decrease after PMA treatment) feed-
ing into the regulatory network that was under the control of miR-132. The in vitro exper-
imental system in Chapter 3 was further investigated using an ABM (Chapter 4), in order
to dissect the regulatory properties of this network and further the knowledge in miRNA-
mediated control of gene targets (Chapter 5). Although the model was designed and cali-
brated to describe the regulation of miR-132 and its two targets – AGO2 and EP300 – in
LECs, it is possible to extend, modify and calibrate the model to accommodate other targets
or investigate a different miRNA network with different cell baseline expression levels of its
constituents.
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6.2 AGO2 expression is necessary, but not sufficient, for
the prolonged expression of miR-132
Winter and Diederichs (2011) demonstrated that affecting the abundance of AGO1, AGO2
and AGO4 through overexpression or knockdown positively correlated with miRNA abun-
dance. Based on this observation, Chapter 3 detailed how different expression levels of
AGO2 correlated with miRNA abundance. Importantly, experiments with LECs in vitro
demonstrated that alongside of several measured miRNAs, including miR-132, AGO2 pro-
tein was also upregulated as a result of PMA treatment, where AGO2 protein reached
peak expression (up to ~1.5-fold) during the first 6 hours after treatment, and returned to
a steady state expression after 24 hours. Knowing that miRNAs can stabilise AGO2 protein
abundance by forming a miRNA-AGO2 complex (Martinez and Gregory, 2013), the PMA-
induced cell activation could explain some of the increased AGO2 abundance as a result of
possible global miRNA upregulation (Lu et al., 2010). Followed up by measuring AGO2
mRNA levels, suggesting that AGO2 was transcriptionally induced, making transcription
the dominant cause for AGO2 protein upregulation (Figure 3.11). The resulting phenotype
was an increased AGO2 abundance that was maintained only during the first 24 hours after
PMA treatment.
It has been previously reported that miR-132 can be transcriptionally induced during
cell activation (Vo et al., 2005; Remenyi et al., 2010). In this work the PMA treatment
resulted in a 5-6-fold increase of mature miR-132 abundance. The primary transcript of
miR-132 returned to baseline expression by 24 hours after its transcriptional induction by
PMA. The abundance of miR-132 was maintained for a prolonged period of time, still 4-
fold above its baseline expression. Although miR-132 could be stabilised by the increased
AGO2 expression (Winter and Diederichs, 2011) during PMA induction, AGO2 cannot be
the sole contributor towards miR-132 increased abundance reaching as far as 48 hours af-
ter PMA treatment. Since miR-132 half-life was estimated to be 9-10 hours (Nahid et al.,
CHAPTER 6. DISCUSSION AND FUTURE WORK 198
2013), and AGO2 protein expression returned to baseline 24 hours post-PMA treatment, it
is possible that more factors are at play in stabilising the abundance of miR-132. Interest-
ingly, Edbauer et al. (2010) showed that the Fragile X Mental Retardation Protein (FMRP)
is able to stabilise the abundance of miR-132 by direct association. Moreover, the activity of
FMRP is regulated by phosphorylation mediated by Extracellular Signal Regulated Kinase
(ERK)/p70 Ribosomal Protein S6 Kinase 1 (S6K1) signalling, where in its phosphorylated
state it has been found with stalled polyribosomes (Ceman et al., 2003), binding miRNAs
directly and reducing their binding affinity for DICER (Cheever and Ceman, 2009). Tested
by the in silico model (Chapter 5), PMA-induction of AGO2 and miR-132 was insufficient
to explain the prolonged stability of miR-132 abundance. As hypothesised from the in vitro
experiments and Winter and Diederichs (2011), the expectation that AGO2 would be able
to stabilise miR-132 expression and maintain its abundance above steady-state expression
3-4-fold was not met. This reinforced the idea that AGO2 alone is not fully responsible for
the increased abundance of miR-132 after 24 hours from PMA treatment.
The loading of miRNAs onto AGO family proteins is likely to be competitive due to the
low AGO:miRNA ratio (1:10) (Janas et al., 2012). This provides the opportunity for the cell
during its activation to upregulate AGO2 expression in order to accommodate the needed
functionality from miR-132 by simultaneously producing the guide strands (i.e. miR-132)
as well as effector proteins (i.e. AGO2) (Figure 6.1). Such a regulatory feature would favour
enhanced regulation of miR-132 targets during early hours of a viral infection (Lagos et al.,
2010) or increase endothelial cell angiogenic potential (Anand et al., 2010). Cell activation
through B-cell signalling has revealed miR-132 as a regulator of SRY (Sex Determining
Region Y)-Box 4 (Sox4), affecting B-cell development (Mehta et al., 2015a); additionally,
Mehta et al. (2015b) found that miR-132 is upregulated in hematopoietic stem cells (HSCs),
necessary for appropriate hematopoietic function and development, targeting an ageing re-
lated transcription factor, FOXO3. Aside from the function of miR-132 in cell development
and immunity, a large proportion of confirmed miR-132 targets are linked to the regulation of
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gene expression programmes: transcriptional regulation through EP300 (Hasan et al., 2001),
chromatin remodelling through the regulation of Ep300, Mecp2, Jarid1a (Alvarez-Saavedra
et al., 2011) and Silent Mating Type Information Regulation 2 Homolog 1 (SIRT1) (Ya-
makuchi, 2012), and controlling tau mRNA splicing (Smith et al., 2011). With a broad
repertoire of targets, the sustained expression of miR-132 would ensure a gradual recovery
of its target gene expression after cell activation as proposed from the in silico modelling
experiments (Chapter 5).
Figure 6.1: A proposed model for the role of AGO2 upregulation during LEC activation.
Within the first few hours of PMA treatment the expression of PMA-inducible miRNAs is
increased (e.g. miR-132), whereas the abundance of other miRNAs is unaffected (e.g.
miR-126). In order to accommodate the increase in miR-132 expression and allow it to
form functional complexes, new AGO2 needs to be synthesised with an increased rate
during the first 24 hours of PMA-induced transcriptional activation. Since the abundance of
AGO2 protein is more than 10 times lower than the abundance of miRNAs, the loading of
newly produced miRNAs is subject to competitive AGO2 loading. As a net effect, the
induced miR-132 remains in high abundance in the cell after 24 hours from PMA
treatment, whilst the expression of miR-126 is maintained at a steady state.
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6.3 Fine-tuning confers robustness to miRNA function, and
consequently to gene expression
One of the most common functional denominators of miRNAs is their potential to regulate
a broad range of genes, yet rarely exceeding more than a 2-fold change during a regulatory
effect on a single gene target (Baek et al., 2008). This observation has suggested that miR-
NAs maintain protein expression levels by continuously fine-tuning a wide range of targets,
similar to the regulation of miR-132 on AGO2 during the inhibition of miR-132 in activated
LECs (Section 3.5.2). Despite their general role in mildly regulating target gene expres-
sion, it is known that during a cellular activation event (Taganov et al., 2006; Lagos et al.,
2010), even low-expressed miRNAs are increased in abundance, in this case, to regulate the
inflammatory response preventing the overproduction of cytokines. This suggests that miR-
NAs are predominantly acting to buffer gene expression for such activation events, and have
been described as fine-tuners of gene expression (Stark et al., 2005; Herranz and Cohen,
2010; Bosia et al., 2012).
With almost 1 in 20 genes encoding for a miRNA in animals (Bartel, 2004; Berezikov
et al., 2005), this makes them one of the most abundant and conserved functional elements
in the genome. Unlike transcription factors, miRNAs can actively modulate protein expres-
sion at a post-transcriptional level. Although most miRNAs inhibit protein expression, it has
been suggested that some miRNAs can positively regulate target gene expression through
promoter activation (Place et al., 2008). However, miRNA-induced positive regulation of
target genes has been described as a possible artefact of experimental setups where miRNA-
regulated networks are affected through off-target miRNA displacement, resulting in appar-
ent target derepression (Nyayanit and Gadgil, 2015). The latter argument relies on the more
recently described view, the competing endogenous RNA (ceRNA) hypothesis (Salmena
et al., 2011), based on the earlier work by Poliseno et al. (2010) and Cesana et al. (2011).
In such a system, each miRNA is sequestered by the potential target sites accessible in the
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cell; with an increasing target-to-miRNA ratio, the ceRNA effect has potentially large-scale
effects on gene expression programmes. Computational modelling of a ceRNA network
demonstrated the effects of ceRNA regulation during equilibrium and non-equilibrium con-
ditions (Bosia et al., 2013), investigating how ceRNAs function at threshold concentrations
of their potential shared targets.
Challenging the ceRNA hypothesis, Denzler et al. (2014) perform a series of experi-
ments with miR-122 expressed in hepatocytes, in an attempt to experimentally establish the
necessary threshold when the ceRNA effect becomes apparent. The level of miR-122 was
reduced in the experiments from the natural abundance of 1.2× 105molecules per cell to
as low as 1% of total miR-122 abundance (1.2× 103molecules per cell); using the range
of miR-122 expression levels they demonstrated that in order for miR-122 mediated target
regulation to be affected by the ceRNA effect, it would require 1.5× 105 added target sites
per cell; this would physiologically be an unlikely event, therefore, their findings demon-
strating that mRNA target site increase sequestering miRNAs to derepress other mRNAs is
also – unlikely. However, in the context of LECs, where expression of miR-132 at basal ex-
pression is 1× 102 , this may not be the case – LEC activation which is characterised by an
increased expression of miR-132 reaches a level of expression close to 5× 102 Considering
that the abundance of most mRNAs (Schwanha¨usser et al., 2011) is in the low 2-digit range,
the fluctuation of miR-132 levels, as well as increase in transcription of some mRNAs (e.g.
AGO2 Adams et al. (2009)) during cell activation can have regulatory effects coherent with
the ceRNA hypothesis. This is due to the baseline ratio of total miR-132 target sites: mR-
NAs that can be targeted in LECs, provided as many as ~10 unique targets in a 2-digit range
that would present accessible sites for miR-132 interaction, would have a close to 1:1 ratio
of miRNA-to-target. At this threshold level, the fluctuating levels of miR-132 and its targets
as a consequence of transcriptional activation, mRNA turnover and silencing, are likely to
have dynamic regulatory potential that support the ceRNA hypothesis (discussed below).
The baseline expression of the overexpressed sites in the work by Denzler et al. (2014) was
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far too high to be able to draw comparisons of the resulting effect between miRNA to target
ratios, where in most of the experimental conditions the initial target site abundance was
several magnitudes above the physiological level for low-expressed miRNAs. In addition,
their experimental system did not consider low expressed miRNA regulatory properties in
the context of activation, where the ratio of miRNA to mRNA target sites can be lower than
one, using only a highly abundant miR-122 as the core of their findings.
Building on the ceRNA hypothesis, the miR-132 silencing model (Chapter 5) describes
how a non-target AGO2 or EP300 disrupts the regulation of the other target. It is worth
noting, that the model currently only includes 2 targets. Nevertheless, the titrating effect
of miR-132 by a single remaining target when the other target is unavailable causes the
regulatory feedback between miR-132 and one of the active targets to be disrupted. This
effect is more pronounced when AGO2 is not targeted by miR-132. The implications of this
regulatory disruption and change in baseline expression of miR-132 and AGO2/EP300 have
not been yet investigated. The work presented in Chapter 5 compliments the hypothesis
that ceRNA regulation is an important mechanism for the function of miRNA regulatory
networks. The regulatory effect of the ceRNA hypothesis might be prevalent with small
miRNA to target ratios, thresholds of which could be investigated with a range of endoge-
nous low-abundant miRNAs during cell activation.
6.4 AGO2 loading during LEC activation
During PMA induction both AGO2 mRNA and protein was above baseline during the first
24 hours, however the expression of miR-132 remained 4-fold above baseline even 48 hours
post-PMA treatment. In order to address the cause for the increased stability of miR-132, it
would be worth investigating the following:
• Determine the localisation of miR-132 during PMA induction by immunoflorescence,
in the attempt to identify its associated partners for binding and the compartments
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in the cell where miR-132 resides shortly after cytoplasmic processing, including the
relocalisation and phosphorylation of AGO2 that would indicate increased silencing
activity (Zeng et al., 2008)
• The half-life of miR-132 may be increased when it is associated with AGO2, as sug-
gested by Winter and Diederichs (2011). However, AGO2 expression returns to base-
line within 24 hours after PMA treatment. The hypothesis would be that during the
early time points of PMA treatment the induced AGO2 expression alongside the in-
creased miR-132 expression allows miR-132 to compete for AGO2 loading more ef-
fectively, resulting in an accumulation of miR-132 bound AGO2 after 24 hours. Im-
munoprecipitation of AGO2 complexes compared to the total mature miR-132 pool
would allow investigating into whether more miR-132 is bound to AGO2 despite the
restored levels of AGO2 24 hours post-PMA activation.
• It is possible that AGO1 is also induced during PMA treatment, providing more RNA-
binding proteins for miR-132 during processing. A qRT-PCR and western blot com-
paring AGO1 and AGO2 expression over a time course would address this hypothesis.
• FMRP phosphorylation and relocalisation could also affect miR-132 stability by its
association with miR-132 directly (Edbauer et al., 2010)
• If not all of mature miR-132 during LEC activation is used up shortly after its pro-
cessing, it would result in a reduced regulation of miR-132 targets. Therefore, another
likely scenario is that miR-132/AGO2 complexes are stabilised and can be recycled
to perform several silencing events of multiple mRNA copies. An in silico experi-
ment using the miR-132 silencing model could be a starting point for investigate this
hypothesis, as RISC recycling has already been implemented.
Understanding the reason behind the prolonged stability of miR-132 would reveal how
AGO2 protein expression relates to miRNA functional potential during cell activation, i.e.
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the central role of AGO2 loading following miRNA biogenesis, and how it relates to miR-
132 function in endothelial cells (Anand et al., 2010; Lagos et al., 2010). The current model
that attempts to address this was presented in Figure 6.1.
6.5 Reflection on the development of an agent-based model
development on an intracellular scale integrated with
experimental data acquisition
Intracellular molecular interaction models using agent-based technology have existed for
over a decade (Gonza´lez et al., 2003; Pogson et al., 2006; Fredrick et al., 2013; Williams,
2014). Due to the large abundance of some of the molecular components present in cells, the
advancement in computer processing and availability of computing clusters, it has become
possible to execute models with thousands of agents representing molecular interactions
inside the cell.
One of the biggest challenges of developing a computational model, including the miR-
132 silencing model, was calibration of the parameters. Although few parameters govern
the behaviour of each individual agent that represent a biological molecule, 9 types of agents
were considered essential for describing miRNA mediated silencing in the context of LEC
activation. Importantly, the few necessary parameters describing mRNA transcription rates
and life spans of mRNA and protein molecules were difficult to obtain, having to rely on
experiments from a combination of sources. Although copy numbers of miR-132 and miR-
221 were obtained from the same biological system (i.e. HDLECs), with miR-132 being
the central regulatory component of the network, other agent abundances were taken from
similar cell types, which may not necessarily represent the same protein or mRNA stabil-
ity as found in LECs. Inevitably, the calibration of model parameters was necessary to
compensate for possible deviations of biological parameters from their true value in LECs,
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and to reproduce the qualitative behaviour of miRNA mediated regulation due to justifiable
parameter abstractions.
As a consequence of the many requirements imposed by model parametrisation, the inte-
grated approach to investigate miR-132 regulatory properties of its targets could benefit from
ab initio domain model planning strategy: the first few months of the project would involve
the capturing the initial problem domain, which typically would involve the presence of a
subject matter expert. Importantly, this would allow to determine what experiments would
be needed to provide support for the model described in the problem domain, and effectively
support transitions between model development and experimental data acquisition.
6.6 Expansion of the miRNA-regulatory network
During the development of the miR-132 silencing model, the experimental data gathered in
Chapter 3 enabled calibration and investigation of the miR-132 regulatory network with two
of its targets – AGO2 and EP300. Although both targets formed a negative feedback loop
with miR-132, they were distinct in the functional impact of their regulation (regulation of
self-transcription vs regulation of silencing capacity). Moreover, the rate of transcription
of each of the target mRNAs was different, as well as the targeting efficiency of miR-132
between the two target mRNAs. To date, no other agent-based model involving a miRNA
regulatory network has been published aside from the one available resource found online
by Ripoli et al. (2009), making this study of particular interest for investigating the dynam-
ics of miRNA mediated regulation in a system with low abundance of the most essential
molecules - miRNAs and their target mRNAs.
Coherent with the ceRNA hypothesis, the model captures some of the key behaviours
of a ceRNA system: a single miRNA is capable of regulating multiple targets with distinct
transcription/translation dynamics, functional impact on the abundance of miR-132, and
with distinct affinities for interacting with target mRNAs. The model itself can be extended
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to address the biological domain problem of miR-132 stability by investigating:
• The cause behind the loss of miR-132 abundance in the model compared to the in
vitro data 24 hours post-PMA treatment. The experiments are described in the Section
above, and would contribute to the accuracy of the PMA-induced functional readout
of the model.
• The expression of miR-132 expression as a result CREB phosphorylation as the am-
plitude of upregulation of miR-132 in silico is lower than in the corresponding in
vitro experiments. In order to test if the understanding of pCREB induced miR-132
transcriptional activation is representative of the real world domain, it may be inter-
esting to alter the simulation by allowing more miR-132 transcripts to be produced
per pCREB-EP300 complex binding event, which would require model recalibra-
tion. Alternatively, identifying the stoichiometry of the pCREB-EP300 complex to
pri-miR-132 ratio would be useful information in completing the domain knowledge
of miR-132 transcriptional induction.
• Addition of a PMA positively responsive miRNA agent, such as miR-146a, and pre-
dict the impact of miR-132 and miR-146a simultaneous regulation during LEC ac-
tivation as a measure of NF-κB downstream signalling. Rather than using a decoy
miRNA which is downregulated after PMA induced LEC activation (i.e. miR-221), a
miRNA that is positively regulated and in similar abundance to miR-132 in LECs (i.e.
miR-146a, Figure 3.14) would provide novel insight into the dynamics of a 2-miRNA
interaction regulatory network.
• Investigation and incorporation of expression data of additional miR-132 targets would
provide further work and suggest testable hypothesis to support the ceRNA hypothe-
sis (Salmena et al., 2011; Bosia et al., 2013)
• The addition of P-body (currently represented by Foci in the model) localisation func-
tionality for AGO2, by implementing its functional role after possible post-translational
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modification (Zeng et al., 2008); this would require time-lapse imaging data of AGO2
(and phospho-AGO2 at S387) redistribution during cell activation
Given the time available it was not possible to test some of the model predictions in
order to fulfil the systems biology cycle (Kitano, 2002). However, the findings presented in
this Chapter suggested several experiments that benefit the biological domain as a result of
the in silico exploration of miR-132 regulation of AGO2 and EP300 in a closed two-target
gene regulatory network.
6.7 Conclusion
The integrated approach combining wet-lab molecular techniques with computational mod-
elling presented in this thesis benefited the understanding of miRNA-mediated silencing,
yet challenges remain in the development of models capturing the complexity of biological
systems. Utilising the integrated approach to dissect miRNA-mediated regulation within a
network of interacting molecules, the work demonstrated the functional relevance of miR-
132 mediated regulation of a novel target, AGO2, and a previously validated target, EP300.
Together with the experimental data, the predictions and observations made from agent-
based modelling of the miR-132 regulatory network in the context of cell activation provide
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A.1 EP300 antibody optimisation
The EP300 protein is a 300 kDa protein that can be detected by the mouse-monoclonal
Abcam 3G230 antibody. According to the manufacturer’s instructions, it has cross-reactivity
with human and rat species, and is suitable for western blotting.
Based on performed western blots, the antibody detects a band at 300 kDA, but longer
exposures and re-use of the antibody for subsequent western blot membranes increases the
signal to noise ratio. Overall, the antibody detects the EP300 target in LECs and HeLa when
it is the first probed target on a fresh PVDF membrane.
Several configurations of the antibody dilution and buffer were tested in HeLas (Fig-
ure A.1). EP300 was detected most clearly when using a 1:500 primary antibody in 5%
PBS/T-milk, with PBS/T as the washing buffer, and 1:5000 mouse-IgG PBS/T secondary
antibody. The incubation periods and the protocol for staining is described in section 2.1.3.6.
Due to the cost of using a EP300 as a 2nd positive control for miR-132 regulation after the
optimisation, only RASA1 was continued to be used as the only positive control for miR-132
regulation events.
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Figure A.1: EP300 antibody optimisation using HeLa lysates: comparison of 3 buffers (5%
milk-PBS/T, 5% milk-TBS/T, 5% BSA-PBS/T) used in the preparation of the primary
antibody with either 1:500 or 1:1000 concentration. Test lanes for each condition were
loaded with 5 or 10 µg µl−1 of protein lysate. Image displays a 4 minute and an 8 minute
exposure of the hyperfilm to the ECL-treated membrane. Note: the predicted band in
HeLas runs just below the 250 kDa marker.
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A.2 HDLEC morphology
PMA induces a morphological change in HDLECs. This can be attributed to the cell ac-
tivation, where the endothelial cells perform their role in angiogenesis and become more
elongated, as well as actively proliferating (Figure 3.25a). After 24 hours of PMA treatment
activated endothelial cells appear elongated, with miR-132 inhibition showing no apparent



















213Figure A.2: Morphology of miR-132 inhibited LECs 24 hours after PMA treatment.
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A.3 Expression by experimental replicate
Figure A.3: Inhibition (LNA) of miR-132 in PMA-activated LECs: relative expression of
AGO2 protein broken down by experimental replicate. Although there is a trend, where
miR-132 inhibition of PMA-activated LECs derepresses AGO2 protein expression, it does
not reach statistical significance (Figure( 3.13d) (n = 3).
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Figure A.4: Overexpression of miR-132 mimics for 30 hours followed by AGO2−UTR
lentiviral overexpression for 24 hours: relative expression of AGO2 protein broken down
by experimental replicate. Although there is a trend, where miR-132 overexpression
suppresses AGO2 protein expression during AGO2−UTR overexpression, it does not reach




The class inheritance diagram (Figure B.1) for agent classes is presented below. Agents like
miRNAs and mRNAs share a lot of common parameters and functionality for the purpose
of this model. The mRNA class and miRNA class was made an abstract class, with specific
miRNAs (miR-132, miR-221) and mRNAs (AGO2 and EP300 mRNA) as agent classes.
Proteins, on the other hand share little common functionality and most of the movement and
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C.1 Visual model output of the miR-132 silencing model
Several screenshots of the visual output of the model are shown in Figure C.1. The sim-
ulation starts in a state where equilibrium has not been reached. In the 1st iteration (Fig-
ure C.1a) the mRNAs and 100 molecules of miR-132 are present in the cell, localised to the
nucleus, with ribosomes placed randomly outside of the nucleus (the red square indicates
the approximate region of the nucleus). On the 100th iteration (Figure C.1b) most of the
mRNAs have localised to cytoplasmic foci (circled in red as the approximate localisation)
where they are temporarily stored and will enter translation over a period of time by bind-
ing to a ribosome. By the 1000th iteration (Figure C.1c), some EP300 mRNA has been
translated into protein and has localised to the nucleus, allowing it to bind CREB within
the nucleus to initiate miR-132 transcription at the promoter. In addition, more miR-221
has been produced, along-side the translated AGO2 protein. Some of the AGO2 protein
has formed complexes with miR-132 and miR-221 (green or red triangle over a red square,
respectively), that should be visible at a finer zoom of the digital copy of the thesis. Fi-
nally, the 10000th iteration shows that the model becomes soon saturated with agents for
visual display (Figure C.1d), but allows the distinguishing of the nucleus from the cyto-
plasm through the localisation of miR-221 (yellow triangle) in the cytoplasm and EP300
protein in the nucleus (teal circle).
Note: the simulation images displayed are zoomed in to enhance the details of the sim-






















(a) 1st iteration of the simulation (b) 100th iteration of the simulation
(c) 1000th iteration of the simulation (d) 10000th iteration of the simulation
Figure C.1: Model output at the start of the simulation, at the 100th, 1000th and 10000th iteration. Figure legend: light green triangle -
miR-132, yellow triangle - miR-221, blue circle - EP300 mRNA, orange circle - AGO2 mRNA, pink cross - ribosome, white square -
promoter/transcription site, teal square - cytoplasmic foci, dark green circle - CREB protein, teal triangle - EP300 protein, red square -
AGO2 protein.
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C.2 RISC loading – baseline
(a) absolute miR-132 count (b) absolute miR-221 count
(c) absolute AGO2 bound miR-132 count (d) absolute AGO2 bound miR-221 count
Figure C.2: RISC loading distribution during miR-132 mediated silencing of AGO2 and
EP300 in PMA-activated LECs, presenting the molecular abundance baseline in LECs and
baseline perturbation during PMA treatment. The treatment is initiated at 48 hours after the
simulation start time. The mean (green line) and standard deviation (blue area) is
calculated based on 100 replicate simulation runs.
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C.3 RISC loading – during enhanced miR-132 expression
(a) absolute miR-132 count (b) absolute miR-221 count
(c) absolute AGO2 bound miR-132 count (d) absolute AGO2 bound miR-221 count
Figure C.3: RISC loading distribution during miR-132 mediated silencing of AGO2 and
EP300 in PMA-activated LECs with enhanced miR-132 transcription activity (mean - teal
line, standard deviation - green area) compared to baseline PMA activation (mean - red
line, standard deviation - blue area), calculated based on 100 replicate simulation runs. The
treatment is initiated at 48 hours after the simulation start time.
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C.4 RISC loading – during enhanced miR-132 expression
with a non-regulated AGO2 mRNA
(a) absolute miR-132 count (b) absolute miR-221 count
(c) absolute AGO2 bound miR-132 count (d) absolute AGO2 bound miR-221 count
Figure C.4: RISC loading distribution during miR-132 mediated silencing of AGO2 and
EP300 in PMA-activated LECs with enhanced miR-132 transcription activity where AGO2
can (mean - red line, standard deviation - blue area) or cannot (mean - teal line, standard
deviation - green area) be targeted by miR-132, calculated based on 100 replicate
simulation runs. The treatment is initiated at 48 hours after the simulation start time.
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C.5 RISC loading – during enhanced miR-132 expression
with a non-regulated EP300 mRNA
(a) absolute miR-132 count (b) absolute miR-221 count
(c) absolute AGO2 bound miR-132 count (d) absolute AGO2 bound miR-221 count
Figure C.5: RISC loading distribution during miR-132 mediated silencing of AGO2 and
EP300 in PMA-activated LECs with enhanced miR-132 transcription activity where EP300
can (mean - red line, standard deviation - blue area) or cannot (mean - teal line, standard
deviation - green area) be targeted by miR-132, calculated based on 100 replicate
simulation runs. The treatment is initiated at 48 hours after the simulation start time.
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C.6 Two-sample Kolmogorov-Smirnov tests
The K-S test was used to compare the probability distributions of the simulations for results
presented in Chapter 5. Since the data from the simulation is continuous (recorded over
time) and one-dimensional (e.g. a single agent abundance), and the response to PMA treat-
ment creates an effect that propagates over time, K-S statistical test was considered to be
an appropriate way to measure the differences between continuous distributions. The com-
parison was drawn between PMA-activated conditions, starting from the PMA treatment
and lasting 48 hours. The cumulative distributions of 100 replicate runs for each measure
(e.g. miR-132 abundance) were compared, and the K-S statistic and p-values presented in
Tables C.1-C.3. As it is evident, all differences observed were found statistically different
from each other (p-value < 0.001), however the K-S statistic reveals how different the two
experimental conditions were (ranging from 0...1, where 1 indicates a large difference and
0 suggests a small difference between the distributions of two conditions). The K-S test was
carried out in Python using the SciPy package contained stats module, ks 2samp function1.
Table C.1: Comparison of the PMA treatment effect between the abundances of different
molecules or complexes in the baseline miR-132 model versus a model with enhanced
miR-132 expression (Figure 5.3).
LEC baseline compared to enhanced baseline
KS statistic p-value Measure
1.000 0.000 miR-132
0.394 0.000 miR-221
0.303 0.000 AGO2 mRNA
0.629 0.000 EP300 mRNA
0.083 0.000 pCREB
0.578 0.000 EP300 available to pCREB
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Table C.2: Comparison of the PMA treatment effect between the abundances of different
molecules or complexes in the model with enhanced miR-132 expression where AGO2 can
or cannot be regulated by miR-132 (Figure 5.4).
Enhanced baseline with AGO2 compared to AGO2−UTR
K-S statistic p-value Measure
0.542 0.000 miR-132
0.325 0.000 miR-221
0.472 0.000 AGO2 mRNA
0.534 0.000 EP300 mRNA
0.160 0.000 pCREB
0.517 0.000 EP300 available to pCREB
0.424 0.000 AGO2 for miR-132/221
0.221 0.000 RISC-miR132
0.454 0.000 RISC-miR221
Table C.3: Comparison of the PMA treatment effect between the abundances of different
molecules or complexes in the model with enhanced miR-132 expression where EP300 can
or cannot be regulated by miR-132 (Figure 5.5).
Enhanced baseline with EP300 compared to EP300−UTR
KS statistic p-value Measure
0.212 0.000 miR-132
0.334 0.000 miR-221
0.464 0.000 AGO2 mRNA
0.999 0.000 EP300 mRNA
0.070 0.000 pCREB
0.740 0.000 EP300 available to pCREB












BDNF Brain-Derived Neutrophic Factor
BSA bovine serum albumin
Btg2 B-cell Translocation Gene 2
ceRNA competing endogenous RNA
CoSMoS Complex Systems Modelling and Simulation
CPU central processing unit
CREB cAMP-Response Element Binding protein
DGCR8 DiGeorge Syndrome Critical Region 8
DMEM Dulbecco’s Modified Eagle Medium
DMSO dimethyl sulfoxide
EDTA ethylenediaminetetraacetic acid
EGFR Epidermal Growth Factor Receptor
Ep300 E1A-associated Protein p300
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Abbreviations 228
ERK Extracellular Signal Regulated Kinase
EXP1 Exportin 1
EXP5 Exportin 5
FCS fetal calf serum
FMRP Fragile X Mental Retardation Protein
FOXO3 Forkhead Box O3
GO Gene Ontology
GTP guanosine triphosphate
GUI Graphical User Interface
HDLEC Human Dermal Lymphatic Endothelial Cell
HFF Human Foreskin Fibroblast
HPRT Hypoxanthine Phosphoribosyltransferase
HSC hematopoietic stem cell
HSP90 Heat Shock Protein 90
IL22 Interleukin 22
IL6 Interleukin 6
Jarid1a Lysine (K)-Specific Demethylase 5A
K-S Kolmogorov-Smirnov
LBK1 Liver Kinase B1
LEC Lymphatic Endothelial Cell
LHC Latin Hypercube
LPS lipopolysaccharide
LYVE1 Lymphatic Vessel Endothelial Hyaluronan Receptor
MAPK Mitogen-Activated Protein Kinase




ODE Ordinary Differential Equation
p250GAP Rho GTPase Activating Protein 32
PACT Protein Activator of PKR
Paip2 Polyadenylate-binding Protein-Interacting Protein 2
PBS phosphate-buffered saline
PDE Partial Differential Equation
PDPN Podoplanin
Per1 Period Circadian Clock 1
PMA phorbol myristate acetate
PRCC partial rank correlation coefficient
pre-miR precursor miRNA
pri-miR primary miRNA
PROX1 Prospero Homeobox protein 1
PTEN Phosphatase and Tensin Homolog
PVDF polyvinylidene fluoride
qRT-PCR quantitative reverse transcription polymerase chain reaction
RBP RNA-binding protein
RIPA radio-immunoprecipitation assay
RISC RNA-induced silencing complex
RNG Random Number Generator
S.E.M. standard error margin
S6K1 p70 Ribosomal Protein S6 Kinase 1
SCN suprachiasmatic nucleus
SDE Stochastic Differential Equation
SDS sodium dodecyl sulphate
Abbreviations 230
SDS-PAGE SDS-polyacrylamide gel electrophoresis
siRNA small interfering RNA
SIRT1 Silent Mating Type Information Regulation 2 Homolog 1
Sox4 SRY (Sex Determining Region Y)-Box 4
SP1 Specificity Protein 1
SPRED1 Sprouty-Related, EVH1 Domain Containing 1
TIE2 Tyrosine kinase with Ig and EGF homology domains-2
TRBP TAR RNA Binding Protein
TSS transcriptional start site
UML Unified Modeling Language
UTR untranslated region
VEGF Vascular Endothelial Growth Factor
VEGFC Vascular Endothelial Growth Factor C
VEGFR1 Vascular Endothelial Growth Factor Receptor 1
VEGFR3 Vascular Endothelial Growth Factor Receptor 3
YCIL York Computational Immunology Lab
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